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The aim of this thesis was to investigate the role of inflammation in the airways and in the
systemic compartment in COPD compared to healthy subjects, and to investigate the
relationship between inflammation and the clinical and radiological features of COPD.
Methods
182 COPD patients and 96 healthy control subjects were recruited. Post-bronchodilator
spirometry, smoking history, body mass index (BMI), exacerbation frequency, St George's
Respiratory Questionnaire (SGRQ) scores, MRC dyspnoea and chronic bronchitis scores, oxygen
saturations, 6 minute walking distance and BODE index scores were recorded. Highly sensitive
C-reactive protein (CRP), total white cell count and neutrophils were measured in blood.
Percentage (%) neutrophils, IL-lp, IL-6 and IL-8 were measured in induced sputum. COPD
patients had a quantitative CT scan on inspiration and expiration. Lung volume and density
(pixel index -910 HU, pixel index -950 HU, and 15th percentile) were determined using in-house
software.
Results
Systemic inflammation was increased in COPD subjects compared to healthy controls: CRP
(p<0.001), blood neutrophils (p<0.001). Pulmonary inflammation was also increased in COPD
subjects compared to healthy controls: induced sputum % neutrophils (p=0.001), IL-6 (p=0.02)
and IL-8 (p=0.01). Induced sputum IL-1J3 was not increased in COPD compared to controls.
Blood neutrophils, CRP, sputum IL-6 and IL-8 were higher in COPD patients compared to
healthy controls after adjusting for age, gender and smoking status. Induced sputum was not
reliably attainable particularly in healthy control subjects (sample available for 65% of COPD
subjects and 26% of healthy controls). In COPD subjects, blood neutrophils (p=0.03) and
sputum % neutrophils (p=0.004) were independently related to FEVi after adjusting for age,
gender, smoking status and inhaled corticosteroid use. Blood neutrophils and CRP correlated
significantly with each other (r=0.408, p<0.001), but were not associated with any of the
sputum markers of inflammation. Systemic inflammation was associated with SGRQ total score
(neutrophils p=0.02, CRP p<0.001) and MRC dyspnoea score (neutrophils p=0.005, CRP
p=0.003) after adjusting for FEVi and smoking status. Blood neutrophils (p=0.02) were
associated with oxygen saturations < 93%. BODE index scores correlated with blood
neutrophils, (p=0.005), CRP (p=0.03) and sputum IL-8 (p=0.02). After adjusting for potential
confounding factors; exacerbation frequency and BMI were not associated with markers of
blood or sputum inflammation. Quantitative CT lung volume and density (pixel index -910, pixel
index -950 and 15th percentile) on inspiration and expiration were associated with post-
bronchodilator FEVi % predicted and FEVi/FVC ratio (p<0.001) but not with any of the markers
of pulmonary or systemic inflammation. Expiratory CT parameters correlated better with lung
function than inspiratory parameters. Lung volumes were inversely associated with BMI on
inspiration (r=-0.225, p=0.015) and expiration (r=-0.296, p=0.001). BMI was associated with
15th percentile on inspiration (r=0.518, p<0.001) and expiration (r=0.534, p<0.001) and
inversely with pixel index -910 and -950 (p<0.001). BMI was associated with lung density
independent of airflow limitation (p=0.03). Lung volume and density were not associated with
age, gender, current smoking status, smoking pack years, SGRQ scores, MRC dyspnoea or
chronic bronchitis score, exacerbation frequency, oxygen saturations or BODE index.
Conclusion
Markers of inflammation in blood and sputum were increased in COPD compared to healthy
controls. Blood and sputum % neutrophils were associated with airflow limitation, but not with
lung density. Pulmonary and systemic inflammatory markers had different profiles according to
different clinical features of COPD. Inflammatory markers and lung density may be useful in
characterizing COPD patients in addition to airflow limitation alone.
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Chronic Obstructive Pulmonary Disease (COPD] is characterized by chronic
airflow limitation and is currently defined in terms of the forced expiratory
volume in 1 second (FEVi) for the purpose of diagnosis and treatment. (1) The
FEVi is also used to define disease severity in COPD, (2] and has long been
associated with prognosis. (3, 4) The FEVi is an important predictor of outcome
in COPD. Epidemiological studies in the general population have shown that a
reduction in FEVi is an independent predictor of all cause mortality. (5)
However, although FEVi is useful as a defining variable for COPD, which is an
otherwise heterogeneous disease, it is limited as an endpoint for COPD in
several ways.
An ideal diagnostic marker of disease would be dichotomous in order to
differentiate disease and non-disease, but FEVi is a continuous variable with an
arbitrary cut-off that has been refined over time. (6] However, the use of
defined cut-offs has come under criticism recently due to the propensity for
under- and over-diagnosis depending on age and gender. (7-9] This may, for
example, lead to an over-diagnosis of COPD in older age groups as the FEVi/FVC
ratio reduces with age. (10-12] FEVi is also limited as a marker for monitoring
disease progression. It is estimated that 1000 people need to be followed up for
3 years to detect a variation of only 20mls per year in FEVi. (13] This has
implications for clinical trials which require large sample sizes and a longer
period of follow up. Mortality in COPD patients is often due to factors other than
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the severity of airflow limitation. At least one third to one half of deaths in COPD
patients are due to a non-respiratory cause. (5,14) Although FEVi is still the
strongest predictor of outcome in COPD, other clinical parameters, for example
body mass index and C-reactive protein (CRP), predict mortality in COPD
patients independently of FEVi and smoking status. (14-16) In addition, FEVi
does not account for the variation in clinical presentation, disease severity, and
the rate of disease progression in COPD. (17) The degree of airflow limitation
correlates poorly with symptoms (18) and is not associated with the extra¬
pulmonary features seen in COPD. (19) In fact, the regulatory requirement that
FEVi be used as the main endpoint in clinical trials in COPD may actually inhibit
the development of treatments that might impact on other aspects of the
disease such as inflammation and cachexia. (6) There is therefore a need for
markers to better characterize COPD to augment the current definitions of
disease severity and prognosis that are based on lung function.
A biomarker can be defined as "a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic processes,
or pharmacological responses to therapeutic interventions." (20) In clinical
practice, biomarkers can be used to establish a diagnosis, to monitor disease
severity or to predict prognosis. They may also be useful in defining disease
phenotypes and response to a therapeutic intervention. (21) A COPD
"phenotype" has been defined as one of "the outward physical manifestations of
patients with COPD; anything that is part of their observable structure, function
or behaviour." (22) An ideal biomarker should be able to "indicate a patho-
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physiological process relevant to the disease of interest, distinguish a disease
phenotype, respond to treatment in a time frame that precedes changes in
clinical status, be easily measured, minimally invasive, reproducible, and
properly validated." (21, 23) Many potential biomarkers have been investigated
as a means of further characterizing COPD. The following text will focus on
some of the markers that have potential for defining COPD phenotypes. These
include biological markers, symptomatic markers, physiological markers, and
markers of structure and anatomy.
Biologicalmarkers
There are three established mechanisms for the pathogenesis of COPD. These
are inflammation, oxidative stress and protease/anti-protease imbalance. (24)
Inflammation is a central feature of COPD and is included in the working
definition of the disease. (2, 25) Each of these pathogenic mechanisms can be
directly linked by inflammation and are not mutually exclusive. For example,
oxidative stress induced by cigarette smoke up-regulates the inflammatory
process by activating the transcription factor nuclear factor kB (NF-kB). This in
turn induces the transcription of pro-inflammatory cytokines. (26, 27) The main
inflammatory effectors cells in COPD are neutrophils and macrophages. They
are key sources of proteases in the lungs and therefore directly impact on the
balance of between proteases and anti-proteases. Inflammatory cells and
mediators may therefore be useful biomarkers in COPD.
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Pulmonary inflammation
Pulmonary inflammation is a key pathological process in COPD. (28] Airway
inflammation, parenchymal destruction and tissue remodeling occur in COPD as
a result of the complex interaction of cells and inflammatory mediators. All
smokers have some inflammation in the lungs particularly in their small
airways. (29) However, in 15-20% of smokers (30) and more commonly in
heavy smokers, (31) the "inhalation of noxious particles or gases" results in a
persistent chronic abnormal inflammatory response in the lungs that persists
even after cessation of cigarette smoking. (1) This chronic inflammation, when
established, is self-perpetuating. (24) The mechanism behind the
transformation from the 'normal' to the abnormal inflammatory response in the
development of COPD, and the reason it occurs in only a proportion of smokers
is unknown, but genetic factors may be implicated. (32) Expression of pro¬
inflammatory genes is determined in part by the modification of histones, for
example, by acetylation and deacetylation. The inhibition of histone deacetylase,
which is involved in the control of gene transcription, may have a role in
enhancing the inflammatory response. Histone acetyl transferases (HATS)
activate, whereas histone deacetylase (HDAC) represses gene expression.
Cigarette smoke exposure inhibits histone deacetylation leading to the
increased transcription of pro-inflammatory genes. (33)
Many methods for assessing pulmonary inflammation have been explored.
Exhaled breath condensate, sputum and induced sputum, bronchoalveolar
lavage, endobronchial biopsy and resected lung specimens have all been
13
analyzed. (34) In these samples, the cellular composition of the airways has
been examined and many inflammatory mediators have been identified and
quantified. There is also some evidence that biomarkers of inflammation and
oxidative stress may predict therapeutic responses. For example, there is some
evidence that the presence of airway eosinophilia may predict response to
steroid therapy in patients with airways disease. (35, 36)
Neutrophils
The neutrophil is a key cell in the pathogenesis of COPD. (37) Neutrophilic
inflammation occurs in healthy lungs and constitutes an important part of the
innate immune response. The neutrophil is characteristically the predominant
cell type in induced sputum and bronchoalveolar lavage fluid in subjects with
COPD. (38) Neutrophils are activated to release reactive oxygen species (ROS)
and proteases. Once released, these result in damage to lung cells. (39)
Neutrophil proteases such as neutrophil elastase, cathepsins and matrix
metalloproteinases (MMPs) are thought to induce lung damage through
degradation of the extracellular matrix. (40) The serine proteases secreted by
neutrophils are also potent stimulators ofmucus secretion in the airways. (41,
42) The function and activity of neutrophils is altered in COPD. Neutrophils in
the airways in COPD patients are activated such that there is an increased
release of reactive oxygen species and proteases. (34) The rate of neutrophil
apoptosis is also increased in COPD patients compared to controls, and is
increased further in COPD patients with more severe airflow limitation
(FEVi<50% predicted). (43) Neutrophil numbers in the airways increase as
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airflow limitation progresses. (44) Increased numbers of induced sputum
neutrophils have been associated with a more rapid decline in FEVi. (45) A
meta-analysis of cross-sectional studies in COPD found that the sputum
neutrophil count was one of the few biomarkers showing a trend towards a
separation between stages of disease in COPD. (46)
Macrophages
Macrophages are also key cells which mediate and perpetuate the chronic
inflammatory process in COPD. (47, 48) Macrophages are increased in all
regions of the lungs in COPD patients, whereas neutrophils are increased
predominantly in the airways. (34) As with neutrophils, the number of alveolar
macrophages in the airways increases with the degree of airflow limitation in
COPD. (49) Activated macrophages in COPD patients release increased numbers
of pro-inflammatory cytokines and matrix-metalloproteinases. Alveolar
macrophages from COPD patients have a greater release of MMP-9 than those
from healthy smokers. (50, 51) Interestingly, corticosteroids are less effective in
inhibiting release of these mediators from alveolar macrophages in COPD
patients compared to controls, (52) possibly as a result of reduced HDAC.
Lymphocytes
T lymphocytes are involved in both the innate and adaptive immune responses
but predominantly in the latter. Originating from thymocytes, they differentiate
into CD8+ (cytotoxic) and CD4+ (T helper) cells. These lineages further
differentiate into type 1 or type 2 cells which differ in their cytokine profiles.
Type 1 cells secrete interferon-y, which activates macrophages in response to
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bacterial and viral infections. Type 2 cells secrete cytokines such as IL-4, IL-5
and IL-13, which are involved in the IgE mediated response usually associated
with asthma and allergy. (53) CD8+ T lymphocytes cause cell destruction both
by inducing lysis of cell membranes by granzymes and perforins, and by
inducing apoptosis. (54) There is some evidence that CD8+ and CD4+ T cells
proliferate in regional lymph nodes in a sustained immune response to chronic
infection or to other antigenic stimuli. (55)
T lymphocytes are increased in the lung parenchyma and airways of COPD
patients and the ratio of CD8+ to CD4+ T cells is increased. (47) Finkelstein and
co-workers found that the number of T lymphocytes in the alveolar wall was
increased in smokers and correlated with the extent of emphysema. (56) CD8+ T
lymphocytes have been associated with the degree of airflow limitation in
COPD. (57) An association has been found between smoking pack years and
both the number of T cells in the alveolar wall and the degree of apoptosis. (58)
CD8+ cells are increased in the circulation of COPD patients and the number of
abnormally activated T cells is increased. (59, 60) The function of these cells
may be affected by cigarette smoking and inhaled corticosteroid use. (59) It has
even been proposed that COPD may be an autoimmune disease that is mediated
by auto-reactive T cells. These may respond to auto-antigens on lung cells
structurally altered by neutrophil and macrophage mediated acute
inflammation. (58, 61)
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Other cells and inflammatory mediators in the lungs
A number of other inflammatory cells and mediators are active in the
inflammatory process in COPD. Eosinophils are more typically associated with
asthma, but are increased in the airways of some COPD patients. When
identified in COPD patients, sputum eosinophilia was associated with increased
corticosteroid responsiveness. (36] However, a meta-analysis found that
macrophage and neutrophil counts distinguished between COPD patients and
healthy subjects, whereas eosinophil counts did not. (46) Interestingly, patients
with asthma who develop chronic airflow limitation have a higher number of
neutrophils in the airways. (62)
Dendritic cells have a vital role in the detection ofmicroorganisms and in
linking the innate and adaptive immune responses. (63) They are found in
increased numbers in the airways of smokers. These antigen-presenting cells
are instrumental in the activation of both the innate and adaptive immune
responses and in the activation of other inflammatory cells. They are present in
abundance in all regions of the lungs and may initiate an immune response to
inhaled particles in cigarette smoke. (34)
Epithelial cells are important in the defense of the airways through secretion of
mucus, anti-oxidants, anti-proteases and IgA. (34) These cells also have a role in
aiding neutrophil migration from the circulation into the airways by the release
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of inflammatory mediators such as IL-1(3 and IL-8 in response to cigarette
smoke. (64, 65)
Cytokines are central to the inflammatory process in COPD although their role
and interactions in the pathogenesis of COPD is not fully understood. They have
a role in the recruitment of inflammatory cells and the activation and
suppression of inflammatory and immune responses. More than 50 cytokines
have been identified in asthma and COPD. These can be classified into
lymphokines, pro-inflammatory cytokines, chemokines, anti-inflammatory
cytokines and growth factors. (66)
Tumour necrosis factor alpha (TNFa), interleukin-1 beta (IL-1 j3) and
interleukin-6 (IL-6) are pro-inflammatory cytokines and amplify the
inflammatory cascade through the activation of NF-kB. Increased TNFa is
associated with the weight loss seen in COPD. Blocking the action of TNFa is
efficacious in chronic inflammatory conditions like rheumatoid arthritis and
inflammatory bowel disease. TNFa blockade has some benefits in asthma, (67,
68) but trials of anti-TNFa therapy have not been effective in COPD. (69, 70) In
fact, an increased incidence of infection and neoplasia was observed in COPD
patients treated with TNF antibody. (70) However TNFa levels may be affected
by factors not considered in these studies, such as disease severity and
exacerbation frequency. IL-6 is a pro-inflammatory cytokine. Increased IL-6
levels in induced sputum have been described in stable COPD patients and
further increases are seen during exacerbations. (71) Sputum IL-6 levels
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increase over time in COPD and higher levels are associated with a more rapid
decline in FEVi. (72] IL-8 (or CXCL-8] is a chemokine. IL-8, leukotriene B4
(LTB4) and TNFa act as chemotactic factors and facilitate neutrophil and
monocyte migration into the airway lumen. (73] Other facilitators of neutrophil
migration such as the intra-cellular adhesion molecule (ICAM] -1 (74] are also
up regulated in COPD. E-selectin enables adhesion of circulating neutrophils,
and is up-regulated on vascular endothelial cells in bronchial biopsy samples in
COPD. (74] IL-8 levels have been increased in sputum in COPD compared with
smoking and non-smoking controls in small studies. (75] IL-8 was increased in
bronchoalveolar lavage fluid (76] in stable COPD and IL-8 levels correlated with
neutrophil numbers. (71]
IL-1(3 is a potent activator of macrophages in COPD and promotes the release of
inflammatory cytokines, chemokines and MMP-9. (66] Matrix-metalloproteases
are proteolytic enzymes that degrade the extra-cellular matrix and this action is
opposed by specific anti-proteases (Tissue inhibitors of MMPs - TIMPs]. They
are involved in pulmonary remodeling and have been implicated in the
pathogenesis of COPD and asthma. (77] Levels ofMMP-1, -8 and -9 were
increased in sputum in COPD patients compared to healthy smokers and
asthmatics. (78]
Growth factors such as TGF-(3 stimulate the proliferation of fibroblasts, resulting
in fibrosis of the small airways. (66] Vascular endothelial growth factor (VEGF]
is associated with increased vascularity and vascular leakage in asthma. But
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where VEGF levels were increased in asthma, (79) levels of VEGF and its
receptors were reduced in the lungs and sputum from COPD patients. Blockage
of the VEGF receptor led to apoptosis and the development of emphysema in rat
models. (80)
Systemic inflammation in COPD
In addition to the effects on the lungs, COPD is now considered to have
important systemic effects. (2) A large body of evidence indicates that a
systemic inflammatory response is present in a proportion of patients with
COPD. (81, 82) Airflow limitation is associated with increased systemic
inflammation in population studies. In the Burden of Lung Disease (BOLD)
initiative in Iceland, investigators found that increased circulating IL-6 and CRP
were associated with reduced FEVi and FVC (n=758). (83) A French population
study of 531 subjects followed over 8.5 years found that increases in CRP over
time were associated with a greater decline in FEVi. (84) Data from The Third
National Health and Nutrition Examination Survey (NHANES) in the United
States demonstrated a relationship between systemic inflammation
(neutrophils, fibrinogen and CRP) and reduced FEVi that was independent of
current smoking status. (85)
Co-morbidity and systemic features of COPD
Several co-morbidities are considered to be systemic sequelae of COPD, such as
atherosclerosis, (86) weight loss, (87, 88) skeletal muscle dysfunction, (89)
osteoporosis, (90) depression and anxiety. (91) These associations are
particularly important as they have a major influence on morbidity and
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mortality in COPD. (92] In fact, the presence of co-morbid conditions, and in
particular cardiovascular disease, is an independent predictor of mortality in
COPD patients. (90, 93] And yet the majority of therapies for COPD currently
focus on the airways. While these treatments improve symptoms, they do not
convincingly impact on mortality. Systemic inflammation could explain some of
the systemic consequences of COPD and it's associated co-morbid conditions.
Treating co-morbidities may reduce mortality in COPD, (92] but understanding
the mechanisms behind the systemic inflammatory state and the association
between local airway and systemic inflammation is likely to further expand the
therapeutic possibilities.
Markers of systemic inflammation in COPD
Markers of systemic inflammation may be useful in predicting prognosis in
COPD. A meta-analysis of systemic inflammatory markers found that blood
leukocytes, C-reactive protein, fibrinogen and TNFa levels were increased in
COPD patients compared to healthy controls. These markers of systemic
inflammation were increased in COPD patients irrespective of smoking status.
(82] Increased circulating leukocytes are associated with the symptoms
traditionally associated with COPD such as chronic cough, sputum production
and dyspnoea. (94, 95] Increased peripheral blood white cell count is associated
with airflow limitation, rate of decline in FEVi and smoking status. (96, 97] It is
also associated with increased all cause mortality and with mortality associated
with cardiovascular disease, independent of smoking history and the degree of
airflow limitation. (95] Fibrinogen is an acute phase reactant, synthesized by
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the liver under the control of IL-6. Raised levels of circulating fibrinogen and
blood neutrophils are also associated with a faster rate of decline in FEVi. (72)
C-reactive protein is a strong independent predictor of hospitalization and
death in COPD, independently of FEVi and smoking history. (16, 98) C-reactive
protein is widely used in clinical practice to detect and monitor systemic
inflammation. Like fibrinogen, it is produced by hepatocytes in response to
stimulation by IL-6. In addition to being a marker of inflammation, it has a role
in the regulation of the inflammatory cascade by activating complement,
augmenting leukocyte adhesion and recruiting pro-inflammatory cytokines. (85,
88, 99) What is less clear is the extent to which CRP is itself pro-inflammatory.
This has been the subject of debate in the cardiovascular literature. (100,101)
There is evidence that CRP is pro-inflammatory in the setting of acute ischaemia
where it has been found to increase tissue damage through a complement
dependent mechanism. (102) It has also been associated with the progression of
atherosclerosis. (103) An elevated resting level of CRP in COPD has been
confirmed in population studies, (104) and levels increase with the severity of
airflow limitation. (105) Raised CRP levels are associated with a more rapid
decline in FEVi. (106) It is now established as a marker of chronic inflammation
with prognostic implications, not only in COPD. (16,107)
Theories linking pulmonary and systemic inflammation in COPD
The role of systemic inflammation in the pathogenesis of COPD and its
relationship with pulmonary inflammation is not well understood. (82) The
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most common theory is that pulmonary inflammation "spills over" into the
systemic compartment, resulting in chronic low-grade inflammation. It is
postulated that cytokines such as IL-6 reach the systemic circulation and
increase the production of inflammatory mediators like CRP in hepatocytes.
(108) These then perpetuate the low-grade systemic inflammation. This theory
is supported by evidence that pulmonary anti-inflammatory therapies such as
inhaled corticosteroids may improve outcome in COPD. (109) Inhaled
corticosteroids may reduce systemic markers of inflammation in COPD and
resulted in a 40% reduction in circulating CRP in one study, (110) but other
studies showed conflicting results. (Ill, 112) There is a lack of evidence of an
association between pulmonary and systemic markers of inflammation in COPD.
Diesel exhaust inhalation causes a rise in markers of acute inflammation in the
pulmonary and systemic compartments in healthy volunteers. (113,114) But a
number of studies have failed to show a relationship between markers of
pulmonary and systemic inflammation in COPD subjects. (72,115,116)
The alternative theory of reverse causation (that systemic inflammation drives
pulmonary inflammation) must also be considered. There is evidence that
inflammatory cytokines increase adhesion of inflammatory cells to the
pulmonary capillary endothelium, augmenting neutrophil sequestration in the
pulmonary vasculature with a resultant increase in the influx of inflammatory
mediators from the circulation to the lungs. (84) Cardiovascular disease is
strongly associated with increased markers of systemic inflammation such as
CRP and IL-6. (104) In chronic inflammatory conditions like diabetes, obesity
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and ischaemic heart disease (IHD), surface adhesion molecules such as ICAM-1
and VCAM-1 are up-regulated on the endothelium, causing leukocyte adhesion
and enhanced chemotaxis.
Smoking is an obvious link between COPD and systemic inflammation. But
hypertension, ischaemic heart disease, osteoporosis, muscle weakness and
diabetes mellitus are more common in COPD, independently of the effects of
smoking. (89] It is possible that a core susceptibility to inflammation is
represented by each of these co-morbidities. Inactivity is also a factor common
to many of these conditions and has been proposed as a possible cause of
systemic inflammation. (91] Hypoxic, genetic and autoimmune mechanisms
may provide additional links between systemic and pulmonary inflammation.
Skeletal muscles and pulmonary hyperinflation are other potential causative
factors associated with systemic inflammation in COPD. (88,117]
Symptomatic and physiological markers
Although FEVi is established as an outcome measure in COPD, it is not the best
indicator of a patient's functional abilities. Many clinical markers of symptoms
and function have been investigated in COPD with a view to identifying
additional disease phenotypes, predicting outcome and monitoring response to
therapeutic interventions. This thesis will focus on the symptom scores St
George's Respiratory Questionnaire (SGRQ] and MRC dyspnoea score,
exacerbation frequency, body mass index (BMI], oxygen saturations and the
Body mass index, airflow Obstruction, Dyspnoea and Exercise capacity (BODE]
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index. [118] These features were chosen as non-invasive, well validated
measures associated with prognostic importance in COPD. They also each depict
manifestations of COPD that potentially link pulmonary and systemic
inflammation.
Health status
FEVi is not closely associated with health-related quality of life in COPD
patients. (119) Tools measuring health status and quality of life take into
account symptoms, physical function, psychosocial and emotional factors,
activity levels and the degree of adaptation to disease. (120) Therapeutic impact
on symptoms and quality of life are more important to patients than
improvement in spirometry. (121) Symptoms like dyspnoea - a key
determinant of quality of life in COPD - are poorly correlated with FEVi (122)
FEVi takes no account of physiological factors such as dynamic hyperinflation,
which is associated with an increased perception of breathlessness. (123)
Health status tools like the St Georges Respiratory Questionnaire (SGRQ) and
the MRC dyspnoea score are linked to prognosis in COPD. (118,124) These
tools are increasingly used as outcome measures in clinical trials. (125) Health
status can be improved by use of inhaled bronchodilators, inhaled
corticosteroids and pulmonary rehabilitation. (126-128)
The SGRQ is a well-validated, self-administered questionnaire with 76 weighted
components. It is specific to patients with respiratory disease. It gives an overall
score (total score) that can be broken down into three domains: symptoms,
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activity and the impact of disease on daily life. (129) A 4-point change in the
SGRQ total score is established as the minimal clinically important difference
(MCID) when it used as an outcome measure in clinical trials. (125) In the
National Emphysema Treatment Trial (NETT), a sustained improvement in
SGRQ total score was seen at 2 years post lung volume reduction surgery. (130)
The SGRQ may capture features of COPD not encompassed in lung function. For
example, SGRQ total score was associated with multi-dimensional tools for the
assessment of COPD severity such as the BODE index, though not with GOLD
stage which is based on spirometry. (131,132) SGRQ predicts mortality after
adjusting for age, FEVi and BMI (133) and is a more consistent predictor of
mortality than other quality of life scores. (89) In a study of 102 subjects with
COPD, SGRQ was associated with increased sputum macrophages, although
there was no association between SGRQ and FEVi. (117) Low SGRQ scores were
associated with raised systemic CRP. (105) Combinations of inhaled
corticosteroid and long acting beta agonists improve health status in COPD.
(127) In a study of 289 COPD patients, inhaled fluticasone and salmeterol led to
an improvement in health status. But while specific lung markers of
inflammation improved (surfactant protein D), there was no difference in
general systemic inflammatory markers (CRP or IL-6). (110) This suggests that




Exacerbations have been extensively studied in COPD. They are associated with
reduced quality of life, [134) increased hospitalization, morbidity and mortality.
(135-137) Increased frequency of exacerbations may be associated with a faster
decline in lung function. (138,139) The definition of an exacerbation of COPD is
based on respiratory symptoms. An exacerbation is defined as an acute increase
in cough, dyspnoea and/or sputum production that may require a change to
regular medication. (1,140) Exacerbation frequency may be used to define
clinical phenotypes of COPD. The exacerbation rate in COPD is variable.
Donaldson and co-workers measured exacerbation frequency in their cohort
using diary cards. They reported a mean annual exacerbation frequency of 2.5
and they reported that the exacerbation frequency in the first year was highly
correlated with exacerbation frequency in subsequent years. (139) In contrast,
a significant proportion of COPD patients experience no exacerbations in an
average year. This group may therefore constitute a distinct clinical phenotype.
(6) Frequency of exacerbations is increasingly used as an endpoint in clinical
trials. (6,141) Treatmentwith combined inhaled corticosteroid/long acting
beta agonist or with long acting anti-cholinergic pharmacotherapy have both
been associated with a significant reduction in exacerbations frequency and a
decline in FEVi. (142,143)
The aetiology of exacerbations in COPD is not fully understood. They are not
explained by infection alone. While around 50% of exacerbations are associated
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with a bacterial infection (usuallywith Haemophilus influenzae, Moraxella
catarrhalis, or Streptococcus pneumoniae), (137) the causative role of bacteria in
exacerbations has been questioned. (144) A longitudinal cohort study of 104
patients over 7 years found insignificant differences in bacterial load during
exacerbations, though there was a small but significant change in the
concentration of new strains ofHaemophilus influenzae and Moraxella
catarrhalis. (145) Viruses are implicated in exacerbations in asthma and COPD,
(146) and air pollution has been proposed to have a role in inducing
exacerbations of COPD. (147) Genetic (148) and immunological factors (149) in
response to tobacco smoke are associated with susceptibility to exacerbations.
Exacerbations are associated with increased pulmonary inflammation.
Neutrophils, eosinophils and other inflammatory mediators are increased in the
airways during exacerbations compared to the stable state. (150) Exacerbation
frequency is also linked with increases in many markers of systemic
inflammation. (151,152) For example, in microarray analysis, 24 serum
biomarkers were associated with exacerbation frequency (153) Systemic
inflammation and inactivity are key mechanisms relating COPD to it's associated
co-morbidities. Exacerbations are associated with both of these factors and may
be a key link between pulmonary and systemic inflammation and the systemic
consequences of COPD. (91)
Body composition (Body Mass Index) and the BODE index
Body mass index is an established measure of nutritional status. (154) A
proportion of COPD patients develop significant loss of body mass with
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progression of disease. In the GOLD stage IV group from the Copenhagen City
Heart Study, 30% ofwomen and 15% ofmen were underweight (BMI <18.5%).
(15) The clinical features associated with this phenotype are low body mass
index, reduced fat free mass (a surrogate for skeletal muscle mass), skeletal
muscle dysfunction, exercise intolerance and leg weakness. (90) The causes of
reduced body mass index and muscle dysfunction in COPD are likely to be multi¬
factorial. These include inactivity, steroid use, poor nutrition and the effects of
systemic inflammation. (19,155,156) Systemic markers of oxidative stress and
the pro-inflammatory cytokine TNFa have been linked with the 'cachectic'
phenotype of COPD. (157) CRP predicted body mass index and fat free mass
independently of FEVi, age and sex in COPD patients. (105) Body mass index is
also associated with systemic consequences of COPD such as osteoporosis.
(158) Low body mass index and fat free mass are independent predictors of
mortality in COPD and this association was stronger in more severe COPD. (15,
159,160) Body mass index and fat free mass correlate significantly with
exercise capacity (6 minute walking distance). (154) The recognition that body
mass index and exercise capacity have prognostic significance over and above
airflow limitation has led to interest in the development of composite clinical
endpoints. The most well known of these is the BODE index. The BODE index is
a composite 10-point scoring system based on the clinical indices of Body mass
index (BMI), airways Obstruction, Dyspnoea and Exercise capacity (6 minute
walking distance). The composition and scoring system used in the BODE index
is outlined in detail in Chapter 2. This composite score is based on non-invasive
clinical outcomes and has been validated such that a one point increase in the
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BODE index has been associated with a 34% increase in mortality in COPD in
one study population. It has been suggested that the BODE index is a more
effective predictor ofmortality than FEVi alone. (118)
Hypoxia
Hypoxaemia can be measured non-invasively and simply using an oxygen
saturation monitor or more invasively by arterial blood gas. The arterial partial
pressure of oxygen has been associated with outcome in COPD (46) and oxygen
supplementation is one of the few therapeutic measures known to improve
survival in COPD. (161,162) In addition to improving pulmonary vascular
resistance and polycythaemia, (161) exercise capacity, dyspnoea and sleep
consolidation may also be improved with oxygen therapy. (163) Although
hypoxia is more common in severe COPD, it does not develop in all patients with
severe airflow limitation. Hypoxia in COPD may be in part genetically mediated.
The transcription factors NF-kB and hypoxia inducible factor-1 (HIF-1) induce
gene transcription in response to alveolar oxygen levels. HIF-1 consists of two
subunits (a and (3). HIF-la expression in the lungs is regulated by the
concentration of inspired oxygen. (164) This factor may also induce anorexia
through induction of the promoter for the leptin gene. (165)
Hypoxia provides a possible causative link between pulmonary and systemic
inflammation. Hypoxia was associated with increased systemic inflammation
with raised circulating IL-6 and CRP, (166) increased platelet activation and the
up-regulation of intracellular adhesion molecules. (167) These factors, in
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addition to hypoxia-induced haemodynamic stress, which results in tachycardia
and peripheral vasoconstriction, may be one reason for the increased incidence
of cardiovascular disease in COPD. (168) Hypoxia may increase inflammation
through mechanisms that alter vascular responses. (169,170) Remy-Jardin and
colleagues reported interesting findings regarding emphysema and
inflammation using imaging techniques. (171) They found that emphysematous
regions often developed at a site that had previously shown nodules or ground
glass and suggested that these areas may have represented a region of
inflammation or possibly fibrosis. In the presence of inflammation, the usual
pulmonary response of diverting blood flow from hypoxic alveolar regions is
reversed. Some smokers may exhibit blunting of this process, and in these
individuals, inflammatory regions associated with hypoxia may experience a
further limitation in blood flow, resulting in tissue destruction. (172)
Anatomical markers
COPD is a pathologically heterogeneous disease and results in characteristic
anatomical alterations in the lungs. The main features contributing to airflow
limitation in COPD are parenchymal destruction (emphysema) and remodeling
of the small airways. (173) Chronic bronchiolitis and emphysema have long
been recognized as key components of COPD. (174) Emphysema causes loss of
lung elasticity and an increase in total lung volume, whereas inflammation and
fibrosis of the membranous bronchioles, accompanied by mucus plugging
contribute to small airway narrowing. (175-177) There is evidence that airway
remodeling and emphysema develop through different pathogenic mechanisms.
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(177-179) As future treatments are likely to target these processes separately,
(180) it is likely to become important to characterize patients into emphysema
and airway phenotypes for the purposes of treatment and prognosis. CT
provides a means to differentiate these pathological subtypes. (181-183) This
section will illustrate the technological considerations necessary for the
measurement of lung density and airway caliber using computed tomography.
Potential anatomical phenotypes of COPD identifiable on CT will then be
discussed with respect to their utility as markers of disease.
CT measurement of lung density
CT has been used to provide an objective measure of lung density in Hounsfield
Units (HU) since the 1980's. (184,185) The most widely used method for
objectively quantifying emphysema using CT is the "density mask" technique.
(186) In the acquisition of scan data for density analysis, software is used to
separate lung regions from the more dense structures (e.g. chest wall,
mediastinum and hila) by a process known as segmentation. (187) The
development of density mask software is based on the allocation of 3D regions
(voxels) of signal intensity, which are reconstructed using a mathematical
algorithm into 2D regions (pixels). The reconstruction algorithm allocates a
value based on the signal intensity of each voxel, taking account that of
neighbouring voxels. This filter or 'kernel' can be altered depending on the
purpose of the scan. For example a soft filter is more representative for lung
density analysis, whereas a hard filter will give more image definition for
assessing, for example, airway wall dimensions. Regions of signal density are
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then allocated a density value in Hounsfield Units based on their intensity index
on a gray scale. For example, zero HU represents the density ofwater and -1000
HU represents the density of air. A threshold is then applied close to the HU
value for air to dichotomize regions to be denoted as 'normal' lung parenchyma
or as emphysematous. Normal lung at full inspiration has a mean density
between -750 and -850 HU on 10mm slices. Emphysema was initially defined as
a lung density < 2 standard deviations below average density. This is
approximately a density of < 900 HU but can vary depending on the
reconstruction algorithm, slice thickness, the use of contrast, and differences in
collimation. No fixed value has yet been established for this threshold, but
commonly used cut-offs are -910 and -950 HU. Emphysema is considered to be
present when > 10% of pixels fall below this threshold. [188) The low-density
threshold to quantify emphysema has been validated against pathology. [184,
186,189)
Alternatives to the density mask technique such as the volume fraction of
emphysema, mean lung density [MLD) and a CT air-trapping index are also in
common use. [190) Emphysematous regions are often described as the
percentage of low attenuation areas (%LAA) below a given threshold in HU, e.g.
%LAA-950. [191) European studies of alpha-1 antitrypsin deficiency developed
a measurement known as the "percentile point" which was initially utilized in
Edinburgh. [192) Dirksen and coworkers analyzed lung density using 5-15% of
the lowest attenuation voxels. The "percentile point" [e.g. 5th or 15th percentile
point) is advantageous in having less variability than the density mask
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technique. It is also significantly less variable than measurements of pulmonary
function. (193)
Practical considerations
CT protocols for calculating lung density are different from the usual clinical
protocols used primarily for image analysis. The radiation dose from a normal
helical CT scan of the thorax is estimated to be approximately 8.9-10.9
milliSieverts (mSv). Clinical scans use a current of 180-240 milli-Ampere
seconds (mAs) in order to achieve greater image clarity. Quantitative CT scans
for the assessment of emphysema can be undertaken using a lower current (20-
40mAs). This reduces the total radiation dose by approximately 10-fold, (194)
making CT a more attractive option for phenotyping COPD and for assessing the
progression of disease over time. In order to standardize lung density
measurement, the effects of slice thickness, collimation and reconstruction
algorithm must be taken into account. (195) With respect to computed
tomography, collimation refers to the beam width, with thinner collimation (e.g.
1mm compared to 2.5mm) resulting in increased sensitivity to smaller regions
of emphysema. Edge enhancement filters (e.g. "bone" or "lung") are used for
image enhancement in clinical scans. This alters the density measurement and
should not be used in scans for emphysema quantification. (188)
Scanners are usually calibrated at water density (zero HU). For accuracy in
densitometry, calibration at air density (-1000 HU), which is closer to the
density of emphysematous regions, is also required. Calibration with both air
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and water phantoms is recommended. (196) This is particularly important for
multi-centre and longitudinal studies, as have been pioneered in alpha-1
antitrypsin deficiency. (197)
In addition to technical variables, patient factors such as changes in lung volume
affect the density measurement. (198,199) Although some studies support the
use of spirometric gating to help standardize the degree of inspiration, it is
generally accepted that verbal coaching of subjects - to sustain first a breath
hold in inspiration, then again in expiration - yields acceptable results. (200)
Whether scans for lung density should be taken in inspiration or expiration is a
source of debate. Expiratory scans may relate better to physiology as they
represent emphysema and gas trapping even when the inspiratory scan is
normal. (201, 202)
Emphysema phenotypes
CT lung density measurements have been investigated in relation to
physiological measures of pulmonary function. (181,182,192, 203, 204)
Despite the same spirometric stage of disease in COPD, the quantity of
emphysema can vary widely. (205) The extent of emphysema does not
therefore fully account for the expiratory airflow limitation. (206, 207) Patients
can have severe airflow limitation with limited or no emphysema. (206, 208)
Macroscopic emphysema has been demonstrated in never-smokers (209) and in
post-mortem studies significant emphysema can be present in patients with
normal lung function. (210) In a cohort undergoing CT scans for lung cancer
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screening, 78% of smokers had emphysema in the presence of normal
spirometry. (211) Although an inverse relationship between the extent of
emphysema and FEVi exists, (211) quantitative analysis of lung density
correlates better with carbon monoxide diffusion capacity and the degree of
microscopic emphysema (212) than with FEVi. (207) Some studies found that
lung density parameters on expiratory scans correlated more closely with
pulmonary function tests, with correlation co-efficients between lung density
and FEVi improving from 0.5-0.7 between inspiration and expiration. (213,
214)
In addition to whole lung density measurements, the zone distribution of
emphysema may be important in phenotyping COPD. Pathologists describe
three major different patterns of emphysema. Centrilobular emphysema is a
"breakdown in alveolar walls in the central portion of the acini, initially sparing
the peripheral parts of the acinus and lobule." Panlobular emphysema is the
term for "destruction of all portions of the lobule out to the periphery,"
Paraseptal emphysema is "tissue destruction exclusively in the periphery of the
lobule." (188) Classically, centrilobular and paraseptal emphysema were
thought to have upper lobe predominance and be more common in smokers,
while panlobular emphysema has been shown to predominate in the lower
lobes in patients with alpha-1 antitrypsin deficiency. (215, 216) These subtypes
may be important for COPD phenotyping as different patterns of emphysema
type and distribution may develop through different pathological mechanisms.
For example, one study found that narrower peripheral airways were found in
36
centrilobular emphysema suggesting that an airborne mechanism might induce
centrilobular emphysema, whereas a blood-borne mechanism might better
explain the panlobular phenotype. (217] There is evidence to suggest that
regional blood flow abnormalities may be one of the primary abnormalities in
the pathogenesis of emphysema. (171, 218, 219]
Some progress has been made in using CT to assess the pathological types of
COPD (centrilobular, paraseptal and panlobular], (220] by identifying different
sizes and distributions of emphysematous regions, although visual assessment
is still needed to differentiate emphysema types. Software is used to divide the
lungs for example, into left and right lungs, upper and lower halves, and inner
and outer (or core and rind] regions based on 50% of the lung volume.
Separation of the lungs into different lobes, though more complex, has also been
achieved. (172] But for clinical purposes, separation by zones may be adequate
as was demonstrated in patient selection for the NETT trial. (130] Software
used to identify 'hole size distribution' or the 'Alpha' technique was developed
to determine proportions of coalescent areas of emphysematous lung. (221]
This method is based on a fractal geometry technique to make a log-log plot of
the frequency distribution of'holes' of a pre-determined area below a given
density in HU. 'Alpha' is the gradient of the slope of the log-log relationship of
hole-size versus the percentage of holes of that size. This gradient lessens in the
presence of larger emphysematous regions. (172, 221]
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The relationship between the zone distribution of emphysema and lung
function has been investigated. Lower zone emphysema is more closely
correlated with spirometry than upper zone emphysema. (203, 222, 223 2004,
p07330)} Core predominant emphysema is also more closely correlated with
pulmonary function. (203, 224) While lower zone and core emphysema
correlate more closely with airflow limitation, upper zone and core
predominant emphysema are more closely related to carbon monoxide transfer
factor. (191, 225) Several studies have found gender differences in the
distribution of emphysema. (226-228) For example, core predominant
emphysema was more often found in women in the NETT trial. (226)
Emphysema severity and distribution on CT has been utilized in clinical
practice. The distribution of emphysema on CT has been used to assess patients
before and after lung volume reduction surgery. (224, 229, 230) Clinical trials in
alpha-1 antitrypsin deficiency have pioneered the development of protocols for
CT measurement of emphysema in a longitudinal setting for use in clinical trials.
(193,231)
There are few studies investigating emphysema quantity and distribution
phenotypes with clinical parameters in COPD other than lung function. (191,
203) Gas trapping on expiratory scans has been found to correlate with
dyspnoea. (213) Makita and co-workers found that symptoms of bronchitis
were equally distributed irrespective of the degree of emphysema, but that
patients with most emphysema had lower health related quality of life scores.
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(205] Low body mass index was associated with low lung density but not with
airway dimensions on CT. (205, 232] The extent of emphysema on CT was
associated with fat-free mass but not with C- reactive protein in a cohort of
smokers. (233] Emphysema has also been associated with an increase in
sputum MMP-9 (associated with lung parenchymal destruction] and with
worsening BODE index score. (234]
CT measurement of airways
CT protocols for measuring airway dimensions are less well developed than
those for lung densitometry. Three-dimensional reconstruction of
multidetector-row scans enables the accurate measurement of airway
dimensions to a diameter of approximately 2mm (corresponding to 6th
generation airways] (235, 236] and a lumen as small as 1 mm in diameter.
(237] There is as yet, no consensus for the best method of assessing airways
with CT. (238] Some studies focus on airways cut in cross-section on standard
CT images, such as the apical segmental bronchus of the right upper lobe.
Manual measurements (using electronic calipers] have also been used, though
this method is open to significant inter-operator variation. Nakano and
coworkers (181] measured the dimensions in a single airway that was most
often cut in cross section on CT (right apical segmental bronchus], while Parr
and coworkers used a visual scoring system to estimate airway dimensions
using a technique initially utilized by Bhalla and co-workers. (239, 240]
39
Semi-quantitative techniques have been developed to help reduce sources of
error. Techniques for accurately determining the wall edge have been explored.
Of these, the full-width-halfmaximum technique is the most commonly used.
(241-243] X-ray attenuation is measured along a ray projected from a central
seed point in the airway. Wall thickness is determined as the point at which
attenuation is halfway between the minimum attenuation in the lumen or
parenchyma and the maximum attenuation in the middle of the airway wall.
This measure overestimates wall area and underestimates lumen area, with
error increasing in the smaller airways. (244) Alternatives have been explored
such as the "maximum likelihood method" and ellipse fitting algorithms. (241,
245) Montaudon and coworkers demonstrated that removing the effect of
obliquity improved the accuracy of airway measurement. They used software to
map the pathway of an airway, producing wall measurements orthogonal to the
airway centre. This technique reduced the potential for over or underestimation
ofwall dimensions due to obliquity. (235)
Multi-detector row CT now enables image acquisition at <lmm slice thickness.
This allows for segmentation of the airways using a seed-point in the trachea
out to the 5th or 6th airway generation. Airways can then be labeled anatomically
to determine branch points and airway generation, although this can be
problematic due to anatomical variation. Different nomenclatures have been
utilized to aid anatomical identification, but there is increasing difficulty in
discerning branch points in the smaller airway divisions. (172, 246, 247) Fully
automated software is currently being developed using volumetric techniques,
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which may reduce several of these sources of error. However, problems with
branch identification, combined with difficulties in the accuracy of airway wall
identification (particularly in the small airways), and patient factors like the
degree of inspiration and anatomical variation are yet to be overcome. (238)
Airway phenotypes
Remodeling of the airways is common to many chronic lung diseases. In asthma
wall thickness in the conducting airways can be increased between 50 and
300%. (248) The pathological features of airway remodeling in COPD include
squamous metaplasia, loss of cilia, submucosal gland hypertrophy,
neovascularisation, increased smooth muscle mass and fibrosis. (249) Hogg and
co-workers first described the pivotal role of the small airways in COPD in 1968,
when they showed that the major site of airway limitation in patients with
COPD is in airways <2mm in internal diameter. (177) More recently, it was
demonstrated that airway dimensions in COPD parallel the stage of disease as
defined by the degree of airflow limitation. (250) Animal (251) and human
studies (177) have shown that airway remodeling contributes to approximately
25% of the airflow limitation in COPD. Airway dimensions of the large and small
airways are attenuated in COPD such that there is a reduction in lumen area and
increased wall thickness. (252) Bronchial wall thickening is an independent
predictor of FEVi. (236, 253)
Airway dimensions have been related to morphometric measures and lung
function. (181, 254) Nakano and colleagues were first to report an association
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between airway wall thickness and FEVi in patients with COPD. They measured
the lumen area, radius, and airway wall thickness of the apical segmental
bronchus of the right upper lobe. A subsequent study analyzing airways in 114
male smokers showed that wall thickness and percentage wall area correlated
independentlywith spirometric measurements of airflow limitation, but not
with lung diffusing capacity (a physiological surrogate of emphysema severity].
(181] Hasegawa and co-workers studied 52 patients with stable COPD and
found that airway luminal area and wall area were significantly correlated with
FEVi (percent predicted] and that the correlation coefficients improved as the
airways became smaller in size from the 3rd to the 6th generation, concluding
that airflow limitation in COPD is more closely related to the dimensions of the
smaller airways than the more proximal large airways. (236] Nakano and co¬
workers (254] assessed airway dimensions with CT scans and lung
morphometry in 22 resected lungs (mean FEVi 83% predicted]. They found that
airway dimensions on CT correlated with morphometric measurements of
airways dimensions in airways down to an internal diameter of approximately
1.27mm. They also concluded that CT consistently overestimated airway
dimensions particularly in the smaller airways and that the larger cartilaginous
airways provided a reasonable surrogate measure of small airways (r2=0.57,
p<0.01]. Few studies have examined the relationship between CT
measurements of airway dimensions and clinical features other than lung
function in COPD. (213, 255-257]
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Summary
Many potential markers that might augment COPD phenotyping in addition to
FEVi have therefore been explored. Numerous markers of inflammation and
oxidative stress in various body fluid compartments have been analyzed, but
many of the studies have been small and often report conflicting results. Clinical
features have been utilized with some success to help predict prognosis in
COPD. In addition, CT scanning now provides a method for investigating
anatomical profiles as outcome measures in COPD.
There is a need to investigate potential COPD phenotypes in a single well-
characterized cohort of COPD patients and controls in order to establish their
inter-relationship with one another. Most studies in the literature investigate
inflammatory markers in only one body fluid compartment and often do not
take account the potential confounding effect of smoking history. It is also
difficult to compare reports due to differences in study methods. Clinical
features such as body mass index have been investigated with spirometry and
prognosis but little work has been done on the relationship between some of
these clinical features of COPD and markers of inflammation. Lung density
measured by CT has been investigated extensively with lung function
parameters but again, there is little work assessing relationships between lung
density, clinical features and markers of inflammation in COPD.
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Aims
The aim of this thesis was to explore phenotypes of COPD using inflammatory
markers and computed tomography. A cohort of COPD patients and control
subjects was characterized with respect to post-bronchodilator spirometry,
quality of life, and physiological features (dyspnoea, exacerbations, body mass
index, oxygenation and the BODE index). Quantitative computed tomography
was used to measure lung volume and density in the COPD cohort. Biomarkers
of pulmonary and systemic inflammation were related to the clinical
phenotypes defined by spirometry, symptoms, and clinical and anatomical
features. The specific aims were to investigate the role of inflammation in the
airways and in the systemic compartment in COPD patients compared to
controls, and to investigate the relationship of inflammation to clinical and
anatomical phenotypes of COPD.
We hypothesize that:
1. Inflammation in the pulmonary and systemic compartments will be
increased in COPD patients compared to controls.
2. Airflow limitation will be associated with increased inflammation in the
pulmonary and systemic compartments in COPD patients.
3. Inflammation will be associated with clinical features known to be
associated with outcome in COPD.
4. Increased airflow limitation and more inflammation will be associated




COPD patients were recruited from general practices and respiratory medical
outpatient clinics at the Royal Infirmary of Edinburgh. Subjects had a clinical
history consistent with COPD, previous or current exposure to tobacco smoke
with at least a 10 pack year smoking history, and spirometric evidence of
chronic irreversible airflow limitation [defined as a post bronchodilator
FEVi/FVC ratio <70% with <15% or 200ml reversibility following 2.5 mg of
nebulized salbutamol). (2) Patients were studied when clinically stable, at least
6 weeks post-exacerbation. Subjects with other respiratory conditions, systemic
inflammatory diseases or prescribed regular oral corticosteroids were excluded.
Healthy control subjects were recruited through advertisements placed in the
Edinburgh area and by word of mouth. The Lothian Regional Ethics Committee
granted ethical approval.Written informed consent was obtained from all
subjects.
Study design
This was a prospective cross-sectional case-control study. Subjects were asked
to refrain from smoking for 12 hours preceding assessment. Exhaled CO
measurements [Bedfont piCO smokerlyzer, Bedfont scientific Ltd., UK) were
used to confirm abstention indicated by a value of <10ppm. All medications
were withheld for at least 12 hours, with long acting anti-cholinergic treatment
being withheld for 24 hours. A structured questionnaire was administered to
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record past medical history, smoking status, current medication, MRC dyspnoea
score, MRC chronic bronchitis score, total St George's Respiratory Questionnaire
(SGRQ) score and SGRQ subcategory scores. The SGRQ is composed of three
subcategories - symptoms, activity and impact. These combine as a total score,
which is the mean of the three subcategories. Subcategory scores range from 0-
100, with higher scores representing greater impairment. A difference of 4
points is considered a clinically significant difference. (258] Annual
exacerbation frequency (as defined by Rodriguez-Roisin and co-workers] (140]
was assessed by patient recall. Spirometry with reversibility to 2.5mg nebulized
salbutamol was performed in accordance with ATS/ERS standards (2]
(Vitalograph Alpha Spirometer, Ennis, Ireland]. Disease severity was classified
according to GOLD stage. (25] Height and weight were recorded and Body Mass
Index (BMI] was calculated as weight in kilograms divided by height in metres
squared (kg/m2]. Venous blood was collected and stored at -80°C. Six minute
walking distance (6MWD] was measured following the recognition that exercise
tolerance was an important predictor of mortality. (118] 6MWD was performed
according to ATS guidelines, including ATS guidance on statements used to
"encourage" patients to continue. (259] The Body mass index, degree of airflow
Obstruction and Dyspnoea, and Exercise capacity (BODE] Index score was
calculated for the COPD subjects. (118] Components of the BODE index are
displayed in Table 2.1.
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Table 2.1. Variables and point values used for the computation of the Body mass
index, degree of airflow Obstruction and Dyspnoea, and Exercise capacity
(BODE) Index. The total possible values range from 0-10. (118)
Variable
0
Points on BODE Index
1 2 3
FEVi, % predicted >65 50-64 36-49 <35
Distance walked in 6 minutes, m >350 250-349 150-249 <149
MMRC dyspnoea scale 0-1 2 3 4
Body mass index, kg/mz >21 <21
MMRC = modified MRC dyspnoea score. Scores range from 0-4, with a score of 4 indicating that
the patient is too breathless to leave the house or becomes breathless when dressing or
undressing.
Sputum induction
Sputum induction was performed according to a validated procedure. (45) In
brief, subjects were asked to rinse their mouth with water and gargle prior to
attempting sputum induction. COPD patients were asked to expectorate sputum,
which was then discarded. Nebulized hypertonic saline was inhaled for 5
minutes via an ultrasonic nebulizer (Devilbiss Healthcare, Heston, UK) during
normal tidal breathing first with 3, then 4 and 5% saline. FEVi was measured
between each inhalation. Sputum induction was not undertaken in subjects
with FEVi < 0.5 litres. The procedure was abandoned in subjects whose FEVi
fell to < 80% of baseline.
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Subject recruitment, baseline history, examination, height and weight, CO
measurement, administration of symptom questionnaires, spirometry,
collection of blood samples, sputum induction and 6 minute walking distance
measurements were made by me with the help of two experienced research
nurses.
Laboratory analysis
Sputum samples were examined as soon as possible and within 2 hours of
production. The weight of the sample was recorded. Sputum was separated
from contaminating saliva macroscopically using forceps and was placed in a
pre-weighed falcon tube and the weight of sputum was recorded. Each sputum
sample was processed with 4 times its weight of dithiotreitol (DTT, 0.1% in
distilled water), vortexed for 15 seconds and rocked for 15 minutes. The
suspension was filtered through 50 pm nylon gauze and centrifuged at 2000
rpm for 10 minutes. The supernatant was decanted and stored at -80°C for
further analysis. The cell pellet was re-suspended with approximately 1ml of
Hank's balanced salt solution (HBSS) according to macroscopic estimation of
the pellet size. The total cell count was determined with a haemocytometer.
Trypan blue was used to determine cell viability (blue cells being non-viable).
The percentage of viable and non-viable cells per gram of original sputum was
determined and the cell suspension mixed with HBSS to obtain a cell count of
0.6-1.0 x 106 cells/ml of suspension. Cytospins were made using a Cytotek
cytocentrifuge. Cytospin slides were stained with DiffQuik to obtain differential
cell counts made by counting 400 cells per slide. (260, 261)
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IL-8, IL-6, and IL-1(3 concentrations in sputum supernatant were assessed by a
human enzyme linked immunosorbent assay. A monoclonal antibody specific
for the cytokine was pre-coated onto a microtitre plate and standards and
samples added. After washing, an enzyme linked polyclonal antibody was added
followed by a substrate solution for colour development and intensity reading
(Duoset EL1SA - R&D Systems, Oxon, UK). The limit of detection for each of the
assays was 1.95 pg/ml for IL-1(3, 4.69 pg/ml for IL-6, and 15.63 pg/ml for IL-8
(based on the lowest standard of an eight point standard curve). The co-efficient
of variation for each of the assays was 19% for IL-1(3,14% for IL-6, and 8% for
IL-8. Receiver-operator curves (ROC) for COPD patients and healthy subjects
are shown in Figure 2.1 for induced sputum % neutrophils, IL-6 and IL-8 with
the area under the curve (AUC) and confidence intervals (CI). IL-1(3 was not
significantly different between COPD patients and controls.
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Figure 2.1 ROC curves for induced sputum inflammatory markers
2.11 Induced sputum % neutrophils: AUC 0.73, (CI 0.64-0.85)
2.12 Induced sputum IL-6: AUC 0.65, CI (0.53-0.77)
1 - Specificity
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2.13 Induced sputum IL-8: AUC 0.66, (CI 0.54-0.79)
1 - Specificity
Full blood count was measured (Sysmex XE 2100, Norderstedt, Germany) and
serum C-reactive protein (CRP) concentration was measured using a highly
sensitive immunonephelometric assay (Behring BN II nephelometer, Dade
Behring, Marburg, Germany). I took part in the laboratory analysis of induced
sputum and blood samples with the help of two experienced laboratory
technicians. Highly sensitive CRP assays were conducted by laboratory
technicians in a nearby laboratory.
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CTprotocol
Subjects underwent low dose thoracic CT scanning at full inspiration and on
expiration. I attended CT scans with the study subjects and undertook
standardized coaching to achieve as close to total lung capacity and functional
residual capacity as possible. No intravenous contrast was administered. Scans
were acquired in the caudo-cranial direction to reduce artefact. All scans were
acquired using a 16-slice Toshiba Aquilion (Toshiba Medical Systems, Tokyo,
Japan) CT scanner (135kV, 40mA, rotation time 0.5 sec, 16 x 1mm collimation,
pitch 1.45, FC-03 filter, reconstructed at 2.5mm intervals with 5mm thick slices
for lung density analysis. Radiation dose was low at around 1 mSv per scan.
Scanner calibration was undertaken according to the manufacturer's
instructions within 3 hours of the study scan being conducted. The Hounsfield
Unit (HU) for air was recalibrated using a method similar to that described by
Stoel and Stolk (195) using the FC-03 filter to correct for the air offset in
Toshiba CT scanners (about-985 HU instead of the nominal -1000 HU with this
filter). A more detailed explanation of the air calibration method used can be
found in the Appendix. The difference between the FC-03 and FC-12 filters is
demonstrated in Figure 2.2. Water calibration was also undertaken every 3
months using a phantom. Calibration procedures were undertaken by the CT
radiographers and supervised by the medical physicist.
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Figure 2.2. Air calibration using the FC-03 filter compared to the FC-12 filter. A
"region of interest" for air calibration was designated ventrally (indicated by the
white rectangle above each CT image]. The graph corresponding to each filter
shows the difference in air calibration measurement for each. The FC-03 filter
gives a constant measurement for air in Hounsfield Units, compared to the






















Software was developed in-house by Martin Connell (medical physicist) to
measure lung volume and whole lung density. Data collected using this software
has been published in a number of papers. (222, 262, 263) Following
segmentation of the lungs from the chest wall, mediastinum and trachea, lung
volume was calculated on inspiration and expiration. Densitometric indices
were extracted from the frequency distribution histogram of lung voxels. While
"voxel" is the most accurate term representing 3 dimensional units of volume,
the terms voxels and pixels (2-D) are used interchangeably in the CT literature.
For simplicity the term "pixels" will be used throughout the thesis. Lung density
was measured with the 15th percentile point (PD15), and with the pixel index at
the -950 threshold (PI-950) and the -910 threshold (Pl-910). Pixel indices
indicate the percentage of pixels with density values below -950 or below -910
Hounsfield Units (Figure 2.2). (194) The 15th percentile is defined as the value
in Hounsfield Units below which lie 15% of the lowest density pixels. (254)
Figures 2.3 and 2.4 show the pixel frequency distribution histogram with the
derivation of density indices used in the analysis. Airway dimensions including
lumen area, wall thickness and percentage wall area were measured as part of
the study but the airway data required further validation that was outwith the
scope of this thesis.
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Figure 2.3. The graph shows the frequency distribution histogram of CT pixels
for a subject with emphysema compared to a subject with normal lung density
(adapted from Parr et al, 2009). (264) The figure shows the position of the -910
and -950 HU thresholds (not to scale). The number of pixels at each threshold is
higher in patients with emphysema than with normal lung density. -1000 HU is











Figure 2.4. The graph shows the 15th percentile (PD 15) on the frequency
distribution histogram of CT pixels for a subject with emphysema compared to a
subject with normal lung density (adapted from Parr et al, 2009). (264) The
figure demonstrates that the 15th percentile is lower in patients with
emphysema than in patients with normal lung density (not to scale). -1000 HU
is equivalent to the density of air.
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Data analysis and statistics
The method of data presentation and statistical analysis is provided in detail
with each chapter. I did the data analysis with guidance from the statistician. A
sample size calculation was not undertaken due to a lack of prior data. Analyzes
were performed using SPSS version 16 (for Mac]. A p value of < 0.05 was
considered significant except where multiple comparisons were made where a
significance level was taken as 0.05 divided by the number of comparison tests
e.g. if 6 comparisons were made then the significance level was p<0.008. (265)
Logistic regression results were displayed in tabular form as B, standard error,
degrees of freedom (df), Wald, significance and Exp (B). With each table the -2
log likelihood, Cox & Snell R square and Nagelkerke R square were displayed in
addition to the overall significance. B is the regression coefficient. The Wald test
indicates the statistical significance of each co-efficient (B) in the model. When
the sample size is small, the -2 log likelihood is more reliable than the Wald test.
(266) Exp (B) is the relative odds (or odds ratio) for the factor in question e.g. in
COPD patients compared to healthy controls. Therefore for each unit in
variation in that factor (e.g. each year change in age) a subject is Exp (B) times
more likely to be a COPD patient than a healthy subject. The -2 log likelihood is a
measure of deviance or variation in the model. It has a chi-squared distribution
and is a measure of how well the model explains variations in the outcome of
interest. A lower value indicates a closer representation of this outcome e.g. in
COPD patients compared to healthy subjects. The Cox & Snell R square and
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Nagelkerke R square values represent the proportion of variation explained by
the model including all the factors in the table. For example, when Cox & Snell R
square is 0.354 and Nagelkerke R square is 0.494 (as in Table 3.7), the model
explains 35.4 to 49.4% of the variation between healthy controls and COPD
subjects. (267)
Multiple linear regression data were presented in tabular form where: B is the
regression co-efficient (the slope of the regression line for a given variable); SE
is the standard error (of the slope); t is the test statistic (B/SE) and p is the
statistical significance.
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CHAPTER 3: Systemic and pulmonary markers of
inflammation in COPD subjects and healthy controls
Introduction
Inflammation in the pulmonary and systemic compartments is central to the
pathogenesis of COPD. Inflammation is part of the working definition of the
disease (2) and has implications for prognosis. [28, 81, 82) Markers of
inflammation may therefore be useful in defining clinical phenotypes of COPD.
An ideal diagnostic marker should be able to differentiate COPD subjects from
healthy controls, should relate to the severity of disease or a disease phenotype
and should be responsive to therapeutic interventions. However, in clinical
practice few biological markers achieve this. (21) In the case of FEVi, it is
achieved using an arbitrary cut-off that has been refined over time. (6) The FEVi
is still the strongest predictor of outcome in COPD, but additional clinical
parameters have been found to predict prognosis in COPD patients
independently of FEVi and smoking status. (14-16) In order to characterize
phenotypes of COPD using markers of inflammation, it is important to know if
these markers are significantly different in COPD patients compared to healthy
subjects and if they are affected by smoking status.
The association between COPD and cigarette smoking has long been recognized.
(268) There is an established direct causal link between tobacco smoke and
COPD. (269) However, only 10-15% of smokers develop COPD, (270, 271) and
the cumulative smoking history in smoking pack years is not strongly associated
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with the degree of airflow limitation. (46) Cigarette smoking is associated with
pulmonary inflammation. Leukocytes, and in particular neutrophils in the lungs,
are increased in cigarette smokers. (272) Smoking cessation is associated with a
reduction in lung inflammation in asymptomatic smokers (273) and slows the
rate of decline in lung function in early COPD. (274) But a prospective study of
smoking cessation in COPD patients found that airway inflammation increased
even after smoking cessation. (275)
Systemic inflammation is increased in COPD. (276) Cigarette smoking has a long
recognized association with blood leukocytosis. (277) However, an association
has been reported between systemic inflammation and airflow limitation that is
independent of smoking status. (82, 85) The NHANES III study reported that
current smoking added to the systemic inflammation present in subjects with
airflow limitation. (85) An increase in systemic inflammatory markers
(peripheral white cell count and CRP) is associated with poor outcome in COPD,
independent of smoking status and the degree of airflow limitation. (16, 95)
Sputum induction provides a relatively non-invasive means of assessing the
cellular and inflammatory composition of the airways. Sputum induction
procedures have been standardized. (278) But obtaining a reliable sputum
sample is not always possible. (175) However, when compared to analysis of
pulmonary inflammation by alternative means, induced sputum remains an
attractive alternative for assessing inflammatory biomarkers in COPD. (23) For
example, the accurate measurement of inflammatory markers in exhaled breath
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condensate remains controversial (279) and bronchoalveolar lavage and lung
biopsy are more invasive. Induced sputum has a higher yield of viable cells than
spontaneous sputum. (71) It has been shown to be repeatable but with
significant inter- and intra-patient variability. (280) Induced sputum can be
used to obtain samples from the airways of subjects who do not usually produce
sputum.
This chapter investigates the utility ofmarkers of inflammation in blood and
induced sputum as potential biomarkers in COPD, taking into account current
smoking status. The hypothesis is that markers of inflammation in blood and
induced sputum with be increased in COPD patients compared to controls after
controlling for the effect of smoking.
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Aims
In a cohort of stable COPD subjects and healthy controls:
1. To investigate levels of blood and sputum markers of inflammation in
COPD patients compared to controls.
2. To investigate the effect of smoking status on markers of blood and
sputum inflammation.
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Methods and data analysis
Subjects were recruited as described in Chapter 2. Demographic data were
recorded for COPD subjects and healthy controls according to smoking status.
COPD and control subjects were compared with the unpaired t-test
(parametric) or Mann-Whitney U tests (non-parametric) for continuous
variables and with the Chi-squared test for categorical data. COPD subjects and
control groups were then analyzed according to smoking status. Groups were
compared using analysis of variance (ANOVA) or the Kruskall Wallis test. This
was followed by the Bonferroni post-hoc test or the Mann Whitney U test for
comparison between groups.
Significant variables in the univariate analysis were analyzed using binary
logistic regression. For the purpose of inclusion in the regression analysis,
significance was taken as p<0.1. Subjects were divided by smoking status into
two categories: current smokers and ex- or non-smokers. CRP and sputum IL-8
were log-transformed to achieve a normal distribution for analysis. In the
absence of pre-defined cut-off values, low and high categories (50th percentiles)
were defined for sputum % neutrophils (< 87% and > 87%) and sputum IL-6 (<
22 pg/ml and > 22 pg/ml). COPD patients, male sex, current smokers and the




182 COPD subjects and 96 healthy controls were recruited. The baseline
characteristics of the COPD patients and healthy controls are shown in Table
3.1. The COPD patients were older than the controls and had a higher
proportion ofmen. In the COPD group, disease severity ranged from GOLD stage
I to IV: GOLD I n=13 [7%), GOLD II n=70 (39%), GOLD III n=73 (40%), GOLD IV
n=26 (14%). As expected, the COPD groups had significantly more airflow
limitation and lower oxygen saturations than controls. 65% of COPD patients
and 26% of control subjects were able to produce an induced sputum sample
for analysis. Sputum induction was not attempted in COPD subjects whose
baseline FEVi was < 0.5 litres (n=8).
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Table 3.1. Characteristics of COPD patients and healthy controls. Data are
presented as number (%] or mean ± SD. Groups were compared with the




Age 68 ±8 58 ±11*
Gender, (% male) * 112 (62%) 41 (43%)*
Smoking, pack years 48 ±24 18 ±16*
Body mass index, kg/mz 26 ±6 27 ± 4*
Oxygen saturation, % 95 ±2 98 ±2*
FEVi, post bronchodilator %
predicted
50 ± 19 106±14*
FVC, post bronchodilator %
predicted
79 ±21 104 ±49*
FEVi/FVC ratio, % post
bronchodilator
48 ±13 79 ±7*




The subjects were divided according to smoking status for further analysis
(Table 3.2). Age was significantly different between groups (p<0.001) except
between COPD smokers and healthy ex-smokers (p=0.9) and between healthy
smokers and healthy ex- and non-smokers (p=0.3 and 1.0 respectively).
Cumulative smoking history in pack years was significantly higher in COPD
patients compared to controls (p<0.001) except for healthy smokers (p=0.03).
Oxygen saturation, FEVi and FEVi/FVC ratio were significantly lower in COPD
patients compared to the control groups (p<0.001). BMI was significantly lower
in COPD current smokers (p<0.05). When analyzed according to smoking status,
current smokers in both groups produced a higher yield of induced sputum:
78% COPD smokers compared to 50% of COPD ex-smokers, 52% healthy
smokers compared to 17% of healthy ex-smokers and 19% of healthy non-
smokers.
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Table 3.2. Clinical characteristics of COPD patients and healthy controls are
presented according to smoking status. Data are presented as number (%) or














n=76 n=106 n=23 n=41 n=32
Age, years 65 ±8 71 ± 7 55 ± 11 §63 + 10 55 ± 9
Gender, % male* §52% 72% 30% §51% 40%
Smoking, pack 51 ± 25
years
Body mass index, S24 ± 5
kg/m2
Oxygen saturations, 95 ± 2
%
44 ±24 30 ± 13 26 ±11 '0 ± 1
27 ±5 27 ±4 28 ±5 27 ±5










FVC, post 77 ±21
bronchodilator %
predicted
FEVi/FVC ratio % 52 ± 14
post
bronchodilator






49 ± 14 v78 ±8 v79 ± 7 V81 ± 7
= significantly different from both COPD groups (p<0.05).
§ = significantly different from COPD ex-smokers (p<0.05).
H = significantly different from all other groups (p<0.05].
1 = significantly different from COPD ex-smokers and healthy ex-smokers (p<0.05).
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Systemic inflammation
Markers of systemic inflammation were compared between COPD patients and
controls (Table 3.3). White cell count, neutrophils and C-reactive protein were
each significantly higher in COPD patients compared to healthy subjects. These
markers were analyzed in COPD patients and healthy controls according to
smoking status (Table 3.4).
Table 3.3. Markers of systemic inflammation in COPD patients and healthy
controls are displayed. Data are presented as mean ± SD (parametric) or median
(IQR) (non-parametric). Data were analyzed with the unpaired t-test. As CRP
was not normally distributed, it was log-transformed for analysis.
COPD CONTROLS P
Blood white cell count, xlO 9 7.6 ±2 6.4 ±2 <0.001
Blood neutrophil count, xlO 9 4.9 ±2 3.8 ±1 <0.001
hsCRP, mg/L 3.8 [2-7] 1.4(1-3] <0.001
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Table 3.4. Markers of systemic inflammation are displayed for COPD patients
and healthy controls according to smoking status. Data are presented as mean ±
SD. Differences between groups were analyzed with ANOVA and the Bonferonni
post-hoc test. CRP was not normally distributed. It is presented as median (IQR)






















5.1 ±2 4.7 ±2 4.3 ± 1 v3.6 ± 1 v3.6 ± 1 <0.001
hsCRP, mg/L 3.7 (2-8] 4.4 (2-7) v1.6 (1-2) v1.9 (1-3) v1.3 (1-2) <0.001
v
= significant difference between this group and COPD smokers and COPD ex-smokers
(p<0.05);
* = significant difference between this group and COPD smokers only (p<0.05)
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When analyzed according to current smoking status, blood leukocytes were
significantly higher in COPD current and ex-smokers compared to healthy ex-
and non-smokers [p<0.001], There was no significant difference between
current or ex-smoking COPD patients and healthy current smokers [Figure 3.1].
C-reactive protein was compared between groups according to smoking status.
There was no difference between CRP levels in COPD smokers compared to
COPD ex-smokers [p=0.96]. CRP was significantly higher in COPD smokers
compared to healthy smokers [p<0.001], healthy ex-smokers [p=0.002], and
healthy non-smokers [p<0.001]. CRP was also significantly higher in COPD ex-
smokers compared to healthy smokers [p<0.001], healthy ex-smokers
[p=0.004], and healthy non-smokers p<0.001]. CRP was therefore significantly
increased in COPD patients compared to controls irrespective of current
smoking activity [Figure 3.2].
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Figure 3.1. Box and whisker plot showing blood neutrophil counts in COPD
patients and healthy control subjects according to smoking status (p<0.001,
ANOVA). Blood neutrophils were higher in COPD current and ex-smokers
compared to healthy ex- and non-smokers (p<0.001). There was no significant
difference in blood neutrophils between COPD smokers or ex-smokers and
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Box plot values:
The top of the box represents the 75th percentile, the bottom of the box represents the 25th
percentile, and central line represents the 50th percentile. The whiskers represent the highest
and lowest values that are not outliers or extreme values. Outliers (between 1.5 and 3 times the
interquartile range) are represented by circles (o). Extreme values (more than 3 times the
interquartile range) are represented by stars (*).
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Figure 3.2. Box and whisker plots showing blood C-reactive protein levels in
COPD and control subjects according to smoking status. COPD smokers and ex-
smokers had significantly higher CRP compared to healthy smokers (p<0.001),
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CRP values for outliers not seen due to scale of x axis: COPD smoker 136, COPD ex-smokers 71
and 75, healthy ex-smoker 32, healthy non-smoker 327.
72
Pulmonary inflammation
Percentage of neutrophils in induced sputum and levels of IL-1(3, IL-6 and IL-8
were measured in COPD patients and healthy controls (Table 3.5). Sputum IL-1(3
was below the limit of detection of the assay in 33% of COPD patients and 32%
of healthy controls. There was no significant difference either in the number of
patients with detectable sputum IL-ip (p=0.5) or of the level of IL-1(3 (p=0.3)
between COPD patients and controls. Sputum IL-6 was below the limit of
detection of the assay in 22% of COPD patients and 40% of healthy controls
(p=0.03). Induced sputum neutrophils, IL-6 and IL-8 were significantly higher in
COPD patients compared to healthy controls (Figures 3.3, 3.4 and 3.5).
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Table 3.5. Inflammatory markers in induced sputum are displayed in COPD
patients and healthy controls. Data are presented as median (IQR) or *number
(%). Groups were compared using the Mann Whitney U test or *Chi-square test.
COPD Controls P
n=112 n=25
Neutrophils, % 89 [78-95] 77 [60-85] 0.001
IL-ip, pg/ml 9 [0-35] 5 [0-15] 0.326
IL-ip < LOD* 37 [33%] 8 [32%] 0.536
IL-6, pg/ml 28 [6-62] 8 [0-36] 0.018
IL-6 < LOD* 25 [22%] 10 [40%] 0.027
IL-8, pg/ml 458 [266-797] 279 [158-584] 0.010
LOD = limit of detection of assay
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Figure 3.3. Box and whisker plot showing the percentage of neutrophils in




The top of the box represents the 75th percentile, the bottom of the box represents the 25th
percentile, and central line represents the 50th percentile. The whiskers represent the highest
and lowest values that are not outliers or extreme values. Outliers (between 1.5 and 3 times the
interquartile range) are represented by circles (o). Extreme values (more than 3 times the
interquartile range) are represented by stars (*).
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Figure 3.4. Box and whisker plot showing induced sputum IL-6 levels in COPD
















The top of the box represents the 75th percentile, the bottom of the box represents the 25th
percentile, and central line represents the 50th percentile. The whiskers represent the highest
and lowest values that are not outliers or extreme values. Outliers (between 1.5 and 3 times the
interquartile range) are represented by circles (o). Extreme values (more than 3 times the
interquartile range) are represented by stars (*).
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Figure 3.5. Box and whisker plot showing levels of induced sputum IL-8 levels in




















The top of the box represents the 75th percentile, the bottom of the box represents the 25th
percentile, and central line represents the 50th percentile. The whiskers represent the highest
and lowest values that are not outliers or extreme values. Outliers (between 1.5 and 3 times the
interquartile range) are represented by circles (o). Extreme values (more than 3 times the
interquartile range) are represented by stars (*).
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Sputum markers of inflammation were analyzed according to smoking status
[Table 3.6). As sputum IL-6 and IL-1(3 levels were often below the limit of
detection of the assay, the number of subjects whose results were below the
limit of detection were tabulated for these cytokines. Sputum neutrophils were
significantly different between groups but there were no significant differences
in % neutrophils in sputum between the control groups [Figure 3.6). There
were no significant differences in sputum cytokines.
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Table 3.6. Sputum inflammatory markers in COPD and control subjects are
displayed according to smoking status. Data are presented as median (IQR] or
*number (%). Groups were compared using the Kruskall Wallis test with the













n=59 n=53 n=12 n=7 n=6
Neutrophils
%
85 (72-93) 91(87-96) 69 (46-76)v 84 (62-90) 78 (35-85) <0.001
IL-ip, pg/ml 2 (0-26) 12 (4-39) 8 (0-17) 7(1-12) 5 (0-15) 0.101
IL- 1(3 < LOD* 27 (46%)v 10 (19%) 5 (42%) 2 (29%) 1 (17%) 0.049
1L-6, pg/ml 22 (7-51) 34 (0-88) 16 (0-45) 0 (0-19) 2 (0-46) 0.127













= significant difference between this group and COPD ex-smokers (p<0.005)
LOD = limit of detection of assay
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Figure 3.6. Box and whisker plot showing the percentage of induced sputum
neutrophils in COPD patients and healthy controls according to smoking status
(p<0.001). Sputum % neutrophils were increased in COPD ex-smokers
compared to COPD current smokers (p=0.006), COPD smokers compared to
healthy smokers [p=0.02], COPD ex-smokers compared to healthy smokers
(p<0.001) and COPD ex-smokers compared to healthy non-smokers (p=0.02).
There was no significant difference between COPD smokers and healthy non-
smokers (p=0.3). The only significant difference was in COPD ex-smokers









1 , 1 1 1
COPD COPD ex- Healthy Healthy ex- Healthy
smoker smoker smoker smoker non-smoker
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Multiple regression models
In the univariate analysis age, gender and current smoking status, blood
neutrophils, CRP, sputum % neutrophils, sputum IL-6 and IL-8 were
significantly different between COPD patients and healthy controls. These
factors were entered into a binary logistic regression model. Age, gender and
current smoking status were investigated with blood and sputum inflammatory
markers separately (Tables 3.7 - 3.10) and then together (Tables 3.11-3.12)
Blood neutrophils and CRP were significantly and independently increased in
COPD patients compared to healthy controls after adjusting for age, gender and
current smoking status (Table 3.7). COPD patients had significantly higher
sputum neutrophils after adjusting for age and smoking status (p=0.034) but
not after adjusting for gender (p=0.065) (Table 3.8). IL-6 (p=0.005) and IL-8
(p=0.002) were significantly higher in COPD patients compared to healthy
controls after adjusting for age, gender and current smoking status (Tables 3.9
and 3.10). When included in the model together, as expected, they were not
independent of each other. When analyzed together with markers of systemic
inflammation, sputum IL-6 and IL-8 were not independent of blood neutrophils.
But sputum IL-6 (p=0.008) and sputum IL-8 (p=0.003) and CRP were
significantly and independently higher in COPD patients compared to healthy
controls (Table 3.11 and 3.12).
When cumulative smoking history (smoking pack years) was included in the
model instead of current smoking status, blood neutrophils (p=0.009), CRP
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(p=0.03), sputum IL-6 (p=0.043) and sputum IL-8 (p=0.006) were significantly
higher in COPD patients. Sputum % neutrophils (p=0.3) were not significantly
higher in COPD patients after adjusting for smoking pack years. CRP and
neutrophils were not independent of each other when included in the model
together (CRP p=0.01, blood neutrophils p=0.12). Sputum IL-6 and IL-8 were
not independent of each other (IL-6 p=0.043, IL-8 p=0.023]. CRP and sputum IL-
8 were independent of each other after adjusting for smoking pack years (Table
3.13] but sputum IL-6 was not independent of CRP (p=0.053].
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Table 3.7. Binary logistic regression of blood neutrophils and CRP in COPD
patients compared to healthy controls, adjusting for age, gender and current
smoking status.
B SE Wald df P Exp (B)
Intercept -10.1 1.549 42.7 1 <0.001 <0.001
Age 0.129 0.022 33.7 1 <0.001 1.9
Current smoker 1.730 0.414 17.5 1 <0.001 5.6
Blood
neutrophils
0.328 0.153 4.6 1 0.032 1.4
Log CRP 0.353 0.175 4.1 1 0.044 1.4
Male sex -0.618 0.368 2.8 1 0.093 0.5
-2 Log likelihood205.7 (Cox % Snell R Square 0.354, Nagelkerke R square 0.494], p<0.001
Table 3.8. Binary logistic regression of sputum % neutrophils in COPD patients
compared to healthy controls, adjusting for age, gender and current smoking
status.
B SE Wald df P Exp (B)
Intercept 10.3 3.081 11.1 1 0.001 <0.001
Age 0.174 0.045 14.7 1 <0.001 2.1
Current smoker 2.627 0.846 9.6 1 0.002 13.8
Sputum %
neutrophils
-1.4 0.779 3.4 1 0.065 0.2
Male sex 0.731 0.680 1.2 1 0.283 2.1
-2 Log likelihood 64.3 (Cox % Snell R Square 0.322, Nagelkerke R square 0.511), p<0.001
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Table 3.9. Binary logistic regression of sputum IL-6 in COPD patients compared
to healthy controls, adjusting for age, gender and current smoking status.
B SE Wald df P Exp (B)
Intercept -8.07 2.112 14.6 1 <0.001 <0.001
Age 0.142 0.032 19.8 1 <0.001 1.2
Sputum IL-6 1.636 0.585 7.8 1 0.005 0.2
Current
smoker
1.649 0.650 6.4 1 0.011 5.2
Male sex 1.319 0.597 4.9 1 0.027 3.7
-2 Log likelihood 94.2 (Cox % Snell R Square 0.266, Nagelkerke R square 0.426), p<0.001
Table 3.10. Binary logistic regression of sputum 1L-8 in COPD patients compared
to healthy controls, adjusting for age, gender and current smoking status.
B SE Wald df P Exp (B)
Intercept -15.3 3.6 17.8 1 <0.001 <0.001
Age 0.129 0.032 16.4 1 <0.001 1.1
Log sputum IL-8 1.205 0.386 9.7 1 0.002 3.3
Current smoker 1.542 0.667 5.3 1 0.021 4.7
Male sex 1.434 0.629 5.2 1 0.023 4.2
-2 Log likelihood 87.5 (Cox % Snell R Square 0.266, Nagelkerke R square 0.430), p<0.001
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Table 3.11. Binary logistic regression of CRP and sputum IL-6 in COPD patients
compared to healthy controls, adjusting for age, gender and current smoking
status.
B SE Wald df P Exp (B)
Intercept -11.2 2.846 15.6 1 <0.001 <0.001
Age 0.124 0.034 13.1 1 <0.001 1.1
Male sex 1.900 0.698 7.4 1 0.006 6.7
Sputum IL-6 1.772 0.663 7.1 1 0.008 5.8
Current
smoker
1.617 0.702 5.3 1 0.021 5.0
Log CRP 0.724 0.325 4.9 1 0.026 2.1
-2 Log likelihood 80.4 (Cox % Snell R Square 0.304, Nagelkerke R square 0.492], p<0.001
Table 3.12. Binary logistic regression of CRP and sputum IL-8 in COPD patients
compared to healthy controls, adjusting for age, gender and current smoking
status.
B SE Wald df P Exp (B)
Intercept -15.8 4.016 15.4 1 <0.001 <0.001
Age 0.116 0.034 11.5 1 0.001 1.1
Sputum IL-8 1.298 0.433 9.0 1 0.003 3.7
Male sex 1.802 0.699 6.6 1 0.010 6.1
Current
smoker
1.539 0.722 4.5 1 0.033 4.7
Log CRP 0.661 0.329 4.0 1 0.045 1.9
-2 Log likelihood 74.3 (Cox % Snell R Square 0.303, Nagelkerke R square 0.497], p<0.001
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Table 3.13. Binary logistic regression of CRP and sputum IL-8 in COPD patients
compared to healthy controls, adjusting for age, gender and smoking pack years.
B SE Wald df P Exp (B)
Intercept -13.8 4.0 12.2 1 <0.001 0.001
Smoking pack
years
0.086 0.026 11.1 1 0.001 1.1
Log sputum IL-8 1.2 0.471 6.7 1 0.010 3.4
Log CRP 0.751 0.374 4.0 1 0.044 2.1
Age 0.063 0.035 3.2 1 0.073 1.1
Male sex 1.4 0.79 3.2 1 0.073 4.1
-2 Log likelihood 62.1 (Cox % Snell R Square 0.366, Nagelkerke R square 0.601], p<0.001
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Discussion
The aim of this chapter was to establish whether biomarkers of pulmonary and
systemic inflammation differentiated COPD from healthy controls. Each of the
biomarkers analyzed was increased in COPD compared to controls with the
exception of induced sputum IL-ljL This finding remained consistent after
adjusting for age, gender and smoking history (both current smoking status and
smoking pack years], except for sputum neutrophils, which were increased in
COPD patients after adjusting for current smoking status but not after adjusting
for smoking pack years. After adjusting for potential confounding factors
including smoking status and smoking pack years, CRP and sputum IL-8 were
independently increased in COPD patients. The yield of induced sputum was
low, particularly in healthy subjects.
Pulmonary and systemic inflammation in COPD
Markers of systemic inflammation were significantly higher in COPD subjects
than in healthy controls in our study. This is in keeping with previously
published work. (82,104) Induced sputum markers of inflammation
(percentage neutrophils, IL-6 and IL-8) were also significantly increased in
COPD subjects compared to healthy controls. This confirms previous published
work in the case of IL-8 in studies investigating between 13 and 33 COPD
patients. (75, 281, 282) But while IL-6 in induced sputum has been associated
with COPD disease severity, (283) there were no comparable studies showing
results of induced sputum IL-6 between COPD patients and healthy controls.
This may be partly due to our finding that in a large number of healthy subjects,
87
IL-6 in induced sputum was below the limit of detection of the assay. The level
of induced sputum IL-6 in our cohort was lower than that found in COPD
patients in the study by Hacievliyagil and co-workers. (283) But this may be due
to the use of a chemiluminescence method instead of an ELISA. They also had a
smaller number of COPD patients (n=24). Bhowmik and co-workers also found
higher levels of IL-6 (median 64 pg/ml) and IL-8 (median 3953 pg/ml) than
seen in our COPD patients, and used the same R&D ELISA assay used in our
cohort. (71) However, they sometimes took several attempts to obtain an
induced sputum sample, and some patients were sampled only 3 weeks post-
exacerbation. In a meta-analysis of potential biomarkers in COPD, Franciosi and
co-workers reported that there was insufficient data on IL-6 in BAL and induced
sputum to draw conclusions. (46) And Comandini and co-workers do not list IL-
6 in an otherwise comprehensive review of induced sputum biomarkers in
COPD. (284) No studies investigating IL-1(3 in induced sputum from healthy
smokers has yet been published. (284) Our results therefore add significantly to
the literature by evaluating IL-1(3, IL-6 and IL-8 in the same cohort of COPD
patients compared to healthy controls.
IL-1[3 was the only marker measured in our cohort that was not increased in
COPD patients compared to controls. Reported levels of IL-1(3 in COPD have
been contradictory. Studies in BAL suggest that IL-ip may be up regulated in
smokers and COPD subjects. (285, 286) Whereas one EBC study and two ex-vivo
studies found that cigarette smoking either reduced IL-1(3 or did not affect the
levels. (287-289) It may be that the importance of IL-1(3 in the pathogenesis of
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COPD is in its role as a mediator of airway remodeling and fibrosis, rather than
as an inflammatory mediator, (290, 291) as IL-1(3 had a role in the induction of
emphysema and small airway remodeling in mice, with an effect that is similar
to TNFa. (292) Or perhaps the increased pro-inflammatory action of IL-lp in
COPD is best determined not by measuring overall levels of IL-1(3, but by
measuring the difference between IL-1 and it's antagonists (IL-lsRII and IL-
1RA), which are found in reduced numbers in COPD. (293) One study found
reduced levels of both IL-1 antagonists in plasma from COPD patients compared
to controls. (293) However, it is important to remember that our assessment of
IL-ip in induced sputum uses a technique to sample airway secretions and not
the distal airspaces, which may be the main site of inflammation in COPD. (294)
Our results suggest that further measurement of IL-1J3 in induced sputum is not
likely to be helpful in differentiating COPD patients from healthy subjects.
Effects of smoking on pulmonary and systemic inflammation
Acute smoking, current smoking and cumulative smoking history may all impact
on inflammation. We controlled for the effect of acute smoking by asking
patients to abstain from smoking for 12 hours prior to testing, and confirmed
abstention with an exhaled carbon monoxide measurement. The effects of
current smoking and cumulative smoking history in pack years were controlled
for in the logistic regression analysis.
Blood leukocytes and CRP were both increased in COPD independently of
smoking status. This has been previously reported, (82, 85, 276) but
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importantly, we found these systemic inflammatory markers were increased in
COPD independently of each other. No other studies were found investigating
both of these systemic inflammatory markers in the same cohort of patients.
Different profiles of these markers have been reported in relation to smoking
habit. A UK population study (n=6902) found that current smoking had a more
pronounced effect on circulating white blood cells than the cumulative effect of
smoking in pack years. (295) In addition to increased numbers of circulating
neutrophils, current cigarette smoking was associated with an increase in
neutrophil myeloperoxidase activity (296) and increased activation of epithelial
cells. (297) Peripheral blood white count was associated with annual decline in
FEVi in current smokers in a longitudinal study, but not in ex- or never-
smokers. (96) In contrast, CRP may be elevated in ex-smokers. In the
Framingham cohort, evaluation of a panel of inflammatory markers showed that
CRP was significantly higher in ex-smokers compared to never-smokers. (298)
While most smoking related inflammatory changes reversed with smoking
cessation, (299) CRP levels remained elevated in "healthy" ex-smokers for 10-
20 years after quitting. (300) There was a trend towards an increased CRP in
both ex-smoking groups in our cohort, which may in part be explained by the
higher body mass index in these groups. But mechanisms for the more chronic
elevation of CRP seen in ex-smokers are not fully understood. (299)
When assessed according to smoking status and smoking pack years, sputum IL-
6 and IL-8 were significantly higher in COPD patients compared to healthy
subjects, but sputum % neutrophils were not. However, the results should be
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interpreted with caution due to small sample numbers from healthy control
subjects. In addition, levels of sputum IL-6 and IL-ip were below the limit of
detection of the assays in a large proportion of subjects. Airway inflammation
has previously been associated with cumulative smoking history, but while the
induced sputum markers IL-6, IL-8 and TNFa have been associated with
smoking pack years in COPD exacerbations, (283) there is little in the literature
regarding induced sputum markers and cumulative smoking history in stable
COPD subjects. This may be partly due to our finding that induced sputum
markers such as IL-6 and IL-1(3 are difficult to detect in stable subjects. IL-8 has
been associated with smoking pack years in asthma. (301) Interestingly, Ito and
co-workers found that genetic polymorphisms associated with a high
production of IL-8 were more likely to be found in never- and ex-smokers. They
therefore proposed that the inflammatory phenotype associated with increased
IL-8 levels might act as a deterrent to cigarette smoking. (302) Previous studies
have investigated markers of airway inflammation in other body fluid
compartments in response to cumulative smoking history and current smoking
status. Studies in BAL found that neutrophils were highly correlated both with
smoking pack years (r2=0.65) and with the number of cigarettes smoked per
day (r2=0.41), (303) which is consistent with our findings in induced sputum. A
dose-response relationship was found between smoking pack years and
neutrophils, macrophages, IL-lp and IL-8 in BAL. (286) One study of 9 healthy
young smokers reported lower IL-6 levels in BAL and EBC in these subjects
compared to never-smokers. Two of these smokers with the highest BAL cell
counts also had higher IL-8 levels than non-smoking controls. (304) While
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assessment of induced sputum inflammatory profiles are known not to be
representative of the more distal airspaces, it is interesting to speculate that IL-
8 may an important factor in smokers who subsequently develop COPD. We
found that while smoking history significantly influenced sputum %
neutrophils, sputum IL-6 and IL-8 remained significantly elevated in COPD
patients after adjusting for both current smoking status and cumulative
smoking history in pack years. These markers may therefore be useful in further
characterizing COPD patients. In addition, we found that blood CRP and sputum
IL-8 were independently increased in COPD patients after adjusting for smoking
history, suggesting that pulmonary and systemic inflammation are independent
of each other in COPD.
There was a trend towards higher levels of sputum % neutrophils in ex-smoking
COPD subjects and healthy ex-smokers compared to COPD current smokers and
healthy current smokers. Increased airway inflammation has been reported
after smoking cessation in COPD patients, but not in healthy smokers. (275,
305] This suggests that in a proportion of subjects, cigarette smoking induces
an abnormal inflammatory response, which persists even after smoking
cessation. It was proposed that this was partly due to ongoing repair of smoking
related tissue damage. [275] But it raises the possibility of an autoimmune
(306) or infective (307] mechanism resulting in persistent inflammation in
susceptible smokers. Smoking cessation has nevertheless been associated with
a reduced rate of decline in FEVi in early COPD. (308] From our results it is not
possible to make conclusions about the effect of smoking status on markers of
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sputum inflammation due to small numbers in the healthy control groups. But it
is interesting that there was a trend towards higher sputum % neutrophils in
ex-smoking groups suggestive of ongoing airway inflammation in these patients,
even in the "healthy" ex-smoking group.
Additional factors influencing inflammation
Several factors may have influenced levels of inflammatory markers in addition
to COPD and smoking history. We found no difference in systemic inflammation
in men compared to women in the COPD group or the healthy controls, but
sputum neutrophils were higher in men in the cohort as a whole, which could be
explained by cumulative smoking history. However, each of the inflammatory
markers measured (except sputum % neutrophils and sputum IL-1P) remained
significantly elevated in COPD patients after controlling for gender and smoking
status. Results from the MONICA survey found significant gender differences in
systemic inflammation in response to smoking. (309) In this study peripheral
WCC was significantly associated with current smoking, number of cigarettes
smoked per day, smoking pack years and the duration of smoking in years in
men and women. CRP was also associated with these parameters in men. While
CRP was associated with smoking pack years in women, there was no
relationship between CRP and smoking status, number of cigarettes smoked per
day or the duration of smoking (years) in women. This group reported a
reduction in WCC and CRP after smoking cessation in men but not in women.
(309) This gender difference in levels of CRP and white blood cells adds to our
finding that levels of these markers were also differently affected by smoking
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history. This suggests that CRP and blood neutrophils may reflect different
systemic inflammatory pathways.
Inflammatory markers other than those measured may play an important role
in the inflammatory response in COPD. Circulating polymorphonuclear
neutrophils (PMNs) are increased in the circulation of smokers as a result of
chronic stimulation of the bone marrow. (310) Circulating 1L-6 stimulates bone
marrow to release leukocytes (311) and is associated with leukocyte
sequestration in the lung in animal models. (312, 313) In the MONICA III North
Glasgow study, IL-6 was increased in the circulation of current smokers,
whereas ex-smokers had similar levels to never smokers. This group also found
that IL-6 correlated significantly with blood leukocytes and fibrinogen. (314)
Pathways involving IL-6 may therefore be associated with neutrophilia and are
affected by smoking status. While we cannot substantiate these results, as IL-6
was not measured in blood in our subjects, it is interesting that induced sputum
levels of IL-6 and circulating CRP were independently increased in COPD after
adjusting for current smoking status.
Oxidative stress is another factor potentially linking smoking and inflammation.
One puff of cigarette smoke contains 1017 oxidant molecules. (315) However,
data linking oxidative stress to systemic inflammation show mixed results.
Systemic oxidative stress was increased in current smokers who had an
increased plasma oxidative burden and reduced levels of plasma antioxidants.
Thiobarbituric acid reactive substances (TBARS) were increased in smokers
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compared to non-smokers (316) and were associated with increased airflow
limitation. (317) However, although the Trolox-equivalent anti-oxidant capacity
(TEAC) of plasma was significantly lower in smokers than non-smokers, (318)
no relationship was found between TEAC and airflow limitation. (319)
Therefore, while current smoking is associated with an increased systemic
oxidative burden, the relationship between systemic oxidative stress and
airflow limitation remains unclear.
Bacterial load can influence airway inflammation in subjects with COPD.
Haemophilus influenza colonisation was associated with increased sputum
neutrophils, IL-1J3 and IL-12, but notwith IL-6 or IL-8 in patients with moderate
COPD. (320) A study of 30 COPD patients found that bacterial load and induced
sputum IL-8 were associated with the rate of decline in FEVi over a 12 month
period. (321) Bacterial load was not investigated in our cohort.
Inhaled corticosteroids may have influenced levels of sputum inflammation in
our COPD subjects, but several studies report no effect on sputum IL-8 in
response to inhaled corticosteroid use. (322-324) This is investigated further in
our COPD cohort in Chapter 4, but the use of inhaled corticosteroids was not
associated with the ability to produce sputum in our patients.
Induced sputum yield
Production of induced sputum in this cohort was low compared to other studies
(325-327) particularly in the control groups. Current smoking was associated
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with a higher yield of induced sputum samples as was a history of symptoms of
chronic bronchitis. The low yield of analyzed samples of induced sputum may in
part be due to a low threshold for discarding unsuitable samples. However,
other important factors may also be important. The low yield in COPD subjects
is partly because sputum induction was not attempted in those with a very low
post-bronchodilator FEVi (< 0.5 litre) (n=8). Most studies publishing data from
induced sputum samples are in small numbers of subjects. Many studies simply
do not comment on the yield of acceptable induced sputum samples (e.g.
O'Donnell and co-workers) (328) and therefore may include only those subjects
producing sputum. Some groups have overcome this problem by pre-selecting
patients for study based on their known ability to produce adequate samples of
induced sputum. (329) A study of similar design to ours had an even lower
sputum yield, reporting induced sputum IL-8 results for 43 of 148 stable COPD
subjects. In this study, spontaneous and induced sputum were both used for
analysis. (72)
A wide range of levels of inflammatory cytokines was seen in our "healthy"
controls. This may indicate that production of adequate induced sputum is not
"normal," but may be associated with underlying asymptomatic airway
inflammation. Snell and Newbold (330) question the ability of'healthy' and
therefore usually non-spontaneous sputum producers to produce a sample of
induced sputum. However, they quote an 80-90% sample yield from sputum
induction in their 'healthy subjects' overall. The two largest studies of induced
sputum in healthy controls, both ofwhich were designed to establish the normal
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variation in differential cell counts in healthy subjects, reported a yield of 81%
(n=118) and 84% (n=114) respectively. (326, 331) The first of these studies
used the same hypertonic saline nebulization protocol used in our cohort - 3%,
4% and 5% saline nebulized for 5 minutes each. (326) In this study, subjects
had a median induced sputum % neutrophils of 37%. This is much lower than in
our healthy subjects (median 77%) but the age of the healthy subjects in this
study was not mentioned and it was likely that subjects were much younger
than in our study. Spanevello and co-workers also reported a low median
percentage of induced sputum neutrophils (29%). They used a sputum
induction protocol comprising 4.5% nebulized saline for increasing time
periods - for 1, 2 4, 8 and 16 minutes. Again, the age of the cohort is not
reported, but that it had a "normal age distribution," and subjects are likely
therefore to be substantially younger than in our study. (331)
Numbers of induced sputum neutrophils increase with age. (332) While our
COPD patients were not age matched with healthy controls, this was taken into
account as a potential confounding factor in the logistic regression analysis. The
percentage of sputum neutrophils in our healthy subjects was consistent with
the 11 patients over 60 in the study by Thomas and co-workers, in which the
neutrophil differential was 68.5%, compared to 26.9% in those under 30. This
study also found that sputum neutrophil differential count does not continue to
increase after 50 years of age. (332) Another potential confounding factor is
inhaled corticosteroid use. The effect of inhaled corticosteroid use in our cohort
was further analyzed in Chapter 4, where we found that COPD patients taking
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inhaled corticosteroids did not have increased markers of blood or sputum
inflammation. Induced sputum neutrophil differential count in a previous study
was not affected by inhaled or oral corticosteroid use. (333)
Limitations
We had a low yield of induced sputum in this cohort. This has potential to
introduce bias. In addition, the stability and reproducibility of induced sputum
cytokine data is not clearly established. This would be particularly pertinent in
longitudinal analysis. A significant number of induced sputum cytokines were
below the limit of detection of the assay for IL-1(3 and IL-6. For this reason, work
to define a valid cut-off point for positive values for these cytokines in COPD
might be useful. However, as a proportion of values were below the limit of
detection it may simply mean that these markers are not useful in
differentiating between COPD patients and healthy controls. Caution should be
exercised with cut-off values used for sputum % neutrophils and IL-6 used in
the regression analysis as the 50th percentiles are different for COPD patients
and controls. An exclusion bias was implemented for COPD subjects (avoidance
of sputum induction in those with a low FEVi) for safety reasons. (334-336) Had
these patients produced sputum, it is likely that it would have served to
strengthen our finding that inflammation is increased in COPD, as published
work suggests that many inflammatory markers increase with the severity of
airflow limitation. (45, 46, 325) In addition, the detection of soluble mediators
may have been affected by the use of the mucolytic agent dithiothreitol (DTT).
While this agent improves cell yield by improving the homogenisation of
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induced sputum, the yield of soluble factors like cytokines may be reduced.
(337)
It would have been interesting to assess a larger selection of markers of
systemic inflammation. Blood levels of IL-1(3, IL-6 and IL-10 were analyzed in a
subset of 39 COPD patients and controls from this cohort. Of these only IL-6 was
significantly higher in COPD subjects (p=0.049). In the full cohort analysis,
blood leukocytes and highly sensitive C-reactive protein were chosen to
measure systemic inflammation due to their important association with
prognosis in COPD. (16, 95)
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Conclusion
Systemic and pulmonary inflammation was increased in COPD patients
compared to healthy controls after adjusting for age, gender, current smoking
status and smoking pack years. Induced sputum IL-ip was not increased in
COPD compared to controls. Induced sputum was not reliably attainable in
healthy control subjects. After adjusting for current smoking status and
smoking pack years, CRP and sputum IL-8 were significantly and independently
increased in COPD patients and may therefore be useful in the characterization
of subjects with COPD.
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CHAPTER 4: Pulmonary and systemic inflammation and
airflow limitation in COPD
Introduction
COPD is characterized by excessive inflammation in the lungs, (1, 2) but it is
accepted that in addition to abnormal inflammation in the lung parenchyma,
COPD is associated with a systemic inflammatory response. (19, 338) We have
shown an increase in both lung and systemic inflammation in COPD patients
compared to healthy subjects in Chapter 3. Several studies confirm that markers
of systemic inflammation such as numbers of blood neutrophils, blood white
cell count and CRP are increased in stable COPD compared to healthy subjects,
(46, 85, 339) but the cause of systemic inflammation in COPD is not known. One
hypothesis is that lung inflammation causes systemic inflammation by a "spill¬
over" effect. (338) Relatively few studies have investigated the relationship
between inflammatory markers in the systemic and pulmonary compartments
in the same cohort of COPD patients, and these studies are in small patient
numbers. (115,116, 340, 341) None of them found a direct association between
markers of pulmonary and systemic inflammation. It was therefore suggested
that pulmonary and systemic inflammation might be regulated independently.
(116) Indirect mechanisms linking pulmonary and systemic inflammation in
COPD have therefore been considered, including alterations in mechanisms
controlling degradation and repair and the hypothesis that COPD is an
autoimmune disease. (155, 342)
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Markers of systemic inflammation have been associated with disease severity
and prognosis in COPD independent of airflow limitation and smoking history.
(95] CRP and blood neutrophils are two of the most frequently assessed
markers of systemic inflammation in COPD populations. They have both been
consistently associated with all cause mortality and airflow limitation in
population studies. (5, 83-85] Both lung and blood neutrophil numbers have
been linked to airflow limitation and the rate of decline in FEVi. (44, 45, 96, 97]
Assays measuring low levels of (highly sensitive] CRP enable the investigation
of "resting" levels in chronic disease (343] and it is now established as a marker
of chronic inflammation with prognostic implications, not only in COPD. (16,
107]
Pulmonary markers of inflammation have been associated with airflow
limitation in COPD. Not only are neutrophils the predominant cells in the
airways in the early stages of COPD, they are also increasingly prevalent with
increasing severity of the disease. (46] In a meta-analysis of cross-sectional
studies in COPD, sputum neutrophils and IL-8 were the only sputum biomarkers
showing a trend to separation between stages of disease in COPD, with
inadequate data for sputum IL-6. (46]
This chapter investigates the relationship between markers of inflammation in
induced sputum and blood in a cohort of stable COPD patients. The hypotheses
are that pulmonary and systemic inflammatory markers will correlate
significantly with each other and with airflow limitation in stable COPD patients.
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Aims
In a cohort of stable COPD subjects:
1. To investigate the relationship between markers of inflammation in the
pulmonary and systemic compartments.
2. To investigate the relationship between pulmonary and systemic
inflammation and airflow limitation.
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Methods and data analysis
One hundred and eighty two COPD patients were recruited as described in
Chapter 2. Demographic data were compared for those with and without an
induced sputum sample. Continuous variables were compared using the
unpaired t-test (parametric] or Mann-Whitney U test [non-parametric].
Categorical variables were compared with the Chi-square test. Blood and
sputum inflammatory markers were correlated with each other and with post-
bronchodilator spirometry using Pearson's correlation (parametric] and
Spearman's correlation (non-parametric] co-efficients. The severity of airflow
limitation by GOLD stage was analyzed with the blood and sputum
inflammatory markers using ANOVA (parametric variables] or the Kruskall-
Wallis (non-parametric variables] test. Dunnett's T3 post-hoc test was used for
comparison between groups. Variables significantly associated with post-
bronchodilator FEVi (% predicted] in univariate analysis (p<0.1] were entered
into a multiple linear regression model. Sputum neutrophils were cubed for
analysis in the linear regression model in order to obtain a normal distribution
but were also analyzed in 2 categories: highest (> 89.6%] and lowest (< 89.6%]




In the cohort of 182 patients, mean post-bronchodilator FEVi was 50 ± 19%
predicted, post-bronchodilator FVC 79 ± 21% predicted, and FEVi/FVC ratio 48
± 13% predicted. GOLD stage ranged from I to IV (GOLD I n=13 (7%], GOLD II
n=70 (39%], GOLD III n=73 (40%], GOLD IV n=26 (14%]. Baseline data for
these patients is displayed in Table 4.1.
One hundred and nineteen subjects (65%] produced a sample of induced
sputum. Sputum induction was not attempted in 8 COPD subjects (4%] whose
baseline FEVi was < 0.5 litres. Subjects producing induced sputum had the same
degree of airflow limitation as those without induced sputum. Subjects able to
produce a sample of induced sputum reported a higher number of
exacerbations, poorer quality of life (SGRQ total score] and a higher percentage
had chronic bronchitic symptoms. There were significantly more current
smokers in this group although they had a lower cumulative smoking history in
pack years than subjects not producing an induced sputum sample. Systemic
markers of inflammation were the same for both groups (Table 4.2].
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Table 4.1. Clinical data for the COPD cohort is displayed. Data are presented as
number (%) for categorical variables, mean ± SD for parametric data, and
*median (IQR) for non-parametric data.
COPD subjects n=182
Age 68 ±8
Gender (% male) 112 (62%)
Smoking pack years 48 ±24
Taking inhaled corticosteroids (%) 121 (66%)
Taking statins (%) 23 (13%)
FEVi, post bronchodilator % predicted 50 ± 19
FVC, post bronchodilator% predicted 79 ±21
FEVi/FVC ratio, post bronchodilator 0.48 ±0.1
St Georges Respiratory Questionnaire (SGRQ) total score 51 ±20
Body mass index, kg/m2 26 ±6
Oxygen saturation, % 95 ±2
Annual exacerbation frequency 2 (1-3)*
MRC chronic bronchitis symptoms 83 (46%)
MRC dyspnoea score 3 (2-4)*
Blood white cell count, xl09/L 7.6 ± 2
Blood neutrophil count, xl09/L 4.9 ±2
Blood hsCRP, mg/L 3.8 (2-7)*
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Table 4.2. Clinical data are presented for subjects with and without induced
sputum samples. Results are presented as number (%] for categorical variables,
mean ± SD for parametric data and *median (IQR) for non-parametric data.
Groups are compared with the un-paired t-test, Mann-Whitney U test* or Chi-
square test.+
Induced sputum Induced sputum not
produced produced
(n=119) (n=63)
Age 67 ± 9 70 ± 7*
Gender (% male)* 77 [65%) 35 [56%)






Smoking pack years 43 ± 19 51 ± 26*
75 (63%) 46 (73%)
Taking statins (%)* 14 (12%) 9 (14%)
50 ±20 50 ±18
78 ±21 79 ±20
Post bronchodilator FEVi, %
predicted
Post bronchodilator FVC, %
predicted
Post bronchodilator FEVx/FVC 0 49 ± 0 1 0 48 ± 0 1
ratio
St Georges Respiratory ^ + ^
Questionnaire (SGRQ) total score
44 ± 20*
Body mass index, kg/m2 26 ± 5 25 ± 6
Oxygen saturation, % 96 ± 2 95 ± 2
Annual exacerbation frequency* 2 (1-3) 1 (0-2)*
61 (55%) 22 (39%)*
MRC dyspnoea score* 3 (2-4) 3 (2-4)
Blood white cell count, xl09/L 7.8 ±2 7.3 ± 2
Blood neutrophil count, xl09/L 5.0 ±2 4.6 ± 2
Blood hsCRP, mg/L* 3.9 (2-8) 3.3 (1-7)
* = p<0.05
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Systemic inflammatory markers were analyzed with airflow limitation,
measured by post-bronchodilator FEVi, FVC and FEVi/FVC ratio (Table 4.3).
Blood total white cell count and neutrophil count correlated significantly with
FEVi and FVC but not FEVi/FVC ratio. There was no correlation between CRP
and spirometric measures. The relationships between markers of lung
inflammation and post-bronchodilator spirometry are shown in Table 4.4.
Percentage neutrophils in sputum correlated inversely with FEVi and FEVi/FVC
ratio. There was also a negative association between sputum % neutrophils and
FVC (r=-0.198, p=0.051). IL-1(3, IL-6 and 1L-8 in induced sputum did not show
any significant correlations with spirometric values. Total blood white cell
count (p=0.044), neutrophil counts (p=0.012) and induced sputum %
neutrophils (p=0.002) increased with severity of COPD as assessed by the GOLD
stage (Figures 4.1 and 4.2).
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Table 4.3. Correlations between markers of systemic inflammation and post-
bronchodilator spirometry are displayed. Data are presented as Pearson's
correlation co-efficient [parametric data) or *Spearman's correlation co¬




White cell count, xl09/L -0.245 0.001
Neutrophils, xl09/L -0.267 <0.001
C-reactive protein, mg/L -0.117* 0.119
Post bronchodilator FVC,
% predicted
White cell count, xl09/L -0.248 0.001
Neutrophils, xl09/L -0.260 0.001
C-reactive protein, mg/L -0.110* 0.144
Post bronchodilator FEVi/FVC
ratio
White cell count, xl09/L -0.067 0.382
Neutrophils, xl09/L -0.082 0.283
C-reactive protein, mg/L -0.011* 0.884
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Table 4.4. Correlations between markers of inflammation in induced sputum
and post-bronchodilator spirometry are displayed. Data are presented as




Neutrophils, % -0.312 0.002
IL-ip, pg/ml -0.163 0.083
IL-6, pg/ml -0.019 0.840
IL-8, pg/ml -0.148 0.119
Post bronchodilator FVC,
% predicted
Neutrophils, % -0.198 0.051
IL-ip, pg/ml -0.067 0.483
IL-6, pg/ml -0.123 0.193
IL-8, pg/ml 0.031 0.745
FEVi/FVC ratio, post
bronchodilator
Neutrophils, % -0.255 0.011
IL-ip, pg/ml -0.096 0.309
IL-6, pg/ml -0.038 0.685
IL-8, pg/ml -0.100 0.294
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Figure 4.1. Box and whisker plot showing the relationship between blood
neutrophils and the severity of airflow limitation by GOLD stage in the COPD
cohort (p=0.012, ANOVA). There were no significant differences between
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GOLD stages: GOLD stage I (Mild): FEVi/FVC ratio < 70% predicted, FEVi% predicted > 80%
(n=13); GOLD stage II (Moderate): FEVi/FVC ratio < 70% predicted, FEVi% predicted 50-80%
(n=68); GOLD stage III (Severe): FEVi/FVC ratio < 70% predicted, FEVi% predicted 30-50%
(n=72); GOLD stage IV (Very Severe): FEVi/FVC ratio < 70% predicted, FEVi% predicted < 30%
(n=25)
Box plot values: The top of the box represents the 75th percentile, the bottom of the box
represents the 25th percentile, and central line represents the 50th percentile. The whiskers
represent the highest and lowest values that are not outliers or extreme values. Outliers
(between 1.5 and 3 times the interquartile range) are represented by circles (o) beyond the
whiskers. Extreme values (more than 3 times the interquartile range) are represented by stars
(*) beyond the whiskers.
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Figure 4.2. Box and whisker plot showing the relationship between induced
sputum % neutrophils and airflow limitation by GOLD stage in the COPD cohort
(p=0.002, Kruskall-Wallis). There were significant differences between GOLD





























GOLD stages: GOLD stage I (Mild): FEVi/FVC ratio < 70% predicted, FEVi% predicted > 80%
(n=13); GOLD stage II (Moderate): FEVi/FVC ratio < 70% predicted, FEVi% predicted 50-80%
(n=68); GOLD stage III (Severe): FEVi/FVC ratio < 70% predicted, FEVi% predicted 30-50%
(n=72); GOLD stage IV (Very Severe): FEVi/FVC ratio < 70% predicted, FEVi% predicted < 30%
(n=25)
Box plot values: The top of the box represents the 75th percentile, the bottom of the box
represents the 25th percentile, and central line represents the 50th percentile. The whiskers
represent the highest and lowest values that are not outliers or extreme values. Outliers
(between 1.5 and 3 times the interquartile range) are represented by circles (o) beyond the
whiskers. Extreme values (more than 3 times the interquartile range) are represented by stars
(*) beyond the whiskers.
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The relationship between induced sputum and blood inflammatory markers
was assessed (Table 4.5). Blood neutrophils and CRP correlated significantly
with each other (r=0.41, p<0.001). Sputum neutrophils were not significantly
associated with blood neutrophils (r=0.12, p=0.23) or CRP (r=0.15, p=0.15). The
sputum cytokines correlated significantly with each other (p<0.001) but only IL-
1(3 correlated with sputum % neutrophils (p<0.001). Blood inflammatory
markers showed no significant correlations with any of the induced sputum
inflammatory markers.
Table 4.5. Correlations between markers of inflammation in blood and induced
sputum are displayed. Data are presented as Spearman's correlation co-efficient











Blood hsCRP 0.408* ■■Sputum %
Neutrophils
0.124 0.148 k
Sputum IL-lp 0.145 0.088 0.403*
Sputum IL-6 0.091 -0.005 0.134 0.440*
Sputum IL-8 0.058 -0.078 0.173 0.438* 0.347*
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The cohort was analyzed according to inhaled corticosteroid [ICS] use (Table
4.6). 66% of patients were using ICS at the time of data collection.When divided
by severity of airflow limitation, 6 (46%) of GOLD stage I, 40 (57%) GOLD stage
II, 55 (75%) GOLD stage III, and 20 (77%) GOLD stage IV patients were on ICS
treatment. ICS use did not significantly affect the number of patients producing
an induced sputum sample and there was no significant difference in any of the
pulmonary inflammatory markers measured in patients using ICS compared to
those not using ICS, but CRP was significantly higher in patients using ICS in the
mild-moderate GOLD stage group (p=0.009).
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Table 4.6. Markers of inflammation in blood and sputum according to GOLD
stage and inhaled corticosteroid use (ICS). GOLD stages are divided into l-II
(mild-moderate) and III-1V (severe-very severe). Results are displayed as mean
± SD or *median (IQR). CRP was significantly higher in subjects taking ICS
therapy in the mild-moderate GOLD group (p=0.009).v
GOLD STAGE I and II III and IV
ICS Yes No Yes No
n=46 n=37 n=75 n=24
BLOOD
WCC, xl09/L 7.4 ±2 6.9 ±2 7.9 ± 2 8.3 ± 3
Neutrophils, xl09/L 4.5 ± 1 4.3 ± 2 5.1 ± 2 5.6 ± 3
CRP, mg/L* 4.8 (2-8)V 2.9 [1-5]v 3.3(2-8] 4.7(3-8]
SPUTUM
Neutrophils, %* 86(73-92] 79(62-93] 91 (84-95] 91 (80-95]
IL-l(f, pg/ml* 4.9(0-22] 5.5(0-26] 14(0-53] 7(0-106]
IL-6, pg/ml* 25 (0-47] 19(8-44] 46(6-88) 28(12-44)
IL-8, pg/ml* 392 (230-677) 394(257-876) 460(230-867) 579 (436-1164)
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Statin therapy was investigated in the cohort (Table 4.7). 23 patients (13%)
were taking statin therapy at the time of data collection. One patient (8%) in
GOLD stage 1,13 (23%) GOLD stage II, 5 (7%) GOLD stage III, and 4 (18%)
patients in GOLD stage IV were taking a statin. In the whole COPD cohort, there
was no significant difference in statin use when analyzed by COPD severity
according to GOLD stage (p=0.18, Pearson's Chi sq). There was no difference in
statin use between patients producing and not producing an induced sputum
sample, and there was no difference in any of the pulmonary or systemic
inflammatory markers measured in patients taking statins compared to those
not on statins. Statin use was therefore not included in the multiple regression
analysis. When divided according to COPD severity by GOLD stage, sputum %
neutrophils (p=0.023) were significantly higher in patients with mild-moderate
COPD (GOLD stages I and II) receiving statin therapy, but only 9 subjects
produced an induced sputum sample in this group.
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Table 4.7. Markers of inflammation in blood and sputum according to GOLD
stage and statin use. GOLD stages are divided into I-II (mild-moderate) and III-
IV (severe-very severe). Results are displayed as mean ± SD or *median (IQR).
Sputum neutrophils were significantly higher in subjects taking statin therapy
in the mild-moderate GOLD groups (p=0.023).v










WCC, xl09/L 7.3 ±2 7.1 ±2 8.9 ±4 7.9 ±2
Neutrophils,
xl09/L
4.8 ±1 4.4 ±1 6.1 ±3 5.2 ±2
CRP, mg/L* 4.8 (2-8) 2.9 (1-5) 3.3 (2-8) 4.7 (3-8)
SPUTUM
Neutrophils, %* 93 (88-95)v 79 (62-92)v 91 (90-94) 91 (83-95)
IL-1|3, pg/ml* 19 (2-37) 4 (0-20) 16(10-25) 11 (0-60)
IL-6, pg/ml* 39 (8-47) 19 (0-40) 15 (0-72) 36 (10-88)
IL-8, pg/ml* 596(207-737) 383 (253-743) 476 (229-1173) 479 (297-849)
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Multiple linear regression
The linear regression model (Table 4.8) shows that sputum % neutrophils and
blood neutrophils were independently associated with post-bronchodilator %
predicted FEVi after adjusting for age, gender, current smoking status and
inhaled corticosteroid use. Post-bronchodilator % predicted FEVi was
significantly lower in female subjects, those using inhaled corticosteroids, and in
subjects with higher blood neutrophils counts and higher sputum %
neutrophils.
Blood neutrophils (p=0.01) and sputum % neutrophils (p=0.001) remained
significantly and independently associated with post-bronchodilator %
predicted FEVi when the model was repeated with smoking pack years instead
of current smoking status (adjusted R square 0.183) and when sputum %
neutrophils were analyzed as a categorical variable in high and low 50th
percentiles. IL-ip was not associated with post-bronchodilator % predicted
FEVi after adjusting for potential confounding factors (p=0.1).
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Table 4.8. Multiple linear regression of sputum % neutrophils and blood
neutrophils with FEVi (post-bronchodilator % predicted] as the dependent
variable, adjusting for age, gender, current smoking status and inhaled
corticosteroid use.
B SE t P
Intercept 58.8 15.1 3.884 <0.001
Age -0.031 0.209 -0.146 0.884
Male sex 10.342 3.411 3.032 0.003
Current smoker 3.825 3.515 1.088 0.279
ICS -10.281 3.267 -3.147 0.002
Blood neutrophils -1.721 0.757 -2.275 0.025
Sputum neutrophils %
(cubed)
-1.83 x 10"5 <0.001 -2.917 0.004
R squared = 0.299 (Adjusted R Squared = 0.251), p<0.001




The aim of this chapter was to investigate the relationship between pulmonary
and systemic inflammation and the relationship of inflammatory markers to
airflow limitation in COPD. The markers of systemic inflammation (CRP and
neutrophils) correlated significantlywith each other, but neither was associated
with markers of pulmonary inflammation. Blood and sputum neutrophils were
independently associated with airflow limitation but did not correlate with each
other. Blood CRP and sputum cytokines were not related to airflow limitation in
this cohort. The strength of this study is in the investigation of both systemic
and pulmonary inflammation in the same COPD cohort, with adjustment for
potential confounding factors. The results show that neutrophilic inflammation
in the pulmonary and systemic compartments is associated with airflow
limitation, but suggest that pulmonary and systemic inflammation are not
directly related to each other.
This is the first study to investigate these inflammatory markers in the lung and
circulation in the same cohort of COPD patients. Neutrophils increased with the
severity of airflow limitation in both the pulmonary and systemic
compartments. Blood and sputum neutrophils both correlated with post-
bronchodilator FEVi (r=0.261 and r=0.311 respectively). This is consistent with
the existing literature, which shows that numbers of neutrophils in the small
airways (250) and induced sputum (45, 325) increase with the severity of
airflow limitation in COPD. However, contrary to expectation, levels of blood
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and sputum neutrophils did not correlate significantly with each other.
Therefore, although they were both associated with the severity of airflow
limitation, they were independent of each other, suggesting that they are not
causally related. In fact, although they correlated significantly with each other,
none of the sputum markers correlated significantly with either of the systemic
inflammatory markers that were measured.
The ability of pulmonary inflammation to induce a systemic inflammatory
response has been reported. For example, a systemic response has been elicited
in response to the inhalation of noxious particles like diesel exhaust fumes.
(108,114] However, a lack of correlation between lung and systemic markers
has previously been reported in COPD. Vernooy and co-workers found no
relationship between blood and sputum levels of soluble TNFa, although the
cohort that was studied was small (n=18). (116) Bizeto and co-workers also
investigated blood and sputum markers of inflammation in a small cohort
(n=20) and found that sputum neutrophils increased with the severity of
airflow limitation but CRP showed no relationship with COPD severity. (115]
Another UK study found no relationship between blood and sputum markers -
circulating fibrinogen and sputum IL-6 - in stable COPD patients. (72] Our data
concur with these results, which suggest that there is not a direct relationship
between pulmonary and systemic inflammation in COPD. The hypothesis that
there is an overflow of inflammatory mediators from the lung into the systemic
compartment (82] in COPD is not supported by these results. Other mechanisms
linking systemic and pulmonary inflammation in COPD have been considered.
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Possible candidates include systemic hypoxia, (344) genetic factors and
autoimmune mechanisms. (306) However, there is a lot of variability in the data
and the sample sizes in our study are small.
It is interesting that CRP, unlike blood leukocytes, was not related to the
severity of airflow limitation in this cohort, and yet CRP was significantly
increased in COPD patients compared to healthy controls (see Chapter 3). Blood
neutrophils and CRP were only moderately correlated with each other,
suggesting that the increase in these markers in COPD may derive from
different mechanisms. While this may be partly due to the effects of cigarette
smoking (which was significantly associated with increased levels of blood and
sputum neutrophils), neutrophils in blood and sputum were significantly
associated with the severity of airflow limitation independently of current
smoking status or smoking pack years. The cause of systemic inflammation in
COPD has not been determined. But the presence of systemic inflammation in
COPD has been associated with poor prognosis and has been linked to clinical
phenotypes such cachexia, as well as cardiovascular disease and osteoporosis.
(82) Our results suggest that CRP and blood neutrophils may each have a role in
characterizing COPD with regard to disease stage and prognosis, but this would
need further investigation in longitudinal studies. Further investigation of
clinical features such as exacerbation frequency and oxygenation may further
elucidate factors influencing the presence of systemic inflammation in COPD.
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Sputum cytokines were not related to airflow limitation in this cohort. More
current smokers produced an induced sputum sample, which may have
influenced the results but was not significantly associated with airflow
limitation in multiple regression analysis. We found no difference in sputum
markers between COPD current and ex-smokers. In fact contrary to expectation
current smokers had a trend towards lower levels of induced sputum %
neutrophils. The lack of association seen between sputum cytokines and lung
function in our cohort is in contrast to results from smaller studies. Keatings
and co-workers found that sputum IL-8 and neutrophils were increased in
COPD patients compared to healthy smokers (n=14), and Yamamoto and co¬
workers found that IL-8 levels increased with the severity of airflow limitation
(n=33). (75, 281) It is likely that the variability in detectable levels of cytokines
contributed to the disparity of results found between our results and those from
smaller studies. And yet, despite a low yield of induced sputum, we analyzed
sputum from 119 COPD patients, which is a substantially greater sample size.
Airflow limitation represents only one method ofmeasuring disease severity in
COPD. This is recognized in the combined European Respiratory Society and
American Thoracic Society COPD guidelines. (2) It may be that sputum
cytokines may reflect a different aspect of disease severity in COPD and may
have a role in differentiating clinical phenotypes such as frequent exacerbators
and those with cachexia in the COPD population.
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Limitations
Our data suggested that pulmonary and systemic inflammation were
independent of each other in COPD. However, induced sputum is thought to
mainly be representative of inflammation in the larger airways and may not
closely represent inflammation in the distal airspaces or lung parenchyma.
(345} A percentage of patients were unable to produce an acceptable induced
sputum sample. Successful sputum induction is not always possible, particularly
in patients with more severe COPD. (175) It is likely that patients with more
severe airflow limitation would have increased levels of sputum inflammation,
which would serve to strengthen our results.
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Conclusion
Neutrophils in blood and induced sputum were independently related to the
severity of airflow limitation in COPD. Systemic inflammatory markers (CRP and
neutrophils] were associated with each other but not with airflow limitation.
Blood markers did not correlate with sputum markers of inflammation. These
findings suggest that lung and systemic inflammation may be regulated
independently in COPD.
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CHAPTER 5: Inflammation and clinical phenotypes associated
with prognosis in COPD
Introduction
COPD is defined in terms of FEVi for the purpose of diagnosis and treatment.
But FEVi does not capture all aspects of COPD and in particular, does not reflect
the systemic features of the disease. [2) Additional variables have been used to
better describe COPD and it's functional and phenotypic heterogeneity. Many of
these factors have been used as outcome measures, or are associated with
outcome measures in COPD. (346) Examples include measurement of health
related quality of life using the St George's Respiratory Questionnaire (SGRQ),
MRC dyspnoea score, body mass index (BMI), exacerbation frequency and
measurement of oxygenation (using either the partial arterial pressure of
oxygen or haemoglobin oxygen saturation). In addition to providing useful
endpoints in COPD studies, some of these measures used to describe COPD may
relate to different sub-types or phenotypes within the COPD population. Some
of these features relate to outcomes better than FEVi alone. For example, low
BMI has been associated with prognosis in COPD (347) and frequent
exacerbations in COPD subjects have been associated with a faster rate of
decline in FEVi. (139)
Inflammation is central to the definition of COPD (2) and is postulated to
provide a mechanistic link between COPD and some of its systemic effects and
co-morbidities. (276) If this is the case, it is likely that markers of inflammation
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will be associated with some of the features of COPD associated with outcome
measures other than FEVi. To investigate this hypothesis, the following
outcome measures were selected for investigation of their association with
markers of pulmonary and systemic inflammation in a stable COPD population.
St George's Respiratory Questionnaire
Quality of life measures have been linked to prognosis in COPD and are often
utilized as outcome measures in clinical trials. (6,124) Numerous
questionnaires exist to measure quality of life in patients with respiratory
disease. One of the best known is the St George's Respiratory Questionnaire
(SGRQ). SGRQ is a validated tool for assessing the impact of COPD on health
related quality of life (129) and has been identified as an important predictor of
mortality in COPD. (124) The SGRQ is composed of three domains: symptoms,
activity and the impact of COPD on quality of life. These are combined as a total
score, which is the mean of the three subcategories. Subcategory scores range
from 0-100, with higher scores representing greater impairment. A difference of
4 points is considered a clinically significant difference. (258)
MRC dyspnoea score
Dyspnoea is a complex subjective sensation, which is relevant to the assessment
of cardiac and respiratory disease. (348) The MRC dyspnoea score was
developed in the 1940's when questions were devised to quantify
breathlessness in Welsh coalminers with pneumoconiosis. By the 1950's it was
established in clinical practice and for research purposes. (349) It comprises 5
simple categories which ask a patient to define the presence of dyspnoea
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according to the activity level at which it is experienced. The MRC dyspnoea
score is now regarded as an important clinical endpoint, which is independently
associated with all cause mortality, not only in COPD patients. (95) In the
assessment of COPD, it has been incorporated in the BODE index due to it's
importance as an independent prognostic indicator. (118) The MRC dyspnoea
score correlates poorly with FEVi and as such may provide important additional
information on functional status in COPD. (122)
Body mass index
A number of COPD patients experience significant loss of body mass in
association with progression of disease. Loss of body mass has a number of
associated clinical features, including low fat free mass (a surrogate for skeletal
muscle mass), skeletal muscle dysfunction, exercise intolerance and lower limb
muscle weakness. (90) Low body mass index and fat free mass are independent
predictors of mortality in COPD and this association is stronger in more severe
COPD. (15,159,160) Multi-dimensional staging systems using clinical features
like BMI and dyspnoea have been shown to improve the prediction of prognosis
in COPD. (347)
Exacerbation frequency
Frequent exacerbations of COPD are associated with reduced quality of life,
(134) increased hospitalization, morbidity and mortality and a faster decline in
lung function. (135-139, 350, 351) Reducing exacerbation frequency is a
therapeutic target in COPD and frequency of exacerbations is increasingly used
as an endpoint in clinical trials. (6,141) The annual number of exacerbations
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varies between COPD patients. A median annual exacerbation frequency of 2.5
per year is typical in COPD populations. (71,139) Exacerbation frequency
recorded in the first year is highly correlated with exacerbation frequency in
subsequent years in individual subjects. (139) The "frequent exacerbator"
constitutes a recognized clinical phenotype in COPD, meanwhile a significant
proportion of COPD patients with the opposite "phenotype" experience no
exacerbations in an average year. (6) Due to its association with prognosis in
COPD, exacerbation frequency has been incorporated in the DOSE
multidimensional scoring system and is associated with hospital admissions
and respiratory failure. (352)
Hypoxia
Hypoxia is associated with prognosis in COPD (46) and can be measured
reliably and non-invasively by pulse oximetry. (353) Oxygen supplementation is
one of the few therapeutic measures known to improve survival in COPD. (161,
162) In addition to improving pulmonary vascular resistance and
polycythaemia; (161) exercise capacity, dyspnoea and sleep consolidation may
also be improved with oxygen therapy. (163) Hypoxia is more common in
severe COPD, and yet it does not develop in all patients with severe airflow
limitation. Chronic hypoxaemia increases mortality at any stage of the disease.
(354)
BODE index
A number of multi-dimensional scoring indices have been developed in order to
better reflect the multi-system effects of COPD. The best known of these is the
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Body mass index, airflow Obstruction, Dyspnoea and Exercise capacity Index
(BODE). (122) The BODE index is a better predictor ofmortality in COPD than
FEVi alone. (122)
In this chapter, the validated quality of life measure SGRQ, the MRC dyspnoea
score and the pulmonary and systemic features of COPD measured by body
mass index, exacerbation frequency, oxygenation and the BODE index will be
explored in relation to markers of systemic and pulmonary inflammation in a
cohort of COPD patients. These features have been chosen due to their known
association with prognosis in COPD. The hypothesis is that these features will be




To investigate the associations between pulmonary and systemic inflammation
in a cohort of stable COPD subjects and the following clinical parameters:
1. Quality of life and dyspnoea





Methods and data analysis
182 COPD patients were recruited as described in Chapter 2. Inflammatory
markers in blood and induced sputum were analyzed with clinical features in
the recruited COPD cohort. SGRQ total scores were analyzed with inflammatory
markers using the Pearson's or Spearman's correlation co-efficients. SGRQ total
score was then categorized in quartiles for further analysis. Groups were
compared with the Kruskall Wallis test with Mann-Whitney post hoc analysis
(abnormally distributed variables] or ANOVA with the Bonferroni post hoc test
(normally distributed variables]. The MRC dyspnoea score was categorized into
3 groups for analysis. Dyspnoea scores were grouped together as 1-2, 3 and 4-5
to obtain equal numbers between groups for comparison. Body mass index,
exacerbation frequency and oxygen saturations were categorized for analysis.
BMI was categorized into 2 groups (< 21kg/m2 and >21kg/m2]. This division is
utilized in the BODE index as an inflection in survival has been shown to occur
in COPD patients with a BMI of < 21kg/m2. (118] Oxygen saturation was
categorized using a cut-off of < 93%. Pulse oximetry Sa02 < 92% effectively
represents systemic hypoxia (sensitivity 100%, specificity 86%] compared to
measurement by arterial blood gas analysis. (355] A cut-off of < 93% was
chosen in this study to give large enough numbers for comparison in each
group. 25 patients had Sa02 < 93%. In patients with induced sputum for
analysis, 14 subjects had Sa02 < 93% whereas only 7 subjects with Sa02 < 92%
had induced sputum for analysis. Exacerbation frequency was dichotomized
into < 2 exacerbations per year and > 2 exacerbations per year. Other groups
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have utilized this cut-off. (71) BODE index total scores, which followed a normal
distribution, were analyzed with inflammatory markers using Pearson's and
Spearman's correlation co-efficients.
Statistically significant factors in the univariate analysis were analyzed using
multiple regression models. SGRQ total score was investigated with multiple
linear regression. Exacerbation frequency, BMI and oxygen saturations were
analyzed in binary logistic regression models using the above categories. MRC
dyspnoea score was also analyzed using binary logistic regression, with subjects
categorized into scores of < 2 or > 2 in order to obtain approximately equal
numbers between groups. Age, gender and height were not included separately




Baseline data for the cohort of 182 COPD patients is shown in Table 5.1.
Table 5.1. Clinical data for the COPD cohort. Data are presented as number (%)




Gender (% male) 112 [62%)
Smoking pack years 48 ± 24
Inhaled corticosteroids (% taking inhaled steroids) 121 [66%)
FEVi, post bronchodilator % predicted 50 ±19
FVC, post bronchodilator % predicted 79 + 21
FEVi/FVC ratio, post bronchodilator 0.48 ± 0.1
St Georges Respiratory Questionnaire (SGRQ) total score 51 ±20
SGRQ impact 38 ±22
SGRQ symptoms 62 ±21
SGRQ activity 66 ±24
Body mass index, kg/m2 26 ±6
Oxygen saturation, % 95 ±2
Annual exacerbation frequency 2 [1-3)*
MRC chronic bronchitis symptoms 83 (46%)
MRC dyspnoea score 3 (2-4)*
6 minute walking distance, m 63 ± 38
BODE index 6.4 ± 2
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Health related quality of life: SGRQ
The SGRQ total score was available for 179 patients. Baseline data are shown in
Table 5.2. There was no significant difference in age, gender, inhaled
corticosteroid use or smoking pack year history when analyzed according to
SGRQ total score in quartiles. Inhaled corticosteroid treatment was significantly
associated with a poorer SGRQ symptoms score (p=0.048) but notwith the
other domains, but there was a trend towards a greater ICS use with worsening
SGRQ symptoms, activity and impact domains (p<0.1). Patients with poorer
quality of life were significantly more likely to be current smokers, had
significantly increased airflow limitation and were more likely to be able to
produce a sample of induced sputum. Correlations between SGRQ total score
and markers of blood and sputum inflammation are shown in Table 5.3. SGRQ
symptoms, activity and impact domains were also analyzed with the sputum
and blood markers. All domains of SGRQ were associated with blood leukocytes
and CRP, but not with sputum neutrophils or cytokines. The association
between SGRQ in quartiles and blood neutrophils and CRP are shown in Figures
5.1 and 5.2.
Blood neutrophils and CRP were investigated with SGRQ total score using linear
regression to adjust for confounding factors (Tables 5.4 and 5.5). Blood
neutrophils were significantly associated with SGRQ total score independent of
smoking status, induced sputum production and post-bronchodilator%
predicted FEVi. This significance remained when the model was repeated with
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smoking pack years instead of current smoking status (blood neutrophils
p=0.019). Log CRP was significantly associated with SGRQ total score
independent of smoking status, induced sputum production and post-
bronchodilator % predicted FEVi. This significance remained when the model
was repeated with smoking pack years instead of current smoking status (log
CRP p<0.001). There was a stronger association between SGRQ total score and
log CRP (adjusted R sq 0.356] than with blood neutrophils (adjusted R sq
0.271). But when included in the model together, CRP and blood neutrophils
were not independently associated with SGRQ.
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Table 5.2. Baseline characteristics of the COPD cohort categorized by St George's
Respiratory Questionnaire total score (quartiles I-IV from lowest to highest) are
displayed. Cut-points for each quartile are 0-33.6 (I), 33.7-51.5 (II), 51.6-65.6
(III), 65.7-100 (IV). Data are presented as number (%) for categorical variables
and mean ± SD for continuous variables. Significance between groups taken at
p<0.008 using ANOVA and Dunnett's T3 post hoc test for continuous variables
and Pearson's Chi squared test for categorical variables.
SGRQ total score (quartiles) I II III IV P
n=45 n=45 n=45 IIG
Age 68 ± 10 68 ±7 68 ±8 68 ±8 0.976
Gender, % male 30 (67%) 26 (58%) 28 (62%) 27 (61%) 0.858
Current smokers 10 (22%) 15 (33%) 22 (49%) 20 (45%) 0.002
Smoking pack years 40 ± 18 48 ±26 51 ±26 54 ±24* 0.027















Post bronchodilator FEVi/FVC 0.53 ± 0.1 0.51 ± 0.1 0.46 ± 0.1 0.43 ±0.1* 0.001
Induced sputum produced 21 (47%) 31 (69%) 33 (73%) 33 (75%) 0.016
* = significantly different from quartile I.
v
= significantly different from quartile II.
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Table 5.3. Correlations between St George's Respiratory Questionnaire total
scores and markers of pulmonary and systemic inflammation in the COPD
cohort. Data are presented as Pearson's* (parametric data) or Spearman's
correlation (non-parametric data) co-efficients.
SGRQ total score Correlation P
White cell count, xl09/L* 0.339* <0.001
Blood neutrophils, xlO'/L* 0.306* <0.001
C-reactive protein, mg/L 0.323 <0.001
Sputum neutrophils, % -0.032 0.753
Sputum IL-ip, pg/ml -0.023 0.810
Sputum IL-6, pg/ml 0.000 0.996
Sputum IL-8, pg/ml -0.018 0.848
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Figure 5.1. Box and whisker plot showing the relationship between blood
neutrophils and St George's Respiratory Questionnaire total score in quartiles in
the COPD cohort (p<0.001). Patients in the highest quartile report the poorest
quality of life. In the post-hoc analysis, significant differences existed between
quartiles 1 and 3 (p=0.003), and 1 and 4 (p=0.002).
qj 1 1 1 1
Q1 Q2 Q3 Q4
SGRQ total (quartiles)
Box plot values: The top of the box represents the 75th percentile, the bottom of the box
represents the 25th percentile, and central line represents the 50th percentile. The whiskers
represent the highest and lowest values that are not outliers or extreme values. Outliers
(between 1.5 and 3 times the interquartile range) are represented by circles (o) beyond the
whiskers. Extreme values (more than 3 times the interquartile range) are represented by stars
(*) beyond the whiskers.
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Figure 5.2. Box and whisker plot showing the relationship between highly
sensitive C-reactive protein and St George's Respiratory Questionnaire total
score in quartiles in COPD patients (p<0.001). Patients in the highest quartile
report the poorest quality of life. In the post-hoc analysis significant differences




















SGRQ total score (quartiles)
* * M
Q1 Q2 Q3 Q4
Outlier in quartile 4: CRP value=136.
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Table 5.4. Multiple linear regression of blood neutrophils with SGRQ total score
as the dependent variable, adjusting for current smoking status, induced
sputum production and post-bronchodilator % predicted FEVi.
B SE t P
Intercept 59.7 8.454 7.056 <0.001
FEVi post-bronchodilator
% predicted
-0.396 0.072 -5.509 <0.001
Induced sputum produced 7.481 2.774 2.697 0.008
Current smoker 6.209 2.666 2.329 0.021
Blood neutrophils 1.723 0.700 2.461 0.015
R squared = 0.288 (Adjusted R Squared = 0.271), p<0.001
Table 5.5. Multiple linear regression of CRP with SGRQ total score as the
dependent variable, adjusting for current smoking status, induced sputum
production and post-bronchodilator % predicted FEVi.
B SE t P
FEVi (post-bronchodilator
% predicted)
-0.478 0.067 -7.105 <0.001
Log CRP 4.397 1.135 3.874 <0.001
Induced sputum produced 7.734 2.685 2.880 0.004
Intercept 37.4 13.5 2.777 0.006
Current smoker 7.535 2.753 2.737 0.007
R squared = 0.378 (Adjusted R Squared = 0.356), p<0.001
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Dyspnoea
MRC dyspnoea scores were available for 180 COPD patients. Subjects were
categorized into groups according to the MRC dyspnoea score: 1-2 (n=71), 3
(n=46), and 4-5 (n=63). Baseline data are shown in Table 5.6. There was no
significant difference in age, gender, smoking status, smoking pack years,
inhaled corticosteroid use or in the number of patients producing a sample of
induced sputum when analyzed according to MRC dyspnoea score. There was a
significant association between increased dyspnoea and increased airflow
limitation measured by post bronchodilator FEVi and FVC % predicted and
FEVi/FVC ratio.
Increased MRC dyspnoea score was associated with increased systemic
inflammation measured by blood leukocytes and CRP. There was no
relationship between dyspnoea and induced sputum markers of inflammation
(Table 5.7). Box and whisker plots showing the relationship between MRC
dyspnoea score and blood neutrophils and CRP are shown in Figures 5.3 and
5.4.
Binary logistic regression models of blood neutrophils and CRP with MRC
dyspnoea score are shown in Table 5.8. Blood neutrophils (p=0.005) and CRP
(p=0.003) were significantly associated with MRC dyspnoea score independent
of smoking pack years and FEVi but blood neutrophils were not associated with
MRC dyspnoea score independently of CRP.
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Table 5.6. Baseline characteristics of the COPD cohort are shown when
categorized by MRC dyspnoea score. Data are presented as number (%) for
categorical variables and mean ± SD for continuous variables. Significance
between groups taken at p<0.017 using ANOVA and Dunnett's T3 post hoc test
for continuous variables and Pearson's Chi squared test for categorical
variables.
MRC dyspnoea score 1-2 3 4-5 P
n=71 n=46 n =63
Age 67 ±9 68 ±6 69 ±8 0.128
Gender, % male 43 (61%) 26 (57%) 41 (65%) 0.659
Current smokers 24 (34%) 18 (39%) 26 (41%) 0.826
Smoking pack years 43 ± 19 48 ±24 54 ±28 0.030
Inhaled corticosteroids 42 (59%) 34 (74%) 45 (71%) 0.171
Post bronchodilator predicted FEVi, % 60 ± 18 45 ± 15* 41 ± 16* <0.001
Post bronchodilator predicted FVC, % 89 ±20 75 ± 18* 70 ± 20* <0.001
Post bronchodilator FEVi/FVC 0.53 ± 0.1 0.47 ± 0.1 0.45 ±0.1* 0.001
Induced sputum produced 48 (68%) 52 (52%) 73 (73%) 0.069
* = significantly different from MRC dyspnoea score 1-2.
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Table 5.7. Pulmonary and systemic inflammatory markers are displayed
according to the different categories of MRC dyspnoea score in the COPD cohort.
Results are presented as mean ± SD* or median [IQR]. Higher MRC dyspnoea
scores indicate more breathlessness.
MRC dypnoea score 1-2 3 4-5 P
n=71 v£>IIC n=63
sputum n=47 sputum n=23 sputum n=43
White cell count, xl09/L* 6.9 + 2 7.7 ±2 8.4 + 3 0.001
Blood neutrophils, xl09/L* 4.2 ±1 5.0 ±2 5.6 ±3 <0.001
C-reactive protein, mg/L 2.8 (1-5] 4.5 (2-7] 6.0 (2-9] 0.002
Sputum neutrophils, % 88(76-92] 90 (80-96] 92 (74-95] 0.163
Sputum IL-ip, pg/ml 4 (0-16] 15 (0-42] 14 (0-66] 0.103
Sputum IL-6, pg/ml 28 (10-60] 20 (0-47] 27 (0-94] 0.611
Sputum IL-8, pg/ml 451 (316-781] 526 (271-850] 451 (213-885) 0.805
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Figure 5.3. Box and whisker plot showing the relationship between blood
neutrophils and MRC dyspnoea score in the COPD cohort (p<0.001). In the post-
hoc analysis, there was a significant difference between groups 1-2 and 3

























Figure 5.4. Box and whisker plot showing the relationship between highly
sensitive C-reactive protein and MRC dyspnoea score in the COPD cohort
(p=0.002). Statistically significant differences existed between groups in the




















Outlier for subject with MRC dyspnoea score level 5, CRP value = 136.
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Table 5.8. Binary logistic regression of blood neutrophils with MRC dyspnoea
score (< 2 or > 2) as the outcome variable, adjusting for smoking pack years and
post-bronchodilator % predicted FEVi.




-0.060 0.012 1 23.40 <0.001 0.942
Log CRP 0.452 0.198 1 5.184 0.023 1.571
Blood neutrophils 0.257 0.140 1 3.365 0.067 1.293
Smoking pack years 0.013 0.009 1 2.041 0.153 1.013
Intercept 1.199 1.006 1 1.422 0.233 3.317
-2 Log likelihood 169.0 (Cox % Sneli R Square 0.280, Nagelkerke R square 0.380], p<0.001
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Body mass index
Baseline characteristics and inflammatory markers for the COPD cohort
according to body mass index are shown in Table 5.9. BMI was available for 181
patients. There was no significant difference in age, gender, inhaled
corticosteroid use, statin use or in the frequency of induced sputum samples
produced between COPD patients with a BMI < 21kg/m2 compared to subjects
with a BMI > 21kg/m2. Although there was no difference in smoking pack years
between the groups, there were significantly more current smokers in the low
BMI group (p<0.001). These patients also had a significantly lower post-
bronchodilator FEVi % predicted and FEVi/FVC ratio. BMI < 21kg/m2 was
associated with significantly higher sputum neutrophils and IL-6 (Figures 5 and
6). There was no significant association between BMI and sputum IL-lp
(p=0.07] orIL-8 (p=0.08).
A binary regression model was used to investigate sputum % neutrophils and
sputum IL-6 with BMI adjusting for potential confounding factors (Table 5.10].
Sputum % neutrophils (p=0.042] but not IL-6 (p=0.058] were significantly
associated with BMI after adjusting for current smoking status, but neither were
significantly associated with BMI after adjusting for FEVi.
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Table 5.9. Baseline characteristics and markers of inflammation for the COPD
cohort are shown according to body mass index (low < 21kg/m2, normal/high >
21kg/m2). Data are presented as number (%] for categorical variables, mean ±
SD for parametric variables and median (IQR]* for non-parametric variables.
Groups were compared using the Chi-squared test (categorical], t-test
(parametric] and Mann-Whitney U test (non-parametric].* Significance is taken
at the p<0.05 level.
Body Mass index < 21kg/m2 > 21kg/m2 P
n=46 n=135
sputum n=21 sputum n=94
Age 67 ±7 68 ±8 0.370
Gender, % male 24 (52%) 87 (64%) 0.162
Current smokers 28 (61%) 39 (29%) <0.001
Smoking pack years 46 ±2 49 ± 3 0.467
Inhaled corticosteroids 29 (63%) 91 (67%) 0.593
Post bronchodilator predicted FEVi, % 42 ±2 53 ±2 0.001
Post bronchodilator predicted FVC, % 76 ±2 80 ±2 0.315
Post bronchodilator FEVi/FVC 0.43 ± 0.1 0.5 ±0.1 0.001
Induced sputum produced 29 (63%) 90 (67%) 0.720
White cell count, xl09/L 7.9 ±3 7.5 ±2 0.410
Blood neutrophils, xl09/L 5.3 ±3 4.8 ±2 0.154
C-reactive protein, mg/L* 3.6 (2-6) 4.0 (2-7) 0.375
Sputum neutrophils, %* 95 (80-97) 88 (76-93) 0.020
Sputum IL-ip, pg/ml* 29 (0-81) 7 (0-28) 0.211
Sputum IL-6, pg/ml* 48 (19-93) 22(0-53) 0.023
Sputum IL-8, pg/ml* 481 (416-756) 431 (241-843) 0.453
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Figure 5.5. Box and whisker plot showing the relationship between induced
sputum neutrophils (%) and BMI in the COPD cohort. BMI < 21kg/m2 (n=21],
BMI > 21kg/m2 (n=94), p=0.02.
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Figure 5.6. Box and whisker plot showing the relationship between BMI and






















Body mass index (kg/m2)
151
Table 5.10. Binary logistic regression of sputum % neutrophils and sputum IL-6
with BMI (>21 kg/m2] as the outcome variable, adjusting for current smoking
status and post-bronchodilator% predicted FEVi.
B SE df Wald P Exp (B)
Current smoker -1.683 0.673 1 6.3 0.012 0.186
Intercept 4.854 1.95 1 6.2 0.013 128.2
Sputum %
neutrophils, xlO3
0.0001 0.0001 1 2.5 0.116 1.000
Sputum IL-6 -1.010 0.647 1 2.4 0.118 0.364
FEVi
post-bronchodilator
0.022 0.021 1 1.1 0.285 1.000
% predicted
-2 Log likelihood 71.7 (Cox % Snell R Square 0.139, Nageikerke R square 0.232), p<0.001
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Exacerbations
Baseline data and markers of inflammation according to exacerbation frequency
are shown in Table 5.11. 20% of patients in this cohort reported no
exacerbations in the previous 12 months (n=35). There was no difference in
gender, smoking status or smoking pack years when analyzed according to
exacerbation frequency. COPD patients with > 2 exacerbations per year were
significantly younger, were more likely to be taking inhaled corticosteroids, and
were more likely to have produced a sample of induced sputum. 114 patients
produced induced sputum samples. 70 of these had < 2 exacerbations per year
(comprising 40% of the full cohort and 62% of sputum producers). 44 patients
producing induced sputum had > 2 exacerbations per year (comprising 25% of
the full cohort and 38% of sputum producers). Patients experiencing > 2
exacerbations per year had significantly lower post-bronchodilator FEVi and
FVC % predicted and a lower FEVi/FVC ratio.
Increased blood white cell count was significantly associated with > 2
exacerbations per year (p=0.01) and there was a trend towards an association
between blood neutrophils and exacerbation frequency, which did not achieve
statistical significance (p=0.06). Induced sputum 1L-6 was significantly
increased in COPD patients with > 2 exacerbations per year (Figure 5.7). In
binary logistic regression analysis total WCC, blood neutrophils and sputum IL-
6 were not associated with exacerbation frequency after adjusting for FEVi
(Tables 5.12 and 5.13).
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Table 5.11. Baseline characteristics and inflammatory markers in the COPD
cohort categorized according to exacerbation frequency (< 2 and > 2 per year).
Data are presented as number (%) for categorical variables, mean ± SD for
parametric variables and median (IQR)* for non-parametric variables. Groups
were compared using the Chi-squared test (categorical), t-test (parametric) and
Mann-Whitney U test (non-parametric).* Significance is taken at the p<0.05
level.
Exacerbation frequency <2 >2 P
n=122 n=60
sputum n=73 sputum n=46
Age 69 ±8 66 ±8 0.012
Gender, % male 75 (61%) 37 (62%) 1.00
Current smokers 43 (35%) 25 (42%) 0.424
Smoking pack years 48 ±24 48 ±24 0.886
Inhaled corticosteroids 75 (61%) 46 (77%) 0.046
Post bronchodilator predicted FEVi, % 53 ± 19 43 ± 18 0.001
Post bronchodilator predicted FVC, % 82 ±20 71 ± 20 <0.001
Post bronchodilator FEVi/FVC 0.50 ±0.1 0.46 ±0.1 0.084
Induced sputum produced 73 (60%) 46 (77%) 0.031
White cell count, xl09/L 7.3 ±2 8.3 ±3 0.011
Blood neutrophils, xl09/L 4.7 ±2 5.4 + 2 0.055
C-reactive protein, mg/L* 3.7 (2-6) 4.9 (2-10) 0.107
Sputum neutrophils, %* 90 (76-94) 89 [77-95) 0.986
Sputum IL-lp, pg/ml* 7 (0-31) 11 (0-91) 0.262
Sputum IL-6, pg/ml* 16 (0-47) 40 (8-109) 0.018
Sputum IL-8, pg/ml* 436(268-783) 478 (242-971) 0.648
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Figure 5.7. Box and whisker plot showing the relationship between induced
sputum IL-6 levels and COPD exacerbations. Annual exacerbations < 2 (n=73),
























Table 5.12. Binary logistic regression of blood neutrophils with exacerbation
frequency (> 2 per year] as the outcome variable, adjusting for post-
bronchodilator % predicted FEVi.




-0.028 0.010 7.501 1 0.006 0.973
Blood neutrophils 0.117 0.089 1.739 1 0.187 1.124
Intercept -0.003 0.730 0.001 1 0.997 0.997
-2 Log likelihood 205.8 (Cox % Snell R Square 0.071, Nagelkerke R square 0.099], p=0.002
Table 5.13. Binary logistic regression of sputum 1L-6 with exacerbation
frequency (> 2 per year) as the outcome variable, adjusting for post-
bronchodilator % predicted FEVi.




-0.033 0.013 6.963 1 0.008 0.967
Intercept 0.092 0.897 0.011 1 0.918 1.096
Sputum IL-6 0.092 0.897 0.011 1 0.918 1.096
-2 Log likelihood 141.2 (Cox % Snell R Square 0.098, Nagelkerke R square 0.133), p=0.002
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Oxygen saturations
Oxygen saturations were recorded in 172 subjects. Baseline data and
inflammatory markers according to oxygenation are shown in Table 5.14. There
was no difference in age, gender, smoking status, smoking pack years, inhaled
corticosteroid use or production of induced sputum according to oxygen
saturation. Subjects with oxygen saturations below 93% had more severe
airflow limitation (mean post-bronchodilator FEVi 37% predicted) compared to
the normoxic group (mean post-bronchodilator FEVi 52% predicted, p<0.001).
Blood and sputum neutrophils were significantly increased in COPD patients
with lower oxygen saturations (Figures 5.8 and 5.9) but only blood neutrophils
remained significantly associated with oxygen saturations after adjusting for
potential confounding factors (Table 5.15).
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Table 5.14. Baseline characteristics of the COPD cohort categorized according to
oxygen saturations measured by pulse oximetry (< 93% and > 93%). Data are
presented as number (%) for categorical variables, mean ± SD for parametric
variables and median (IQR)* for non-parametric variables. Groups were
compared using the Chi-squared test (categorical), t-test (parametric) and
Mann-Whitney U test (non-parametric).* Significance is taken at the p<0.05
level.
Oxygen saturation < 93% > 93% P
n=26 n=146
n=17 sputum n=89 sputum
Age 69 ±7 68 ±8 0.668
Gender, % male 16 (62%) 86 (61%) 1.00
Current smokers 10 (38%) 53 (37%) 0.397
Smoking pack years 53 ±23 47 ±24 0.217
Inhaled corticosteroids 17 (65%) 97 (68%) 0.821
Post bronchodilator predicted 37 ± 18 52 ± 18 <0.001
FEVi, %
Post bronchodilator predicted 69 ±23 81 ±20 0.013
FVC, %
Post bronchodilator FEVi/FVC 0.42 ± 0.1 0.49 ± 0.1 0.015
Induced sputum produced 17 (65%) 94 (66%) 1.00
White cell count, xl09/L 8.8 ±4 7.4 + 2 0.059
Blood neutrophils, xl09/L 6.2 ±3 4.7 + 2 0.031
C-reactive protein, mg/L* 5.5 (4-9) 3.5 (2-7) 0.071
Sputum neutrophils, %* 95 (88-97) 88 (74-93) 0.004
Sputum IL-lp, pg/ml* 15 (0-54) 8 (0-30) 0.441
Sputum IL-6, pg/ml* 21 (0-78) 27(8-62) 0.587
Sputum IL-8, pg/ml* 455 (310-748) 451 (266-867) 0.888
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Figure 5.8. Box and whisker plot showing the relationship between oxygen
saturation and blood neutrophils. Oxygen saturations < 93% (n=26), oxygen
saturations > 93% (n=146), p=0.03.
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Figure 5.9. Box and whisker plot showing the relationship between induced
sputum neutrophils and oxygen saturations in COPD patients. Oxygen




























Table 5.15. Binary logistic regression of blood neutrophils with oxygen
saturations (> 93%) as the outcome variable, adjusting for FEVi (post-
bronchodilator % predicted). The model was repeated with log CRP and sputum
neutrophils but neither was significantly associated with oxygen saturations
after adjusting for FEVi.




0.042 0.16 1 7.288 0.007 1.043
Blood neutrophils -0.253 0.109 1 5.422 0.020 0.777
Intercept 1.186 0.962 1 1.519 0.218 3.27
-2 Log likelihood 120.7 (Cox % Snell R Square 0.111, Nagelkerke R square 0.194], p<0.001
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BODE index
Six minute walking distance was recorded in 112 patients and the BODE index
was calculated for these subjects. Induced sputum data were available for 62 of
these patients. Age, gender, smoking status and smoking pack year history were
not associated with the total BODE index score. BODE index score correlated
significantly with SGRQ total score (0.660, p<0.001), exacerbation frequency
(0.411 p<0.001) and oxygen saturations (-0.265, p=0.006). Blood white cell
count, blood neutrophils, log CRP and log sputum IL-8 correlated significantly
with total BODE index score (Table 5.16). SGRQ total score, exacerbation
frequency, oxygen saturations, blood neutrophils, log CRP and log IL-8 were
analyzed with BODE index score using linear regression. SGRQ remained
significantly associated with BODE index after including the other variables in
the model (Table 5.17).
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Table 5.16. BODE index correlations with inflammatory markers. Data are
presented as Pearson's correlation co-efficient (parametric data) and
*Spearman's correlation co-efficient (non-parametric data) with statistical
significance.
Correlation P
White cell count, xl09/L 0.256 0.008
Blood neutrophils, xl09/L 0.271 0.005
Log C-reactive protein, mg/L 0.213 0.025
Sputum neutrophils, %* 0.020 0.882
Sputum IL-ip, pg/ml* -0.120 0.354
Sputum IL-6, pg/ml* -0.070 0.586
Log sputum IL-8, pg/ml -0.302 0.022
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Table 5.17 Multiple linear regression model of BODE index score with log
induced sputum IL-8 after controlling for SGRQ total score, exacerbation
frequency and oxygen saturations. The model was repeated with blood
neutrophils and log CRP but neither were significantly associated with BODE
index after controlling for the other variables.
B SE t P
Oxygen saturation % -0.055 0.089 -0.626 0.534
Intercept 10.852 8.385 1.294 0.202
Exacerbation frequency 0.147 0.091 1.612 0.113
Log sputum IL-8 -0.350 0.209 -1.674 0.100
SGRQ total score 0.056 0.009 6.520 <0.001
R squared = 0.578 (Adjusted R Squared = 0.545), p<0.001
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Discussion
The aim of this chapter was to investigate the relationship between
inflammation and clinical parameters that have been associated with prognosis
in COPD. Quality of life and dyspnoea were associated with markers of systemic
inflammation after adjusting for potential confounding factors, but were not
associated with markers of airway inflammation. Hypoxia was associated with
increased blood neutrophils after controlling for potential confounding factors.
Markers of systemic inflammation and sputum IL-8 correlated with total BODE
index score. Exacerbation frequency and BMI were not associated with blood or
sputum inflammation after controlling for airflow limitation. Sputum IL-6 and
IL-ip were not associated with any of the clinical parameters investigated.
Inflammation and quality of life in COPD
Systemic inflammation was associated with health related quality of life in this
cohort but pulmonary inflammation was not. Blood neutrophils and CRP were
significantly associated with all domains of SGRQ independent of smoking
status, induced sputum production and post-bronchodilator % predicted FEVi.
This is consistentwith previous reports with respect to CRP. Garrod and co¬
workers found that CRP and IL-6 were associated with SGRQ and MRC dyspnoea
scores in COPD subjects (n=41], whereas TNFaand neopterin were not. (356]
Broekhuizen and co-workers found that COPD patients with CRP levels
>4.21mg/L had higher SGRQ total scores compared to those with low systemic
levels of CRP. (105] No previous reports of an association between leukocytosis
and quality of life in COPD were found. Only one study reported an association
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between increased numbers of sputum inflammatory cells and SGRQ in COPD
(n=102], but this study did not investigate markers of systemic inflammation
and found no association between SGRQ and FEVi. (117] Our findings therefore
add to the existing literature by investigating blood and sputum inflammation
with respect to quality of life and dyspnoea in a single COPD cohort.
The association we found between systemic inflammation and poor quality of
life may have implications for symptom management in COPD. An improvement
in health-related quality of life in COPD has been seen in response to
therapeutic interventions, even when there was no improvement in lung
function. (110,127] This may be because treatments impact on systemic and
pulmonary inflammation separately. For example, while treatment with oral
theophylline reduced sputum neutrophils and the sputum total inflammatory
cell count in one study, other sputum markers (IL-8 and MPO], CRP and QOL
scores did not improve. (357] Therefore, while there was some evidence that
lung inflammation was reduced in response to theophylline, there was not the
same effect on systemic inflammation. Combination inhaled corticosteroids and
bronchodilators may also reduce pulmonary inflammation but do not seem to
reduce systemic inflammation. (110, 358] Perng and co-workers reported a
reduction in sputum IL-8 and MMP-9 following treatment with inhaled
fluticasone and salmeterol. But there was no change in induced sputum cell
counts, serum CRP, lung function or quality of life. (358] Inhaled fluticasone and
salmeterol led to an improvement in health status and lung inflammation
(surfactant protein D] in a study of 289 patients, but there was no difference in
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systemic inflammatory markers (CRP or IL-6). (110) Treatment with ICS was a
potential confounding factor in our study but was controlled for in the analysis.
Our data showed a consistent relationship between health related quality of life
and systemic inflammation, so perhaps therapies targeting systemic
inflammation may result in improved quality of life in COPD.
Inflammation and low body mass index
BMI was not associated with systemic leukocytosis in our COPD cohort after
controlling for airflow limitation. This is in keepingwith an otherwise healthy
population where obesity has been identified as a cause of leukocytosis. (359)
But there is some evidence to support increased systemic inflammation in COPD
patients with low BMI. Circulating TNFa and IL-ip have been associated with
cachexia in COPD. (157, 293, 360) Casadevall and co-workers found that IL-6
and TNFa were significantly increased in the intercostal muscles of COPD
patients with a normal BMI compared to healthy subjects. (361) There is a
relationship between systemic inflammation and cachexia in other diseases. IL-
1, IL-6, interferon-yand TNFa are the "classic cachectic cytokines". (362)
Systemic inflammation with increased pro-inflammatory cytokines contributes
significantly to cancer cachexia. (363, 364) Circulating IL-6 and blood
neutrophils were associated with cachexia in gastro-oesophageal cancer
patients, whereas IL-1, IL-8 and TNFa were not. (364) There are little data on
systemic neutrophilia and BMI in COPD. This may be due to difficulty in
extrapolating confounding factors, but we found no association after adjusting
for disease severity and smoking habit.
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We found no relationship between low BM1 and CRP. This is also in concordance
with published data suggesting that CRP is more strongly associated with
obesity. A recent study of 628 COPD patients found, after adjusting for
confounding factors, that CRP was increased in obese and overweight COPD
patients, but not in those with a low BMI. (365) Broekhuizen and co-workers
found a positive association between CRP and BMI (n=102), after adjusting for
FEVi, age, sex, TLco and FFM. (105) A smaller study found that CRP and TNFa
were raised in COPD patients with a low BMI, n=35. (366) A Norwegian
population study reported that elevated BMI was a strong predictor of raised
CRP, independent of airflow limitation. (367) CRP levels may be influenced by
statin use and possibly also by inhaled corticosteroids. In the Norwegian
population cohort (n=3877), statin use was strongly associated with low CRP,
whereas inhaled corticosteroids were not. (367) In a COPD cohort however,
inhaled corticosteroid use was associated with lower circulating CRP. (Ill)
Treatment with pravastatin reduced systemic inflammation (CRP) and
improved exercise capacity in a randomized, double-blind, placebo controlled
trial in COPD (n=125). (368) We found no association between markers of
systemic inflammation and BMI after adjusting for potential confounding factors
including the effects of statins and inhaled corticosteroids.
There is a complex interaction between nutrition, exercise, dyspnoea and
cachexia in COPD. (88,154) Systemic inflammation has been proposed as a
factor in this interaction and there is some data to support this. (88, 369) Eid
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and co-workers found increased levels of systemic inflammation (IL-6, TNFa
and their soluble receptors) in COPD patients with a low creatinine-height index
even when BMI was normal. [88] Systemic levels of TNFa and CRP were lower
in more active COPD patients (n=341). (370) Whereas reduced physical activity
in COPD patients was associated with higher CRP and fibrinogen and with left
ventricular dysfunction. (371) Adipose tissue may influence levels of systemic
inflammation. It has been proposed that inappropriate levels of leptin and TNFa
may lead to altered nutritional parameters and BMI in COPD. (372) Circulating
IL-6 and BMI were predictive of increased insulin resistance in a COPD
population (n=56). (158) TNFa and oxidative stress burden have been
proposed to link weight loss and muscle wasting in COPD. But BMI was not
associated with either circulating TNFa or oxidative stress burden measured by
malonyldialdehyde (MDA) in a study of male COPD patients, n=52 (373) or with
serum or sputum TNFa levels in another study, n=26. (374)
Body mass index was associated with increased sputum leukocytes and sputum
IL-6 after adjusting for current smoking status but not after adjusting for airflow
limitation. BMI has not previously been associated with increases in induced
sputum cells or cytokines. There was no association between BMI and sputum
cell counts in a normal adult population or in those with asthma, n=727. (375)
In 100 COPD patients, Ischaki and co-workers found that FFM was more closely
associated with disease severity (GOLD stage) than was BMI (n=100), but
neither parameter was associated with induced sputum neutrophils or LTB-4.
(154) No other studies investigating the relationship between sputum IL-6 and
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BMI in COPD could be found. Our finding that BMI was not associated with
blood or sputum inflammation is in concordance with existing literature. But
the role of blood neutrophils maymerit further investigation in the sub-
phenotype of COPD patients who lose body mass progressively over time.
Inflammation and exacerbation frequency
Frequent exacerbators had increased blood neutrophils and increased sputum
IL-6 in this cohort, but neither was associated with exacerbation frequency after
adjusting for FEVi. COPD exacerbations have been extensively investigated with
respect to inflammation. Our data confirm the findings of others that sputum IL-
6 was increased in COPD patients with > 2 exacerbations per year. (71, 72,150,
376] But many of these studies did not control for confounding factors such as
the severity of airflow limitation. Bhowmik and coworkers described increased
IL-6 in sputum in stable COPD patients with > 2 exacerbations per year (n=44),
with a further increase in IL-6 during an exacerbation (n=37). (71) Aaron and
coworkers (377) found an increase in IL-8 and TNFocin induced sputum during
COPD exacerbations (n=14) with levels returning to baseline after the
exacerbation. Microbial colonization in COPD was associated with sputum
neutrophilia. (320) In the study by Marin and co-workers, 71% of moderate
COPD patients in the stable state had evidence of bacterial colonization and this
was associated with sputum neutrophilia and a faster decline in FEVi. This
study measured an array of sputum cytokines (TNFoc, IL-1(3, IL-6, IL-8, IL-10 and
IL-12) but only IL-ip and IL-12 were increased in patients with bronchial
colonization, and this was only the case for patients with Haemophilus
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influenzae. [320] Aaron and co-workers (377) found no difference in induced
sputum cytokine levels in patients with and without a documented bacterial or
viral infection, suggesting that bacterial colonization is not likely to be solely
responsible for the increased level of sputum IL-6 found in our cohort. There is
therefore substantial evidence that markers of blood and sputum inflammation
increase during COPD exacerbations, but after controlling for confounding
factors, there was no baseline increased in these markers in stable COPD
patients.
Exacerbation frequency is associated with increased systemic inflammation in
COPD. (72,151,152, 378) Hurst and co-workers from the ECLIPSE study have
recently shown thatWCC was associated with exacerbation frequency after
controlling for potential confounding factors including FEVi. (378) This
suggests that our study may have been under-powered to show this. Other
studies have shown associations between markers of systemic inflammation
and exacerbations frequency. For example, in microarray analysis, 24 serum
biomarkers (a variety of chemoattractants, and markers of inflammation,
destruction and repair) were associated with exacerbation frequency in severe
COPD, although markers such as C-reactive protein were not included in the
analysis. (153) CRP has been found to predict exacerbations in COPD in one
study, (379) and levels take longer to return to baseline following an
exacerbation. (376) But in our cohort, CRP was not significantly associated with
exacerbation frequency in stable COPD patients. In the study by Perera and co¬
workers, CRP was elevated at day 14 post-exacerbation, (376) whereas our
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COPD patients were sampled at least 6 weeks post-exacerbation. Donaldson and
co-workers found that sputum IL-6 and plasma fibrinogen increased during
exacerbations, and yet there was no relationship between these 2 markers.
They therefore suggested that mechanisms other than "overflow" of pulmonary
inflammation into the systemic compartment might be responsible for the
systemic inflammation found during exacerbations. (72) We found a similar
inflammatory profile in blood and sputum from COPD patients with a low BMI
and from frequent exacerbators. While this may be due to confounding from
disease severity and smoking history, systemic inflammation and inactivity are
key mechanisms relating COPD to it's associated co-morbidities. Exacerbations
are associated with both of these factors and may be a key link between
pulmonary and systemic inflammation and the systemic consequences of COPD.
(72,91)
Inflammation and hypoxia
Blood leukocytes were associated with hypoxaemia in this cohort after
adjusting for potential confounding factors. Few studies have reported a
relationship between neutrophilia and hypoxaemia. An influx of neutrophils and
macrophages to the alveolar space occurred in response to moderate
hypoxaemia in rats, (164) and neutrophil numbers are increased in muscle
fibres from hypoxic COPD patients. (380) Hypoxia provides a potential
causative link between pulmonary and systemic inflammation. Hypoxia induces
expression of inflammatory cytokines in vitro (381-383) through the activation
of NFkB. (384) Yet human and animal studies report mixed associations
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between hypoxaemia and levels of inflammatory cytokines. Savransky and co¬
workers and Mikko and co-workers found no increase in inflammatory
cytokines in response to hypoxaemia. (385, 386) Whereas Jammes and co¬
workers found an inverse relationship between resting levels of inflammatory
cytokines (IL-6 and TNFa), oxidative stress (TBARS) and pC>2 in COPD patients,
with a further increase in IL-6 in response to exercise induced hypoxaemia.
They suggested therefore that intermittent hypoxia might have a role in the
induction of inflammation in COPD. (387) Studies at altitude describe an
increase in systemic inflammation (IL-1 receptor antagonist, IL-6 and CRP) that
may be hypoxia induced. (166) We did not find a relationship between CRP and
hypoxaemia, but tissue hypoxia was independently associated with CRP in one
study of 50 patients. (388)
Hypoxaemia is associated with increased platelet activation, the up-regulation
of intracellular adhesion molecules (167) and the development of
atherosclerosis. (385) Some of these factors, in addition to hypoxia induced
haemodynamic stress may be associated with the increased incidence of
cardiovascular disease in COPD. (168) Hypoxaemia increases inflammation
through mechanisms that alter vascular responses. (169,170) Activated T cells
from COPD patients secreted significantly more VEGF in response to hypoxia
than cells from healthy subjects. (386) Hypoxic COPD patients with pulmonary
hypertension confirmed on right heart catheterization had increased levels of
circulating IL-6 and an increase in IL-6 mRNA in response to hypoxia. (389)
Hypoxia inducible factor (HIF-la) has a key role in the regulation of pulmonary
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vascular remodeling in response to hypoxaemia. (Wouters PATS 2005) It was
proposed that the primary defect causing emphysema might result from
disordered vascular flow mediated by hypoxic pulmonary vasoconstriction.
[172] Remy-Jardin and colleagues (171) found that emphysematous regions
often developed at a site that had previously shown signs of inflammation
(nodules or ground glass). In the presence of inflammation, the usual
pulmonary response of diverting blood flow from hypoxic alveolar regions is
reversed. Neutrophils may be implicated in this process. In some cases, smokers
exhibit blunting of this process. In these individuals, inflammatory regions
associated with hypoxaemia experience a further limitation in blood flow,
resulting in tissue destruction. (172) Further work is required to investigate the
role of neutrophils in response to hypoxia in COPD.
The BODE index
Blood neutrophils, CRP and sputum IL-8 were significantly associated with the
BODE index. This is interesting as the BODE index was designed as a composite
score to represent both the pulmonary and systemic features of COPD. The
BODE index has previously been associated with markers of systemic
inflammation. (153, 371) But this is the first study to find an association
between BODE score and sputum inflammation. IL-8 was not associated with
any of the other clinical features of COPD assessed in this chapter. Further work
will be required to establish whether measurement of these inflammatory




We investigated the association between BMI and inflammation. While BMI is
associated with prognosis in COPD, it has been proposed that fat free mass
might be a more pertinent measurement of weight loss and muscle dysfunction
in COPD. (154] However, both BMI and FFM are independent predictors of
mortality in COPD, (15) and BMI instead of FFM is incorporated in the BODE
index. (118)
Exacerbation frequency was recalled subjectively by study subjects and may
therefore be prone to inaccuracy. This was not primarily designed as a study of
COPD exacerbations. Exacerbations have been the focus of study by other
research groups who used more accurate recording of exacerbation frequency
and symptoms, for example with diary cards and telephone follow up. (71, 72)
However, our results are concordant with the findings of others. Microbiology
assessment in sputum was not made in this study, and bacterial colonization is a
potential cause of an increased frequency of exacerbations in COPD. Studies
investigating sputum inflammation in response to bacterial colonization in
COPD show conflicting results. (320, 377)
Hypoxia was measured using oxygen saturations instead of the more accurate
arterial blood gas measurement. Pulse oximetry is particularly useful as a non¬
invasive measure of relative hypoxia (355) in clinical practice and is now the
main tool utilized in the British Thoracic Society oxygen prescribing guidelines.
(390) A large meta-analysis reported that pulse oximetry was accurate to within
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Different profiles of pulmonary and systemic inflammation were expressed with
different clinical features of COPD. Increased systemic inflammation was
associated with reduced quality of life and more dyspnoea. Blood neutrophilia
was associated with hypoxia. Inflammatory markers in blood and sputum were
not associated with BMI or exacerbation frequency after controlling for
potential confounding factors. BODE index was associated with both pulmonary
and systemic inflammation. Pulmonary and systemic markers of inflammation
may be useful in further defining clinical phenotypes for the purpose of
prognosis and treatment in COPD.
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CHAPTER 6. Quantitative computed tomography evaluation
of COPD with clinical and inflammatory features
Introduction
COPD is a pathologically heterogeneous disease. With the increasing use of
radiological imaging in clinical practice, CT scanning may be useful in further
characterizing COPD. COPD results in characteristic anatomical changes in the
lungs, particularly resulting in the development of emphysema. Despite the
same stage of COPD according to lung function, the quantity of emphysema can
vary widely. (205) Patients can have severe airflow limitation with minimal or
no emphysema. (206, 208) Yet macroscopic emphysema has been
demonstrated in never-smokers (209) and post-mortem studies have found
significant emphysema in patients with normal lung function. (210) The extent
of emphysema does not fully account for the expiratory airflow limitation in
COPD, as small airway disease is the predominant factor. (206, 207)
CT can be used to provide an objective measure of lung density in Hounsfield
Units (HU). (184,185, 204) The most widely used method for objectively
quantifying emphysema using CT is the "density mask" technique, (186) in
which regions of signal density are allocated a value in Hounsfield Units (HU)
based on their intensity index on a grey scale. Zero HU represents the density of
water and -1000 HU represents the density of air. A threshold can be applied
(close to the HU value for air) to dichotomize regions to be denoted as 'normal'
lung parenchyma or as emphysematous. No fixed value has yet been established
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for this threshold, but commonly used cut-offs are -910 and -950 HU. (188) The
low-density threshold that quantifies emphysema has been validated against
pathology (184,186, 212, 392)
An alternative measurement of lung density was pioneered in COPD patients in
Edinburgh in the 1980's. (204) This measurement, known as the "percentile
point," was used to characterize the low-density region of the frequency
distribution histogram. This measurement was then developed further in
European studies of alpha-1 antitrypsin deficiency. Dirksen and coworkers
analyzed lung density using 5-15% of the lowest attenuation voxels (e.g. 5th or
15th percentile point). (193) The 15th percentile is defined as the value in
Hounsfield Units below which lie 15% of the lowest density lung voxels. (264)
This method is less variable than the density mask technique and is significantly
less variable than measurements of pulmonary function. (193) In the EXACTLE
study of 77 patients with alpha-1 antitrypsin deficiency, Parr and co-workers
found that CT densitometry was able to detect progressive loss of lung tissue
over a 2.5-year follow-up period and was more sensitive than lung function or
quality of life measures. (393)
In this study, a CT protocol and software were developed to measure lung
volume and density in a cohort of stable COPD patients. Density was measured
using both a density mask (pixel index threshold -910 and -950 HU) and the 15th
percentile point. These parameters were then related to clinical and
inflammatory parameters in a COPD cohort. The hypothesis was that both
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techniques for measurement of density would be similarly associated with lung
function; and that both high lung volumes and low lung density would be
associated with reduced lung function. The secondary objective was to
determine the association between lung density and markers of systemic and
airway inflammation and clinical features of the disease.
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Aims
In a cohort of stable COPD patients to investigate the relationship between CT
lung volume and density parameters with:
1. Lung function
2. Markers of pulmonary and systemic inflammation
3. Clinical features
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Methods and data analysis
COPD patients were recruited and underwent low dose thoracic CT scanning at
full inspiration and on expiration as described in Chapter 2. The details of
patient recruitment and the CT protocol are described in detail in Chapter 2.
Demographic data for the COPD cohort was tabulated using mean (standard
deviation) for normally distributed variables, number (%) for categorical data,
and median (inter-quartile range) for abnormally distributed data. CT data on
lung volumes and density on inspiration and expiration were recorded. Density
was measured using the density mask (pixel index -950 HU and pixel index -910
HU) and the 15th percentile point. Pixel index -950 (inspiration only) and pixel
index -950 and -910 (expiration) had a skewed distribution and were log-
transformed for analysis. CT measurements were then analyzed with
spirometry, markers of inflammation and clinical features using Pearson's
correlation for normally distributed variables, Spearman's correlation for
abnormally distributed variables and the Chi-squared test for categorical
variables. Clinical features and inflammatory markers were categorized or log-
transformed for analysis as described in Chapter 5. Factors associated with lung




CT scans were obtained on inspiration and expiration in 117 COPD patients.
Clinical baseline data for these patients compared to patients in the same cohort
who did not undergo a CT scan are displayed in Table 6.1. More male (64%)
than female subjects (36%), and more ex-smokers (70%) than current smokers
(30%) attended for a CT scan. COPD severity by GOLD stage ranged from I to IV
(GOLD I n=9 (8%), GOLD II n=49 (42%), GOLD III n=45 (38%), GOLD IV n=14
(12%). 67 of 117 patients (57%) produced an adequate sample of induced
sputum for analysis. Compared to these patients, COPD patients from the same
cohort who did not have a CT scan were more likely to be current smokers
(p=0.008), to have a lower post bronchodilator FVC (p=0.02), to have higher
SGRQ scores in all domains and a higher MRC dyspnoea score. Subjects who had
not had a CT scan did not have 6 minute walking distance recorded and
therefore did not have a BODE index calculated.
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Table 6.1. Clinical data for the COPD cohort who had a CT scan compared to
COPD patients for whom a CT scan was not obtained. Data are presented as
mean ± SD for parametric variables, *median (IQR) for non-parametric variables
and +number (%) for categorical variables.
COPD subjects CT No CT P
n=117 n=65
Age 68 ±8 69 ±8 0.395
Gender, % male + 74 (64%) 38 (58%) 0.530
Current smokers, %+ 35 (30%) 36 (55%) 0.008
Smoking pack years 45 ±21 52 ±29 0.087
FEVi, postbronchodilator % predicted 51 ± 19 47 ± 19 0.113
FVC, post bronchodilator % predicted 81 ±21 74 ±20 0.013
FEVi/FVC ratio, post bronchodilator 0.49 ± 0.1 0.48 ±0.1 0.727
Body Mass Index, kg/m2 26 ±6 25 ±5 0.151
Oxygen saturation, % 96 ±2 95 ±3 0.225
Annual exacerbation frequency* 2 (1-3) 2 (1-3) 0.639
St George's Respiratory Questionnaire Symptoms 60 ±22 67 ± 18 0.022
Activity 62 ±25 74 ±20 <0.001
Impact 34 ±21 44 ±22 0.002
Total score 47 ±20 57 ±181 0.001
MRC dyspnoea score+ 1-2 56 (49%) 15 (23%)
3 28 (24%) 18 (28%)
4-5 31 (27%) 31 (48%) 0.001
MRC chronic bronchitis score+ Yes 52 (49%) 31 (48%)
No 55 (51%) 32 (49%) 1.00
6 minute walking distance, m 73 ± 53 -
BODE index 6.7 ±3 -
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Examples of the CT images obtained are shown in Figure 6.1. CT measurements
of lung volume and density were made on inspiration and expiration. These
results are displayed in Table 2. Values for air calibration are also shown in
inspiration and expiration. As described more fully in the main methods section,
CT scanner calibration was undertaken according to the manufacturer's
instructions. The Hounsfield Unit (HU) value for air was recalibrated using a
method similar to that described by Stoel and Stolk. (195] The FC-03 filter was
used to correct for the air offset in the Toshiba CT scanner. CT values for lung
density shown in Table 6.2 were corrected according to the value for air
calibration.
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Figure 6.1. CT images of COPD subjects with (a) mild emphysema and (b) severe
emphysema. The subject in image (b) also has upper lobe predominant
emphysema. The images were acquired at full inspiration and full expiration
(see Chapter 2). Using density mask software, the lungs have been segmented
from other anatomical structures (e.g. mediastinum and chest wall). Air in the
trachea has also been segmented out of the analysis. The highlighted regions
represent emphysema (regions of lung density below -950 Hounsfield Units).
Each colour represents a confluent region of emphysema of a different size: red
representing the largest confluent regions, followed by yellow and green, with
blue representing the smallest confluent regions of low lung density.
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Table 6.2. CT parameters are shown for the COPD cohort (n=117] on inspiration
and expiration. Data are presented as mean ± SD for parametric variables and
median (IQR]* for non-parametric variables. Pixel index and 15th percentile
values are corrected for air calibration. Pixel index -950 (inspiration and
expiration] and pixel index -910 (expiration only] were log-transformed to
achieve normal distribution. Pixel index -910 (inspiration] was normally
distributed.
CT parameters Inspiration Expiration
Volume, L 6.4 ±2 4.9 ± 1
Pixel index -950, % 7% (2-17%]* 3% (1-11%]*
Log pixel index -950 -2.95 ±1.5 -3.73 ± 1.8
Pixel index -910, % 33% ± 18% 14% (6%-32%)*
Log pixel index -910 -1.3 (0.8] -2.2 (1.3]
15th percentile point, HU -934 ±29 -910 ±41
Air calibration, HU -987 ±1 -987 ± 2
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CT parameters and lung function
Correlations between CT parameters of lung volume, density in inspiration and
expiration and lung function parameters are shown in Tables 6.3 and 6.4. Lung
volume and density (pixel index -950, pixel index -910 and 15th percentile
point) were significantly associated with airflow limitation measured by post-
bronchodilator % predicted FEVi and by FEVi/FVC ratio on inspiration and
expiration (p<0.001). The strongest correlations were seen for FEVi/FVC ratio
and the expiratory values. Of the lung density parameters measured, pixel index
-910 was most strongly correlated with FEVi and FEVi/FVC ratio. Post-
bronchodilator % predicted FVC was not associated with CT lung volume or
density measurements on inspiration, but there was a significant relationship
with lung volume on expiration (p=0.003). This "post-bronchodilator percent
predicted FVC" measurement has intrinsic correction for height and gender.
Post-bronchodilator FVC (not taken as % predicted) however, was significantly
associated with lung volume on inspiration (r=0.450, p<0.001), and expiration
(r=0.212, p=0.022) but not with any of the measurements of CT lung density.
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Table 6.3. Correlation of lung function with CT parameters on inspiration.
Pearson's correlation coefficients are displayed for each parameter, together
with statistical significance. Pixel index -950 was log-transformed for analysis to
achieve normal distribution. Pixel index -910 on inspiration was normally
distributed.
Lung function CT parameters, inspiration Correlation p value
FEVi, post bronchodilator %
predicted
Lung volume, L -0.337 <0.001
Log pixel index, -950 HU -0.472 <0.001
Pixel index, -910 HU -0.504 <0.001
15th percentile 0.415 <0.001
FVC, post bronchodilator %
predicted
Lung volume, L -0.141 0.134
Log pixel index, -950 HU -0.055 0.560
Pixel index, -910 HU -0.077 0.411
15th percentile -0.042 0.657
FEVi/FVC ratio, post
bronchodilator
Lung volume, L -0.423 <0.001
Log pixel index, -950 HU -0.688 <0.001
Pixel index,-910 HU -0.731 <0.001
15th percentile 0.588 <0.001
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Table 6.4. Correlation of lung function with CT parameters on expiration.
Pearson's correlation coefficient is displayed for each parameter, with statistical
significance. Pixel index -950 and pixel index -910 were log-transformed for
analysis to achieve normal distribution.
Lung function CT parameters, expiration Correlation p value
FEVi, post bronchodilator %
predicted
Lung volume, L -0.481 <0.001
Log pixel index, -950 HU -0.512 <0.001
Log pixel index, -910 HU -0.545 <0.001
15th percentile 0.498 <0.001
FVC, post bronchodilator %
predicted
Lung volume, L -0.271 0.003
Log pixel index, -950 HU -0.085 0.366
Log pixel index, -910 HU -0.123 0.188
15th percentile 0.103 0.276
FEVi/FVC ratio, post
bronchodilator
Lung volume, L -0.504 <0.001
Log pixel index, -950 HU -0.701 <0.001
Log pixel index, -910 HU -0.702 <0.001
15th percentile 0.636 <0.001
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CT lung volumes on inspiration and expiration increased significantly with
COPD severity according to GOLD stage, p<0.001 (Figure 6.2). Lung density on
inspiration and expiration was significantly lower with more severe COPD
according to GOLD stage, p<0.001 (Figures 6.3 and 6.4), irrespective of the
density parameter that was measured. The difference in lung volumes and lung
density between inspiration and expiration is smaller with worsening airflow
limitation.
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Figure 6.2. The relationship between the severity of airflow limitation (GOLD
stage) and CT lung volumes on inspiration and expiration for the COPD cohort.
More severe airflow limitation was associated with higher lung volumes on
inspiration (p=0.017) and expiration (p<0.001, ANOVA) and a smaller
inspiratory/expiratory volume ratio. The histograms represent the mean and
the error bars represent the standard deviation.
Number of subjects for each GOLD stage: I (mild] n=13, II (moderate) n=70, III (severe) n=73, IV
(very severe) n=26.
Bonferroni post-hoc analysis on inspiration: GOLD II: GOLD IV p=0.04. Bonferroni post-hoc
analysis on expiration: GOLD 1:111 p=0.02, GOLD I:IV p<0.001, GOLD 11:111 p=0.045, GOLD ILIV
p<0.001, GOLD III: GOLD IV p=0.02.
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Figure 6.3. The relationship between CT lung density (Pixel Index -910) and
airflow limitation (GOLD stage) on inspiration and expiration in the COPD
cohort. More severe airflow limitation is associated with lower lung density
(higher pixel index at the -910 threshold) on inspiration (p<0.001) and
expiration (p<0.001, ANOVA). The histograms represent the mean and the error






















Number of subjects in each GOLD stage: I [mild] n=13, II (moderate) n=70, III (severe) n=73, IV
[very severe) n=26.
Bonferroni post-hoc analysis on inspiration: GOLD I:IV p=0.003,11:111 p<0.001, II:IV p<0.001.
Bonferroni post-hoc analysis on expiration: GOLD LIII p<0.001,1:IV p<0.001,11:111 p<0.001, ILIV
p<0.001.
Similar relationships were seen between GOLD stage, pixel index -950 and 15th percentile.
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Figure 6.4. The relationship between airflow limitation (GOLD stage) and the
quantity of emphysema on CT (15th percentile point) on inspiration and
expiration in the COPD cohort. More severe airflow limitation is associated with
lower lung density (more emphysema) on inspiration (p<0.001) and expiration
(p<0.001, ANOVA). The histograms represent the mean and the error bars
represent the standard deviation.
Number of subjects in each GOLD stage: I (mild) n=13, II (moderate) n=70, III (severe) n=73, IV
(very severe) n=26.
Bonferroni post-hoc analysis on inspiration: GOLD 1:1V p=0.056,11:111 p<0.001, II:IV p<0.001.
Bonferroni post-hoc analysis on expiration: GOLD LIII p=0.045,1:IV p=0.001,11:111 p<0.001, ILIV
p<0.001.
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CT parameters and markers of inflammation
Lung volume, pixel index and 15th percentile were analyzed with markers of
pulmonary and systemic inflammation. There was no significant correlation
between blood white cell count, neutrophils or C-reactive protein and the CT
parameters in inspiration or expiration, and there were no significant
correlations between induced sputum percentage neutrophils, IL-1(3, IL-6 or IL-
8 and CT parameters on inspiration or expiration.
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CT parameters and clinical features of COPD
Age and smoking pack years did not correlate significantlywith CT lung volume
or lung density values on inspiration or expiration (Tables 6.5). There was no
difference in lung volumes or density in COPD patients who were current
smokers compared to ex-smokers in inspiration or expiration (Table 6.6 and
6.7). As expected, lung volumes were significantly higher in men than women
(inspiration p=0.004, expiration p=0.015) but there was no gender difference in
lung density.
Body mass index and the BODE index correlated with all CT parameters (Table
6.5 and figures 6.6 and 6.7). Exacerbation frequency, MRC dyspnoea score, MRC
chronic bronchitis score, oxygen saturations and 6 minute walking distance
were not associated with CT lung volumes or lung density. SGRQ scores (total,
activity, symptoms and impact) were not associated with CT lung volumes or
lung density, except SGRQ activity score, which correlated significantly with the
log expiratory pixel index -950 (r=0.209, p=0.03).
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Table 6.5. Pearson's correlation coefficients are displayed for the relationships
between clinical features (continuous variables) in the COPD cohort and CT
volume and density indices on inspiration and expiration. Significant














Volume -0.08 -0.02 -0.09 -0.12 -0.02 -0.10 -0.23* 0.02 0.18*
Log PI -950 -0.04 -0.09 0.05 -0.08 0.17 0.01 -0.43* 0.07 0.33*
15lh perc 0.10 0.16 0.00 0.11 -0.11 0.03 0.52* -0.09 -0.24*
Expiration
Volume -0.12 -0.11 0.05 0.04 0.11 0.02 -0.30* -0.03 0.31*
Log PI -950 -0.09 -0.08 0.11 -0.02 0.21* 0.07 -0.43* 0.02 0.35*
15 th perc 0.11 0.08 -0.07 0.03 -0.17 -0.03 0.53* -0.04 -0.32*
PI = Pixel Index.
15th perc = 15th percentile.
Pack years = smoking pack years.
SGRQ = St George's respiratory questionnaire.
Symp = symptoms.
BMI = body mass index (kg/m2].
6MW = 6 minute walking distance (m).
BODE = BMI, airflow obstruction, dyspnoea and exercise index.
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Table 6.6. CT lung volume and density indices on inspiration are displayed for
categorical variables. CT parameters are displayed as mean ± SD for each
variable. Significance is shown as * representing statistical significance at the
p<0.05 level.
Lung volume, L Log PI-950 15lh percentile
Gender Male 7.1 ± 1* 5.4 ±1 -936 ±28
Female 5.2 ±1 3.9 ± 1 -930 ±29
Smoking status Smoker 6.1 ± 1 -3.2 ± 2 -929 ±28
Ex-smoker 6.6 ±1 -4.8 ± 1 -936 ± 29
Exacerbations < 2 per year 6.3 ±1 -3.0 ± 1 -933 ±27
> 2 per year 6.5 ±1 -2.9 ± 2 -935 ± 32
Oxygen saturations <93 % 6.5 ±1 -2.7 ± 2 -939± 34
>93 % 6.3 ±2 -2.9 ± 1 -934 ±28
MRC bronchitis Yes 6.4+1 -2.7 ±1 -937 ±26
No 6.4 ±2 -3.0 ± 2 -932 ±29
MRC dyspnoea 0-2 6.4 ± 1 -3.1 ± 1 -931± 29
3 6.4 ± 1 -2.8 ± 1 -935 ±29
4-5 6.2 ±0 -2.4 ± 1 -941± 21
PI = Pixel Index
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Table 6.7. Clinical features and CT volume and density indices on expiration are
displayed for categorical variables. CT parameters are displayed as mean ± SD
for each variable. Significance is shown with * (p<0.05].
Lung volume, L Log PI-950 15lh percentile
Gender Male 5.4 ±1* -3.5 + 2 -914 ±41
Female 3.9 ±1 -4.1 ± 2 -904 + 39
Smoking status Smoker 4.8 ± 1 -3.9 ± 2 -906 ± 37
Ex-smoker 4.9 ± 1 -3.6 ±2 -911 ±42
Exacerbations < 2 per year 4.8 ±1 -3.8 ±2 -910 ±36
> 2 per year 4.9 ±1 -3.6 ± 2 -911 ±48
Oxygen saturations <93 % 5.1 ± 1 -3.3 ±2 -920 ±40
>93 % 4.8 ±1 -3.6 ±2 -911 ±40
MRC bronchitis Yes 4.8 ±1 -3.6 ±2 -914 ±38
No 4.9 ±1 -3.9 ±2 -906 ±42
MRC dyspnoea 0-2 4.6 ± 1 -4.0 ± 2 -904 ±39
3 5.0 + 2 -3.6 ±2 -914 ±42
4-5 4.6 ± 1 -3.3 ± 2 -918 ±35
PI = Pixel Index
199
Figure 6.6. The relationship between lung density on inspiration measured by
15th percentile point and body mass index (p<0.001, ANOVA) is displayed. The
lowest 15th percentile quartile represents the lowest lung density (representing
more emphysema). Significance taken as p<0.008 due to multiple comparisons.





Q1 Q2 Q3 Q4
15th Percentile Point on Inspiration (Quartiles)
Bonferroni post-hoc analysis of 15th percentile quartiles with BMI:
Q1:Q2 p=0.008, Q1:Q3 p=0.008, Q1:Q4 p<0.001, Q2:Q4 p=0.02, Q3:Q4 p=0.01
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Figure 6.7. The relationship between CT lung density (pixel index -950) on
inspiration and body mass index (p<0.001, ANOVA) is displayed. The highest
pixel index quartile represents the lowest lung density (representing more
emphysema). Significance is taken as p<0.008 due to multiple comparisons. The




Qi Q2 Q3 Q4
Pixel Index -950 on Inspiration (Quartiles)
Bonferroni post-hoc analysis of Pixel Index -950 quartiles with BMI:
Q1:Q4 p<0.001, Q2:Q4 p<0.001, Q3:Q4 p=0.015.
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Significant associations between lung density and clinical features in the
univariate analysis were analyzed in a multiple regression model (Table 6.8).
Pixel index -950 on expiration was the lung density parameter chosen as the
dependent variable due to expiratory scans reflecting both small airways
disease and emphysema. BMI, BODE index and SGRQ activity score were
included in the model. BODE and BMI were analyzed in the model separately as
they exhibited significant co-linearity due to the BMI component of the BODE
index. BMI was independently associated with lung density after adjusting for
airflow limitation (FEVi/FVC ratio) but SGRQ activity score (p=0.8) and the
BODE index (p=0.6) were not.
Table 6.8. Multiple linear regression of body mass index and SGRQ activity score
with log pixel index -950 (on expiration) as the dependent variable, adjusting
for post-bronchodilator FEVi/FVC ratio.
B SE t P
Intercept 1.843 0.715 2.577 0.011
FEVi/FVC ratio
post-bronchodilator
-0.089 0.011 -7.845 <0.001
Body mass index -0.051 0.023 -2.200 0.030
SGRQ activity 0.001 0.005 0.285 0.777
R squared = 0.517 (Adjusted R Squared = 0.504), p<0.001
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Discussion
High lung volumes and low lung density were significantly associated with
airflow limitation measured by FEVi and FEVi/FVC ratio (post-bronchodilator
% predicted values) and with low body mass index. FEVi/FVC ratio showed the
strongest correlations with CT lung volume and density. Expiratory CT
parameters had a more pronounced association with airflow limitation than
inspiratory parameters. After adjusting for the degree of airflow limitation, CT
measurements of lung volume and density were not associated with SGRQ
scores, MRC dyspnoea or chronic bronchitis scores, exacerbation frequency,
oxygen saturations or the BODE index and there was no significant relationship
between CT parameters and markers of pulmonary or systemic inflammation.
CT quantification of emphysema and lung function
Using an automated method of quantitative CT analysis, we found that different
methods ofmeasuring lung density - both a density mask at two different
thresholds (-910 and -950 HU) and a pre-chosen percentile point (15th
percentile) - were similarly associated with airflow limitation. We found the
strongest correlations between CT lung density (log PI-910) and post-
bronchodilator FEVi/FVC ratio (r=-0.7). Previous studies reported similar
results using a variety of techniques to measure lung density. (181,182,192,
203, 204) Early studies (192, 204) found that the lowest 5th percentile of the
lung density histogram correlated with FEVi/FVC ratio (r=0.73, p<0.001).
Pathologically validated studies using a density threshold of-950 HU found that
CT lung density was associated with FEVi. (212, 392) Studies using semi-
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quantitative assessment of whole lung density found a similar correlation
between lung density and FEVi. (203, 207) Nakano and co-workers (181)
measured lung density in three CT slices and calculated the percentage of low
attenuation areas (%LAA) at a threshold of-950 HU. They found that LAA% was
associated with FEVi % predicted. Using fully automated analysis, Aziz and co¬
workers found that emphysema was significantly associated with FEVi (r=-0.63,
p=0.0005, n=101). (182) Our results therefore confirm the results from
previous work showing strong correlations between quantitative assessment of
emphysema and airflow limitation.
The association between lung density and airflow limitation was more
pronounced on expiration. Other studies also found better correlations between
expiratory CT parameters and pulmonary function tests, correlations with FEVi
improving from 0.5 to 0.7 between inspiration and expiration, which is
consistent with our data. (213, 214) Interestingly, despite correlating well with
FEVi and gas transfer factor, (207) lung density was not clearly associated with
elastic recoil. (394) CT parameters on expiration may enable indirect
measurement of some of the pathological processes occurring in COPD, such as
gas trapping, altered elastic recoil and small airway disease. Yamashiro and co¬
workers (395) found that the ratio of expiratory to inspiratory lung volume was
representative of expiratory to inspiratory mean lung density, reflecting gas
trapping and airflow limitation (n=46). In contrast, they found evidence for
more collapsible lungs, and therefore less gas trapping (increased inspiratory to
expiratory volume ratio) in patients with milder airflow limitation. (395) We
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found that the difference in lung volume and density between inspiration and
expiration becomes smaller as airflow limitation progresses. Our data is
supported by work by O'Donnell and co-workers. (328) This is a potentially
useful phenotypic feature that is likely to be a reliable method of staging
patients. Disease of the small airways (< 2 mm in diameter) is one of the
defining features of COPD. Hogg and co-workers report a 100-fold reduction in
airway lumen area in airways < 2mm in diameter in COPD patients in micro-CT
analysis of pathological samples and reported that this was likely to be one of
the key mechanisms causing increased peripheral airway resistance and
therefore gas trapping in COPD. (396) Micro-CT is not useful in a clinical context
as it uses much higher radiation doses. Airways < 2mm in diameter are difficult
to measure on CT. (254) By providing a means to measure gas trapping,
expiratory CT parameters may therefore provide an indirect measurement of
small airway disease in addition to accurately assessing the extent of
emphysema.
Lung volumes were significantly higher with worsening airflow limitation in our
cohort. There was a clinically significant increase in lung volume with
increasing GOLD stage, with a mean of 3.1 litres in expiration in GOLD stage I
compared to a mean of 6.2 litres in GOLD stage IV. Our results are compatible
with the findings ofO'Donnell and co-workers who reported mean lung volumes
on inspiration of 5.3L on CT. (397) This group reported that CT and helium
dilution measurement of lung volumes gave similar results in patients with
airflow limitation, whereas plethysmography tended to over-estimate lung
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volumes in patients with more severe airflow limitation (FEVi < 30%
predicted], (397) Quantification of lung volume on CT maybe a useful staging
adjunct in COPD patients.
CT quantification of emphysema and clinical features of COPD
Low body mass was significantly associated with lower lung density but not
with lung volume in this COPD cohort, after adjusting for airflow limitation.
Findings from previous studies using semi-quantitative measurement of
emphysema support this conclusion. (205, 398, 399) Ogawa and co-workers
(232) found a negative correlation between BM1 and lung density (r2=-0.557,
p<0.0001) using three CT slices for quantitative lung density analysis. Lee and
co-workers found the same relationship between BMI and lung density using
whole lung quantitative CT in 34 subjects. (190) The extent of emphysema on
CT has also been associated with fat-free mass, (233) and with a worsening
BODE index score. (234) While we found an association between lung density
and BODE index, this was predominantly due to the FEVi component of the
BODE index.
BMI potentially confounds the measurement of lung density by causing artefact,
such that a higher BMI may result in a higher measurement of lung density. The
association between lung density and BMI is also potentially confounded by the
effect of smoking. Current smoking is associated with a lower body mass index
(as was the case in our cohort, see Chapter 5) but we found no association
between CT lung volume or density and current smoking status or smoking
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pack years. The relationship between BMI and lung density may also have been
confounded by disease severity, as BMI was lower in subjects with more severe
airflow limitation. But as with one smaller study, we found that BMI was
significantly associated with lung density after adjusting for airflow limitation.
Renvall and co-workers investigated a cohort of 40 COPD patients and found
that the quantity of emphysema on CT was associated with BMI irrespective of
the degree of airflow limitation (FEVi 20-80% predicted across the cohort], r2 =
0.171, p=0.01. [400] They also found that BMI correlated inversely with
nutritional intake, in that COPD patients with low BMI consumed more calories
than their counterparts with a normal or high BMI, supporting a catabolic state
in these patients. [400]
It is interesting that there was no association between CT lung density and
health related quality of life [SGRQ scores], dyspnoea [MRC dyspnoea score],
MRC chronic bronchitis scores, exacerbation frequency or oxygen saturations in
this cohort. Previous studies of these clinical features with CT parameters
yielded mixed results and our study is one of the few to use a fully automated
technique to measure lung density in association with these features. Han and
co-workers, using an automated quantitative assessment of emphysema, found
that SGRQ score, the SF-12 symptom score, MRC dyspnoea score and 6-minute
walk were associated with emphysema severity on CT, but found no association
between the quantity of emphysema and exacerbation frequency. [401] Gas
trapping on expiratory scans correlated with dyspnoea in 51 patients, using a
technique to measure emphysema on three pre-allocated CT slices. [213] Using
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a visual scoring method to assess emphysema in a cohort of 307 COPD patients,
Makita and co-workers reported that patients with more emphysema had lower
health related quality of life scores and lower BMI. (205) Our group reported an
association between the distribution of emphysema on CT and MRC dyspnoea
and SGRQ score. (222) The position of the CT slices chosen by Makita and co¬
workers may therefore have influenced their findings. Supporting our findings,
they also found that symptoms of chronic bronchitis were unrelated to the
degree of emphysema. (205) Previous studies suggest that thickening of the
distal airways precedes the development of emphysema in many cases. (396)
Symptoms of chronic bronchitis are presumed to co-exist with airway
thickening and there is some evidence to support this. (262) Chronic bronchitis
may therefore be more closely associated with airway measurements than with
the degree of emphysema on CT. In fact, we found this was the case when
analyzing airway data from this cohort. (262)
Inflammation and lung density
There are few previous studies investigating the relationship between
inflammation and the quantity of emphysema. We found no association between
blood or sputum markers of inflammation and lung density. The lack of a
relationship between lung density and blood neutrophils or CRP seemed to
indicate that emphysema was not related to systemic inflammation in this COPD
cohort. Ogawa and co-workers measured serum CRP, cholesterol, albumin,
triglycerides, total protein and cholinesterase and also found no association
between any of these markers and either BMI or %LAA. (232) Our study adds to
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these findings as we used whole lung density measurements whereas this group
used only three CT slices for density analysis. Our cohort was composed ofmale
and female subjects, whereas Ogawa and co-workers investigated only male
subjects. (232) Another study found no association between the extent of
emphysema on CT and systemic C reactive protein levels in a cohort of smokers.
(233) These results support theories suggesting that emphysema develops
through mechanisms not mediated by inflammation, but perhaps through
vascular (402) or genetic mechanisms, (403) or through pathways involving
elastin degradation by proteinases. (404) For example, emphysema has been
associated with an increase in sputum MMP-9, and sputum ratio ofMMP-9 to
TIMP-1 (the main tissue inhibitor ofmatrix metallo-proteinases) in a cohort of
COPD patients, although there was no difference in sputum, urinary or plasma
desmosine (a product of elastin breakdown) between subjects with (n=10) and
without (n=15) emphysema on CT in this study. (234) Increased severity of
COPD in pathological studies has been associated with altered collagen
deposition that may represent developing fibrosis. This may not be mediated
through inflammatory pathways. (396) Hogg describes an overall reduction in
bronchiolar tissue as COPD advances. (396) A lower volume of tissue capable of
producing inflammatory mediators may provide an alternative explanation for
the lack of association we found between pulmonary and systemic inflammation
and the quantity of emphysema. Also, inflammation in the proximal airways
may not be representative of inflammation in the more distal airspaces.
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Interestingly, systemic inflammation (blood neutrophils) was associated with
COPD severity measured by airflow limitation in this cohort but it was not
associated with the quantity of emphysema. For this reason, characterizing
COPD patients according to systemic inflammation, airflow limitation and lung
density may be useful in further characterizing COPD for the purpose of
treatment and prognosis.
Future use of quantitative CT scanning
CT scanning is increasingly utilized in the diagnosis and management of COPD
in clinical practice and should perhaps become routine in the diagnostic work
up for patients with suspected COPD. CT is often able to detect emphysema
before an abnormality is seen on spirometry. In a cohort undergoing CT
scanning for lung cancer screening, 78% of smokers had macroscopic
emphysema but normal spirometry. (211) Early diagnosis may be useful in
encouraging patients in smoking cessation. CT assessment of the quantity and
distribution of emphysema is already used in treatment decision-making to help
select potential candidates for lung volume reduction surgery. (224, 229, 230)
In addition to measuring lung density on inspiration and expiration, the
assessment of airway dimensions on CT may provide more information on the
contribution of airway disease to the airflow limitation in COPD. Methods for
the accurate assessment of airways using CT are currently under development.
(236,237, 405)
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Quantitative CT may be of prognostic value. Our results suggest that lung
volume and density measurements may be useful in staging COPD. Clinical trials
in alpha-1 antitrypsin deficiency have pioneered the development of protocols
for CT lung density quantification in a longitudinal setting for use in clinical
trials. [193, 231) Work is still required to determine the changes in lung
volumes and density over time in COPD patients with smoking related
emphysema.
Limitations
There is some selection bias in the CT data as patients attending for CT were
more likely to be ex-smokers and had significantly lower SGRQ and MRC
dyspnoea scores. However, there was no significant difference in airflow
limitation between these groups.
A number of technical factors may have influenced the results. Our scans were
taken using a low radiation dose (20mAs). But Madani and co-workers reported
that LAA% predicted macroscopic and microscopic emphysema just as
accurately on low radiation dose scans (20mAs) as with a higher dose
[120mAs). (406) A low radiation dose is certainly preferable in clinical practice.
Inspiratory scans were taken with patients asked to breathe to full inspiration,
though this does not achieve total lung capacity when supine. All subjects
should be equally affected by this type I error, but in overweight patients, some
further restriction in inspiration could be expected, which might result in an
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apparent increase in lung density in these subjects. Expiratory scans would not
be so affected by this and yet similar relationships were seen between
expiratory CT values and clinical features, partially controlling for this potential
limitation. Patients with higher BMI also have more chest wall tissue, which
might lead to a reduction in radiation dose to the lungs. This artefact would
however result in an apparent increase in attenuation in these subjects that
might account for our findings.
The 15th percentile is subject to variation depending on the level of inspiration
achieved by a patient on the day of the scan. This was not controlled for in our
study, which was cross-sectional in nature. It would become more important in
a longitudinal analysis and a method to correct for this variation has been
described by Parr (407] and Dirksen. (393]
We did not investigate the relationship between lung density and more detailed
assessment of pulmonary function such as gas transfer as this has already been
measured in previous work. (182,192, 203, 212, 232, 392]
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Conclusions
Lung density and volume can be accurately measured on CT scans and both are
associated with the severity of airflow limitation in COPD. FEVi/FVC ratio
correlated better with lung density than FEVi or FVC. Expiratory CT parameters
correlate more strongly with airflow limitation. Low lung density was
associated with low body mass index independently of smoking history and
airflow limitation. There was no association between inflammation in blood or
sputum and CT lung density in this cohort. CT may be useful in the diagnosis,
staging and characterization of COPD and should perhaps be considered part of
the routine diagnostic work-up for these patients.
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Chapter 7: Discussion
The purpose of this thesis was to investigate a cohort of stable COPD patients
with a view to identifying potential markers to add to the disease
characterization provided by FEVi. Firstly markers of inflammation in blood
and induced sputum were measured in COPD patients compared to healthy
controls. Potential "phenotypes" of COPD were then explored using markers of
inflammation, clinical features and the extent of emphysema.
These were the main findings:
■ Markers of inflammation were increased in blood and sputum in COPD
patients compared to healthy controls.
■ Blood and sputum neutrophils were independently associated with lung
function.
■ Pulmonary and systemic inflammatory markers demonstrated different
profiles according to different clinical features of COPD. After adjusting
for potential confounding factors, health related quality of life and
dyspnoea were associated with systemic inflammation, haemoglobin
oxygen saturation was associated with blood neutrophils, and the BODE
index was associated with blood neutrophils, CRP and sputum IL-8, but
there was no association between inflammatory markers and
exacerbation frequency or BM1.
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■ Emphysema, as assessed by CT lung density was associated with airflow
limitation and body mass index, but not with markers of systemic or
airway inflammation, and not with smoking history.
■ Inflammatory markers and CT lung density each provided information
about COPD that did not always reflect changes in lung function and may
therefore be useful in characterizing COPD patients in addition to lung
function alone.
The inflammatory markers measured in this cohort have not been previously
investigated in both blood and induced sputum in a single cohort of COPD
patients and healthy controls. An important strength of the study was the
inclusion of a range of COPD disease severities, as research has often been
limited to COPD patients with milder airflow limitation. (46) There is very little
previous work investigating the relationship between lung density and
inflammation in COPD and this is one of the few studies to characterize COPD
patients using a quantitative automated method of lung density analysis.
Differentiating COPD from healthy subjects with inflammatory
markers
The aim of this study was to investigate potential biomarkers for COPD. A
biomarker has been defined as "a characteristic that is objectively measured
and evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacological responses to therapeutic interventions." (20) In
COPD, there is a need to identify biomarkers in addition to FEVi, which might be
used to monitor disease severity, to predict prognosis or to define disease
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phenotypes. (21) A COPD "phenotype" has been defined as one of "the outward
physical manifestations of patients with COPD; comprising anything that is part
of observable structure, function or behaviour." (22) In this context, one of the
aims of this research was to establish whether or not markers of inflammation
would be useful in differentiating COPD patients from healthy subjects. In
accordance with the generally accepted concept that COPD is characterized by
an "abnormal inflammatory response in the lungs," (2) all of the markers of
systemic and pulmonary inflammation measured were significantly increased in
COPD patients compared to healthy controls after controlling for age, gender
and smoking status, except for induced sputum % neutrophils and IL-lp. A
wide range of inflammatory markers were measured, and not all COPD patients
exhibited either airway or systemic inflammation according to the markers
assessed. In order to consider the ability of these markers to differentiate COPD
from non-COPD subjects, several additional factors need to be considered.
The systemic inflammatory markers measured - CRP, blood white cell and
neutrophil counts - are not specific for COPD, but the finding that these markers
were increased in COPD compared to controls is consistent with the established
literature. (82,104) There was a considerable overlap in the values for blood
total white cell count and neutrophils in COPD patients compared to controls,
and the mean values for both in stable COPD patients were within the clinically
accepted normal range (mean blood neutrophils 4.9 x 10 9). Total white cell
count and neutrophils are not therefore able to specifically differentiate COPD
from controls. But as levels are significantly higher in COPD patients even when
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stable, they may be useful in defining "phenotypes" within the COPD population.
Highly sensitive CRP was significantly increased in COPD patients compared to
healthy subjects. As there was an overlap in CRP levels in COPD patients
compared to controls, CRP could not be defined as a sensitive or specific
diagnostic tool for identifying COPD patients. However, the median level of CRP
in our COPD patients [3.8 mg/L) was more than twice that of controls (1.4
mg/L), and is consistent with that reported in other COPD populations. (408)
Although these values are both below the clinically accepted normal range of <
5mg/L, measurement of CRP using a highly sensitive assay yielded values for
COPD patients which were significantly higher than healthy controls and this
finding was independent of current smoking status. Again, this is consistent
with previous work. (95) But further studies might focus on defining a useful
cut-off point. From our data, this may be around 3mg/L. As CRP is a strong
independent predictor of hospitalization and death in COPD, independently of
FEVi and smoking history, (16, 98) it may be a useful addition to the diagnostic
and prognostic work up for COPD. Raised CRP is associated with poor
cardiovascular outcomes in the general population. (409) As COPD patients are
at increased risk of cardiovascular disease, (168) measurement of baseline CRP
may also be useful in guiding the management of cardiovascular risk in these
patients.
Induced sputum % neutrophils, IL-6 and IL-8 were each significantly higher in
COPD patients compared to healthy subjects, but after adjusting for age, gender
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and smoking status, only IL-6 and IL-8 remained significantly different in COPD
patients. Of the induced sputum markers measured, percentage neutrophils
showed the greatest differentiation between COPD and healthy subjects with a
median of 89% in COPD compared to 77% in controls. Although not specific for
COPD, sputum % neutrophils are consistently increased in COPD in other
studies, even compared to other airway diseases such as asthma. (23) From our
results, sputum % neutrophils merit further investigation as a potentially useful
method of phenotyping COPD, even although they are significantly affected by
smoking history. In the case of sputum IL-8, our work confirms results of
previous small studies that IL-8 is increased in induced sputum from COPD
patients compared to healthy controls. (75, 281, 282) However, while increased
induced sputum IL-6 has been clearly described during COPD exacerbations,
(71, 72,150, 376) published data on induced sputum IL-6 in stable COPD
compared to healthy subjects is scarce. (46)
As far as the author is aware, this is the first study showing no difference in IL-
1(3 between COPD and controls. No studies investigating IL-1(3 in induced
sputum from healthy smokers have yet been published, (284) which may be due
to positive publishing bias. Results from studies investigating levels of IL-1(3 in
BAL and EBC from COPD subjects have been contradictory. (285-289) Although
we found that IL-1(3 levels in induced sputum supernatant did not differentiate
COPD from healthy subjects, it may still have an important pathogenic role in
COPD. It is possible that IL-1(3 found in induced sputum (generally accepted as a
measure of inflammation in the more proximal airways) does not accurately
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reflect the quantity or activity of IL-1(3 in the distal airways or lung parenchyma.
(294] It is possible that measurement of IL-1(3 alone does not accurately
represent its inflammatory effects, as there is some evidence that the increased
pro-inflammatory action of IL-1(3 in COPD results from a reduction in levels of
IL-1 antagonists rather than an increase in IL-1(3 perse. (293] Alternatively, the
pathogenic role of IL-1(3 in COPD may be mediated through mechanisms other
than inflammation. For example, IL-1(3 is known to affect airway remodeling
and fibrosis and has been implicated in the induction of emphysema. (290-292]
The distribution histogram for sputum cytokines was highly skewed with levels
below the detectable limit for the assay in many cases, particularly for IL-lp and
IL-6. In contrast, IL-8 levels were usually high requiring extra dilution to
achieve levels fitting the standard curve for the assay. For the proper validation
of a biomarker, reproducibility studies need to be performed, and the variability
of cytokine levels and difficulty with detection may limit their usefulness as
reliable diagnostic markers in COPD. Inflammatory marker levels are given as
population based data and generally have wide variation. The real challenge is
to develop a marker relevant to individual patients. The distribution histograms
for IL-1 (3 and IL-6 were similar to that for CRP, indicating that further work to
identify cut-off thresholds for these markers might be useful. For example,
Conway Morris and co-workers (410] proposed threshold levels of IL-1(3 and IL-
8 in bronchoalveolar lavage fluid in a study aimed at identifying markers to aid
the diagnosis of ventilator associated pneumonia in ICU patients. Such a
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strategy may also be of value in COPD. No pre-defined thresholds indicating
"normality" for these markers in induced sputum could be found in the
literature. As a result, they were analyzed using simple non-parametric
correlations, and also by defining cut-off points based on the 50th percentile of
the distribution histogram. As with CRP, the development ofmore sensitive
assays may be necessary to detect low levels of IL-1(3 and IL-6.
The effect of current and cumulative smoking history on inflammation
Smoking has established pro-inflammatory effects and is an important potential
confounding factor in this study. However, blood levels of CRP and blood
neutrophils were increased in COPD patients compared to healthy controls
irrespective of smoking history in our cohort. In contrast to CRP, circulating
neutrophil levels were significantly affected by current cigarette smoking such
that blood neutrophils were increased in COPD patients, but were also
increased in current smokers with normal spirometry. Different profiles of
blood leukocytes and CRP have previously been reported in response to
smoking habit in the literature. Our results are consistentwith previous studies
reporting an increase in leukocytes in current smokers. (85, 295] Leukocytes
are increased in the circulation of smokers as a result of chronic stimulation of
the bone marrow (310) and systemic neutrophilia has been associated both
with current smoking history and smoking pack years. However, a further
increase in blood leukocytes and CRP has been reported in COPD in addition to
the effects of smoking, which concurs with our results. (82, 85, 276) Neutrophils
may be useful for characterizing smokers for the purpose of prognosis as raised
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peripheral blood white count in current, but not ex- or non-smokers, has been
associated with annual rate of decline in FEVi. (96) While blood neutrophils
were increased in current smokers in our cohort, there was a tendency towards
an increase in blood CRP in ex-smokers, as both COPD ex-smokers and healthy
ex-smokers showed a trend towards increased levels of CRP compared to
current smoking groups. This finding is consistentwith data from the
Framingham cohort, which showed that CRP was significantly higher in ex-
smokers compared to never-smokers. (298) There is evidence that CRP levels
remain elevated in "healthy" ex-smokers for many years after quitting. (300)
CRP and blood neutrophils therefore seem to provide complimentary
information about the inflammatory status in COPD patients with reference to
smoking status.
Our results showed that ex-smoking COPD patients had higher % neutrophils in
sputum than COPD current smokers, and that healthy ex-smokers similarly had
increased % neutrophils in sputum compared to healthy current smokers.
While on one hand smoking cessation has been associated with a reduced rate
of decline in FEVi in early COPD, (308) our findings concur with the results of
prospective studies which described an increase in airway inflammation after
smoking cessation in patients with COPD, which was not seen in healthy
smokers. (275, 305, 411) The inflammatory effect of cigarette smoke exposure
is undisputed, as smoking increases inflammation, through mechanisms such as
the inhibition of histone deacetylation, resulting in an increased transcription of
pro-inflammatory mediators. (33) But the finding that lung inflammation is
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further increased in ex-smoking COPD patients' supports the hypothesis that
COPD is responsible for a further increase in inflammation in addition to the
effect of smoking.
Sputum % neutrophils were significantly affected by smoking status. Airway
inflammation has previously been associated with cumulative smoking history.
(295) Neutrophils in BAL were highly correlated both with smoking pack years
(r=0.65) and with the number of cigarettes smoked per day (r=0.41), n=53.
(303) A dose-response relationship with smoking pack years was found with
neutrophils, macrophages, IL-ip and IL-8 in BAL. (286) Although there were
small numbers in the control groups when divided according to smoking status,
sputum IL-6 and IL-8 remained elevated in COPD patients. However, the low
sputum yield in "healthy" subjects (26%) is likely to limit the ability of sputum
IL-6 and IL-8 to effectively differentiate COPD patients from healthy subjects. It
should also be considered that the unexpectedly high levels (of for example
sputum IL-8) seen in some of the "healthy" never-smokers might represent
genuine inflammation in subjects with un-diagnosed underlying lung
inflammation.
Inflammation and lung function
Neutrophils in blood and induced sputum were significantly related to the
severity of airflow limitation after controlling for age, gender, smoking status
and inhaled corticosteroid use, whereas blood CRP and sputum cytokines were
not related to spirometry in our COPD cohort. Blood and sputum neutrophils
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both correlated with post-bronchodilator FEVi (r=0.26 and r=0.31
respectively). Previous studies have shown that neutrophils in the small
airways (250) and induced sputum (45, 325) increase with the severity of
airflow limitation in COPD. But few studies have investigated the relationship
between blood and sputum inflammation and airflow limitation in the same
COPD cohort. Vernooy and co-workers found that sputum IL-8 and soluble TNF
receptor 55 correlated with FEVi in 18 COPD patients (116) and Bizeto and co¬
workers found that sputum neutrophils were associated with airflow limitation
in 22 COPD patients. (115) In a longitudinal study Donaldson and co-workers
found that blood neutrophils and fibrinogen, sputum percentage neutrophils
and sputum IL-6 increased over time and were associated with a faster rate of
decline in FEVi (% predicted) after controlling for age, gender and smoking
history. (72) This is consistent with our findings with respect to blood and
sputum neutrophils. The increase in sputum IL-6 over time in this study was
small, which may explain the discrepancy with our findings, and this was a
longitudinal rather than a cross-sectional study.
CRP was significantly higher in COPD patients compared to controls, but was
not associated with the severity of airflow limitation. Blood neutrophils and CRP
correlated with each other, and yet neutrophils increased significantly with
COPD severity by GOLD stage whereas CRP did not. A disparity in markers of
systemic inflammation in relation to airflow limitation in COPD has previously
been reported. Six systemic inflammatory markers were measured in a
Norwegian COPD cohort. In this study, CRP was increased in COPD patients
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(n=409) compared to healthy controls (n=231) but osteoprotegrin was
significantly lower in COPD patients and other potential markers of systemic
inflammation were not different between COPD and healthy subjects. Of the 6
markers measured in the Norwegian study, only soluble TNF-R1 and
osteoprotegrin were associated with GOLD stage but CRP was not. (412)
Osteoprotegrin is a cytokine from the TNF receptor superfamily with an
established role in the regulation of bone turnover and cell survival. It is also
expressed in immune and vascular tissue and is thought to down-regulate the
immune response by reducing T-cell mediated inflammation and reducing the
survival of dendritic cells. There is some evidence that osteoprotegrin is
instrumental in preventing processes involved in atherosclerosis progression.
(413)
Sputum cytokines were not associated with airflow limitation in our COPD
patients. This is in contrast to results from smaller studies using induced
sputum and similar analytical methods. Keatings and co-workers found that
sputum IL-8 and neutrophils were increased in COPD patients compared to
healthy smokers (n=14), Yamamoto and co-workers found that IL-8 levels
increased with the severity of airflow limitation (n=33) and Hacievliyagil and
co-workers (n=24) found an inverse association between sputum IL-6 and IL-8
with FEVi. (75, 281, 283) It is likely that the variability in detectable levels of
induced sputum cytokines contributed to the disparity between our results and
those found in smaller studies.
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The degree of airflow limitation is the traditional method to assess disease
severity in COPD, but it is not the only method. (2) The finding that sputum
cytokines were not related to spirometry is important as it suggests that
sputum inflammation reflects aspects of COPD not defined by lung function.
However, this is a cross-sectional study and it is not possible to ascertain the
relationship of sputum cytokines to disease progression. Some markers of
pulmonary inflammation have been associated with changes in lung function
over time. D'Armiento and co-workers investigated cell counts and cytokines in
BAL and plasma from 27 COPD patients using a cytokine array technique. BAL
eotaxin-1 levels were significantly higher in rapidly progressive COPD than in
either the healthy control subjects, or than in COPD patients whose lung
function was more stable over time. (414) Further longitudinal studies are
required to determine the association between sputum inflammation and
prognosis in COPD.
Pulmonary and systemic inflammation
The relationship between pulmonary and systemic inflammation was
investigated in the COPD cohort. Markers of systemic inflammation (CRP and
neutrophils) correlated significantly with each other, but neither was associated
with markers of pulmonary inflammation. Blood and sputum neutrophils were
associated with airflow limitation and yet did not correlate with each other.
These findings suggest that lung and systemic inflammation may be regulated
independently in COPD.
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The mechanisms linking lung and systemic inflammation in COPD are yet to be
established. It is hypothesized that systemic inflammation in COPD results from
an "overflow" of inflammatory mediators from the lung into the systemic
compartment (82] but this is not supported by our results as, contrary to
expectation, while sputum markers correlated with each other, none of the
sputum markers correlated significantly with either of the systemic markers
measured. Therefore, although they were both increased in COPD patients
compared to healthy subjects, and were both associated with the severity of
airflow limitation, they were independent of each other, suggesting that they are
not causally related. Our results and those of others demonstrate that there is a
significant inflammatory response in the lungs of patients with COPD. (1] But
the mechanisms for the development of systemic inflammation are not certain.
COPD patients have significant systemic inflammation independent of current
smoking status, evidenced by increased circulating neutrophils, CRP, fibrinogen
and TNFa. (82) While the ability of pulmonary inflammation to induce a
systemic inflammatory response has previously been reported, (108,114] in
COPD there is a notable lack of correlation between lung and systemic
inflammatory markers. (72,115,116] Other mechanisms linking pulmonary
and systemic inflammation must therefore be considered.
Smoking provides a potential causative link for lung and systemic inflammation.
But while systemic and pulmonary inflammatory markers were not related to
each other in our cohort, we found that blood and sputum inflammation was
increased in COPD after controlling for smoking status and smoking history.
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Smoking effects are known to influence cell function and immune regulation
and may plausibly link pulmonary and systemic inflammation in this way. For
example, leukotriene B4 (LTB4) release is significantly reduced in vitro in serum
from cigarette smokers compared to non-smokers. LTB4 influences the immune
response by affecting aggregation, cell margination and enzyme release from
neutrophils. (415) Blood leukocytes and CRP have previously been noted to
increase with cumulative smoking history in a population study. (309) But like
Franciosi and co-workers, surprisingly we found no association between
smoking pack years and disease severity measured by lung function in COPD
patients. (46)
Oxidative stress may also be a factor linking smoking with systemic
inflammation as current smoking results in an increased systemic oxidative
burden. But reports on the relationship between systemic oxidative stress and
the degree of airflow limitation in COPD are contradictory. (319)
As discussed in Chapter 5, hypoxaemia is implicated in a number ofmechanisms
potentially linking pulmonary and systemic inflammation.
Sputum microbiology and bacterial load were not investigated in our cohort.
Bacterial colonization has been associated with pulmonary and systemic
inflammation in the past, (416) though results are not entirely consistent.
Bacterial load has been associated with induced sputum 1L-8 and with the rate
of decline in FEVi in subjects with COPD. (321) In contrast, Haemophilus
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influenzae colonization was associated with increased sputum neutrophils,
sputum IL-1|3 and 1L-12, but not with IL-6 or IL-8 in patients with moderate
COPD. (320) Bacterial colonization should be taken into account as a potential
confounding factor in further study of sputum inflammation in COPD.
Sixty-six percent of our COPD patients were taking inhaled corticosteroid
treatment, but none of the patients were taking oral steroid therapy at the time
of data collection. Inhaled corticosteroid use did not significantly affect levels of
inflammatory markers in blood or induced sputum in our cohort. Inhaled
corticosteroids have been associated with a reduction in systemic markers of
inflammation in COPD, resulting in a 40% reduction in circulating CRP in one
study. (Ill) However, other studies reported no change in systemic
inflammation in response to inhaled corticosteroids. Combination inhaled
corticosteroids and bronchodilators were associated with reduced pulmonary
inflammation but not with reduced systemic inflammation in other studies.
(110, 358) Perng and co-workers reported a reduction in sputum IL-8 and
MMP-9 following treatment with inhaled fluticasone and salmeterol. But there
was no change in induced sputum cell counts, serum CRP, lung function or
quality of life. (358) Inhaled fluticasone and salmeterol were associated with an
improvement in health status and lung inflammation (surfactant protein D) in a
study of 289 patients, but did not alter levels of systemic inflammatory markers
(CRP or IL-6). (110) Several studies have reported no change in sputum IL-8 or
induced sputum neutrophils in response to inhaled corticosteroid treatment,
(322-324, 333) which is supported by our findings.
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Other treatment effects may impact on systemic inflammatory markers. The
anti-inflammatory effects of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA] reductase inhibitors (statins] are increasingly recognized. Statins
treatment has been associated with lower levels of circulating CRP. But in our
cohort, there was no association between statin use and CRP or any of the other
markers of systemic or pulmonary inflammation measured. If a greater number
of patients with severe airflow limitation had also been taking statin therapy,
this could potentially have influenced the lack of association seen between CRP
and airflow limitation in our cohort. But we found no difference in the
frequency of statin use by disease severity according to GOLD stage. In a
Norwegian population study (n=3877) statin use was strongly associated with
low CRP, whereas inhaled corticosteroids were not. (367] Importantly the
authors report that this reduction in CRP in association with statin use was seen
particularly in patients with cardiovascular disease and not in subjects with
airflow limitation. Whereas a randomized, double-blind, placebo controlled trial
(n=125] in COPD patients found that treatment with pravastatin was associated
with a reduction in systemic inflammation (CRP] and improved exercise
capacity. (368] Therefore, while statin use seems to have some effect on CRP
levels, it did not impact on our findings in this cohort.
The markers of systemic inflammation measured in our cohort were
unfortunately limited to CRP and blood leukocytes due to resource limitations.
It would have been interesting to compare results for CRP and leukocytes with
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other systemic inflammatory markers such as circulating fibrinogen, which has
been associated with accelerated decline in FEVi, (417) and with blood IL-6,
which is increased significantly during COPD exacerbations. (418) In one COPD
meta-analysis, blood IL-8 also showed a trend towards association with
worsening airflow limitation, but data were lacking particularly in subjects with
more severe disease. (46)
CTparameters and lung function
We measured lung volumes and whole lung density on CT scans in inspiration
and expiration using an automated method. Lung volume and density were both
associated with the degree of airflow limitation in the COPD cohort, and the
relationships were more pronounced with volume and density measurements
from the expiratory CT scans. High lung volumes and low lung density were
significantly associated with airflow limitation measured by FEVi and FEVi/FVC
ratio (post-bronchodilator % predicted values). As there is no single established
method for measuring lung density on CT, density was measured by 3 different
methods: thresholds of -910 and -950 HU and the 15th percentile point. Each of
these was significantly associated with post-bronchodilator spirometry but the
strongest correlations were seen with FEVi/FVC ratio. The change in lung
volume with increasing COPD severity by GOLD stage was clinically significant
such that subjects had a mean expiratory lung volume of 3.1 litres in GOLD stage
I compared to a mean of 6.2 litres in GOLD stage IV.
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Our results confirm the results from previous work showing strong correlations
between quantitative assessment of emphysema and airflow limitation, (181,
182,192, 203, 204, 207, 212, 392) and with studies showing a stronger
correlation between spirometry and CT lung density on expiration. (213, 214)
CT parameters on expiration may enable indirect measurement of some of the
pathological processes occurring in COPD in addition to emphysema, such as
gas trapping, altered elastic recoil and small airway disease. (395) Disease of
the small airways (< 2 mm in diameter) in COPD is likely to be one of the factors
resulting in increased peripheral airway resistance and therefore gas trapping
in COPD. (396) As airways <2mm in diameter are difficult to measure on CT,
(254) expiratory CT scans may provide a useful surrogate measurement for
small airway disease and gas trapping. Quantification of lung volumes and
density on CT may be useful for characterizing COPD phenotypes, and may also
provide a useful staging adjunct in COPD.
Emphysema and inflammation
Emphysema as assessed by CT lung density was not related to systemic
inflammation measured by total white blood count, neutrophils or CRP, or to
markers of airway inflammation measured in induced sputum. There are few
published studies investigating the relationship between inflammation and the
quantity of emphysema on CT. In agreement with our findings, two recent
studies also found no relationship between CRP and lung density in a cohort of
smokers and in a cohort of COPD patients. (232, 233)
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We have shown that airflow limitation is associated with lung density and with
pulmonary and systemic inflammation. And yet, lung density and markers of
inflammation were not related to one another. Although this was a cross-
sectional study, and as such could not be used to determine causation, our
results suggest that inflammation was not directly associated with emphysema.
However, in concordance with others, we found significant associations
between blood and sputum neutrophils and lung function. (28, 45] Previous
studies investigating the relationship between the presence of emphysema and
inflammation are contradictory. Hogg and co-workers found increased
inflammation in the lung parenchyma in patients with severe emphysema,
(250] and yet like us, others have found no association between inflammation
and emphysema. (232, 233] It may be that we are assessing inflammation in the
wrong compartment, as induced sputum does not effectively sample
inflammation in the distal airspaces, (294] or perhaps we have not sampled the
correct inflammatory mediator cell type. For example, while neutrophils are
found in increased numbers in the large airways, they are found in lower
numbers in the small airways and lung parenchyma in COPD. Instead, in these
regions, the predominant cells are CD8+ lymphocytes and macrophages. (419,
420] Finkelstein and co-workers found that neutrophils in the alveolar space
were not associated with the quantity of emphysema, whereas lung destruction
was associated with the number of alveolar macrophages and T-lymphocytes.
(56] While neutrophils induce elastolysis, they are not predominantly
associated with parenchymal destruction in cystic fibrosis or bronchiectasis, so
this does not fully explain their role in the development of emphysema in COPD.
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(34] Smoking history is likely to be an important confounding factor here, as we
have shown that neutrophils in induced sputum and blood are also significantly
increased in smokers, but current smoking status and cumulative smoking
history in pack years were not associated with lung density in our cohort. This
is in concordance with the finding that emphysema develops only in susceptible
smokers. (270, 271)
As our results showed no association between emphysema and either systemic
inflammation or inflammation in the large airways, it may be that the key
mechanisms for the development of emphysema are regulated not through
inflammatory pathways, but perhaps through vascular (402) or genetic
mechanisms. (403) Or perhaps inflammation occurs as a secondary effect
following another underlying mechanism. It is possible that emphysema
develops through pathways involving elastin degradation by proteinases,
although this too seems to be mediated via inflammatory pathways. (404, 421)
Emphysema severity may be more closely associated with molecular pathways
involved in tissue remodeling rather than inflammation. Emphysema severity
has been associated with biomarkers of tissue remodeling such as sputum
MMP-9, and sputum ratio of MMP-9 to TIMP-1 (the main tissue inhibitor of
matrix metallo-proteinases) in COPD patients. (234) Mast cells, which are also
implicated in tissue remodeling, have been found in greater numbers in the
mucosa and connective tissue in COPD subjects with more severe airflow
limitation. (422) As statins inhibit the release of MMP-1, 3 and 9 and expression
ofmRNA from fibroblasts in vitro, they may counteract fibroblast mediated
233
remodeling, and may therefore provide a potentially useful intervention in this
process in COPD. (423)
Clinical features
One of the aims of this thesis was to investigate the relationship between
clinical parameters of COPD with respect to inflammation and lung density.
When analyzed according to established clinical features, there were significant
differences in the profiles of pulmonary and systemic inflammatory markers.
Quality of life and dyspnoea were associated with systemic but not pulmonary
inflammation, whereas BODE index scores were associated with systemic
inflammation and sputum IL-8. Hypoxia was associated with increased blood
neutrophils, but there were no associations between markers of inflammation
and BMI or exacerbation frequency after adjusting for potential confounding
factors including the severity of airflow limitation. Sputum IL-6 and IL-ip were
not significantly associated with any of the clinical parameters investigated.
Emphysema on CT was associated with BMI but not with any of the other
clinical features measured.
Quality of life and dyspnoea
SGRQ and MRC dyspnoea scores were associated with systemic inflammation
but not with pulmonary inflammation or emphysema severity in our COPD
patients. Raised levels of CRP have been associated with quality of life in other
COPD cohorts, (105, 356) but as far as the author is aware, this is the first study
to report a significant association between systemic leukocytosis and quality of
life in COPD. The only reported association between lung inflammation and
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quality of life in the COPD literature was the finding that increased induced
sputum % macrophages was associated with SGRQ total and symptom scores in
a cohort of 102 patients. However, this study found no relationship between
SGRQ scores and sputum total or other differential cell counts including
neutrophils. (117)
Improvements in quality of life have been reported in response to therapeutic
interventions in COPD, even when this is not reflected in improved lung
function. (110,127) It may be that therapies aiming to reduce systemic
inflammation will have the greatest impact on quality of life for these patients.
However therapies that target lung inflammation alone, may have little impact
on quality of life. For example, theophylline reduced lung inflammation in a
small study, but had no effect on systemic inflammation or on quality of life
scores. (357)
Lung density was not related to SGRQ scores, MRC dyspnoea score or the MRC
chronic bronchitis score. And yet both the MRC dyspnoea score and the SGRQ
total scores were associated with the distribution of emphysema on CT in our
patients. (222) Previous studies have reported associations between quality of
life scores and emphysema severity on CT (SGRQ score, SF-12 symptom score,
MRC dyspnoea score and 6-minute walk) but only one of these studies used a
quantitative method to measure lung density. (205, 213, 401) Parr and
coworkers found an association between emphysema severity on CT and SGRQ
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(n=74) in PiZ alpha-1 antitrypsin patients, and these patients generally had
more severe emphysema in the lower lung regions. (240)
Symptoms of chronic bronchitis might be expected to be present in patients
irrespective of the degree of emphysema as there is evidence that thickening of
the distal airways precedes the development of emphysema in many cases.
(396) In agreement with our results, Makita and coworkers reported that
symptoms of chronic bronchitis were equally distributed irrespective of the
degree of emphysema. (205)
Body mass index
Body mass index is associated with prognosis in COPD and is incorporated in
the BODE index due to it's prognostic value in addition to lung function alone.
The relationship between BM1, inflammation and CT parameters was
investigated in this thesis. Low BM1 was associated with higher lung volumes on
CT and more emphysema but not with markers of blood or sputum
inflammation after adjusting for potential confounding factors.
There are little data on inflammation and BMI in COPD, which may be due to
difficulty in extrapolating confounding factors like disease severity and smoking
habit. But there is evidence to support the presence of increased systemic
inflammation in COPD patients with low BMI. For example, circulating TNFa
and IL-ip have been associated with cachexia in COPD. (157, 293, 360) Our
results showed an association between BMI and blood neutrophils after
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adjusting for current smoking status, but not after controlling for airflow
limitation. Increased inflammation in subjects with a low BMI is in contrast to a
healthy population in which obesity has been identified as a cause of increased
systemic inflammation including leukocytosis. (359) We found no relationship
between low BMI and either blood neutrophils or CRP after controlling for
confounding factors. This is in concordance with published data. (105, 365-367)
We found that BMI was associated with sputum neutrophilia but also with
sputum IL-6 but this association did not persist after controlling for smoking
status and airflow limitation. A population study found no association between
BMI and sputum cell counts, n=727. (375) Two previous studies also found no
association between induced sputum neutrophils, LTB-4 or TNFawith BMI.
(154,374)
Low body mass was significantly associated with greater lung volumes and
lower lung density in our COPD cohort. Findings from previous studies using
semi-quantitative measurements to quantify emphysema support this
conclusion. (205, 398, 399) Ogawa and co-workers (232) found a negative
correlation between BMI and lung density (r2=-0.557, p<0.0001) using three CT
slices for quantitative lung density analysis. Lee and co-workers found the same
relationship between BMI and lung density using whole lung quantitative CT in
34 subjects. (190)
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The association between lung density and BMI is potentially confounded by the
effect of smoking. Current smoking has been associated with a lower body mass
index (as was the case in our cohort, see chapter 6) but we found no association
between CT lung volume or density and either current smoking status or
smoking pack years. The relationship between BMI and lung density may also
have been confounded by disease severity, as BMI was lower in subjects with
more severe airflow limitation, but we found that BMI was significantly
associated with lung density after controlling for airflow limitation. Renvall and
co-workers investigated a cohort of 40 COPD patients and also found that the
quantity of emphysema on CT was associated with BMI irrespective of the
degree of airflow limitation. (400) BMI therefore seems to be an important
phenotype of COPD in addition to airflow limitation and the extent of
emphysema, which supports its inclusion an a prognostic indicator in COPD.
(15,118)
Exacerbation frequency
Frequent exacerbators had increased blood leukocytes and increased sputum
IL-6 in our cohort but this was not significant after controlling for disease
severity. Frequent exacerbations were not associated with lung volumes or
emphysema on CT. COPD exacerbations have been extensively investigated with
respect to inflammation but there is little data linking exacerbation frequency to
lung density. While we found an increase in induced sputum IL-6 in stable COPD
patients with > 2 exacerbations per year which has been previously reported,
(71, 72,150, 376) this was not the case after controlling for airflow limitation.
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Aaron and co-workers (377) found an increase in IL-8 and TNFa in induced
sputum during COPD exacerbations (n=14), with levels returning to baseline
after the exacerbation but we found no association between IL-8 and
exacerbation frequency in stable COPD subjects. We did not analyze sputum for
bacteria or viruses, but sputum neutrophilia has been associated with microbial
colonization. (320) Microbial colonization might be responsible for increased
exacerbation frequency, but Aaron and co-workers (377) found no difference in
induced sputum cytokine levels in patients with or without documented
bacterial or viral infection, which suggests that bacterial colonization is not
likely to be solely responsible for the increased sputum IL-6 described by
others.
Systemic inflammation and inactivity are key mechanisms relating COPD to it's
associated co-morbidities. Exacerbations are associated with both of these
factors and with severity of airflow limitation and may be a key link between
pulmonary and systemic inflammation and the systemic consequences of COPD.
(72, 91) And yet systemic inflammation was not significantly associated with
exacerbation frequency in our subjects. We found a significant association
between exacerbation frequency and blood white cell count (p=0.01) and a
borderline association between exacerbation frequency and blood neutrophils
(p=0.055), but this was not significant after controlling for airflow limitation.
CRP was not associated with exacerbation frequency in our COPD patients.
Exacerbation frequency has been associated with increased systemic
inflammation in COPD. (72,151,152) But this has not been the case for CRP or
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leukocytes. [153, 412) Blood white cell count and neutrophils are frequently
elevated during COPD exacerbations. But our results do not support a chronic
elevation of blood white cells in COPD patients with more frequent
exacerbations, independent of disease severity and smoking status. In some
studies CRP has been associated with COPD exacerbations, such that levels
increased significantly during exacerbations compared to other systemic
markers of inflammation. (151, 379) CRP levels have been shown to take longer
to return to baseline following an exacerbation compared to other markers,
with levels being persistently raised compared to baseline at 14 days post-
exacerbation. (376) Our COPD patients were sampled at least 6 weeks post-
exacerbation, when CRP is likely to have returned to its resting level.
Current smoking is associated with increased blood white cell count and could
be a potential cause ofmore frequent exacerbations. However, there was no
increase in exacerbation frequency in current compared to ex-smoking COPD
patients in our study (p=0.2). We found no association between markers of
inflammation and the extent of emphysema on CT in these subjects. However, in
a subgroup of this cohort (n=56) there was a significant association between
thicker airway dimensions in the proximal airways on CT and an increased




Hypoxia provides a potential causative link between pulmonary and systemic
inflammation as it induces the expression of inflammatory cytokines in vitro
(381-383] through the activation of NFkB. (384) Yet human and animal studies
report mixed associations between hypoxia and levels of inflammatory
cytokines. (385-387)
Blood neutrophils were associated with hypoxia in our COPD cohort after
controlling for potential confounding factors but CRP was not. Few studies have
investigated the relationship between neutrophilia and hypoxia, and yet a few
interesting associations are reported. For example, an influx of neutrophils and
macrophages to the alveolar space occurred in response to moderate hypoxia in
rats, (164) and neutrophils were present in increased numbers in muscle fibres
from hypoxic COPD patients. (380) Tissue hypoxia was independently
associated with CRP in one study of 50 patients, (388) and studies at altitude
describe an increase in systemic inflammation (IL-1 receptor antagonist, IL-6
and CRP) that may be hypoxia induced. (166) Hypoxia is associated with
increased platelet activation, the up-regulation of intracellular adhesion
molecules (167) and the development of atherosclerosis. (385) These factors in
addition to hypoxia induced haemodynamic stress may partly explain the
increased incidence of cardiovascular disease in COPD. (168)
There is some evidence that hypoxia increases inflammation through
mechanisms that alter vascular responses. (169,170) Activated T cells from
COPD patients secreted significantly more VEGF in response to hypoxia than
cells from healthy subjects. (386) Hypoxic COPD patients with pulmonary
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hypertension confirmed on right heart catheterization had increased levels of
circulating IL-6 and an increase in IL-6 mRNA in response to hypoxia. (389]
Hypoxia inducible factor [HIF-la] has a key role in the regulation of pulmonary
vascular remodeling in response to hypoxia. (81] Further work is required to
investigate the role of neutrophils in response to hypoxia in COPD.
We found no relationship between oxygen saturations and lung volumes or lung
density, which is consistent with the historical emphysematous "pink puffer"
phenotype of COPD. Our results are consistentwith findings from an early
study, which reported that CT lung density and Pa02 were not related to one
another, (192] but there is little other published data linking whole lung density
to oxygenation. There is some evidence that upper zone emphysema is
associated with reduced oxygenation. Parr and co-workers have shown that
upper zone emphysema was associated with a greater A-a gradient and
therefore with more hypoxaemia in patients with alpha-1 anti-trypsin
deficiency. (225]
Limitations
A number of limitations of this study need to be considered. This is a cross-
sectional study, and therefore results cannot be extrapolated to make
deductions about causation. Induced sputum is useful as a non-invasive
technique for assessing airway inflammation, but the yield of induced sputum in
this cohort was low, particularly in healthy non-smokers. The implications of
this limitation have been fully discussed in the discussion section of Chapter 3.
Induced sputum is thought to be mainly representative of inflammation in the
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larger airways and may not closely represent inflammation in the lung
parenchyma. (294, 345) Inflammation in induced sputum may therefore not be
assumed to be representative of general lung inflammation. Numbers of induced
sputum neutrophils increase with age. (332) This may have influenced our
results, as our cohort was not age matched, but was controlled for in the
analysis. The percentage of sputum neutrophils in our healthy subjects is
consistent with results reported by Thomas and coworkers, who also reported
that the sputum neutrophil differential count does not continue to increase after
50 years of age. (332) The detection of soluble mediators in induced sputum
may be reduced by the use of the mucolytic agent dithiothreitol (DTT). While
this agent improves cell yield by improving the homogenization of induced
sputum, the yield of soluble factors like cytokines may be reduced. (337)
However, the cytokines measured in our study (IL-ip, IL-6 and IL-8) do not
seem to be affected by DTT. (424)
It would have been interesting to assess a larger selection of markers of
systemic inflammation. Blood levels of IL-ip, IL-6 and IL-10 were analyzed in a
subset of 39 COPD patients and controls from this cohort. Of these only IL-6 was
significantly higher in COPD subjects (p=0.049). Due to resource limitations,
blood leukocytes and highly sensitive C-reactive protein were chosen to
measure systemic inflammation due to their important association with
prognosis in COPD. (16, 95)
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A number of technical factors may have influenced the CT results. Scans were
taken using a low radiation dose, which results in reduced edge definition. But it
has been demonstrated that even a very low radiation dose enables accurate
measurement of lung density, and this has the added benefit of reduced
radiation dose to study subjects. (406]
We did not investigate the relationship between lung density and more detailed
assessment of pulmonary function such as gas transfer as this has already been
measured in previous work. (182,192, 203, 212, 232, 392] Spirometric gating
was not used, but patients were coached to achieve as close to full inspiration as
possible, which is known to give good results. (195] There is some evidence that
spirometric gating helps to standardize CT data acquisition for a given lung
volume, (425] but it is more suited to obtaining data for a number of CT slices,
rather than for whole lung analysis. This consideration is likely to be more
relevant to longitudinal studies. (198] In particular, the 15th percentile is subject
to variation depending on the level of inspiration achieved by a patient on the
day of the scan. This was not controlled for in our study, which was cross-
sectional in nature. A method to correct for this variation has been described by
Parr (407] and Dirksen. (393]
Future directions
The association between inflammation and prognosis, and between lung density
and prognosis are yet to be established. Current features of COPD known to be
associated with prognosis include FEVi and the other components of the BODE
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index. Our results suggest that inflammation and lung density are able to further
characterize COPD in addition to lung function, but whether these parameters
give useful prognostic information will need to be tested in longitudinal studies.
Of the inflammatory biomarkers measured, blood neutrophils and CRP, and
induced sputum % neutrophils and IL-8 showed significant associations with
clinical features in COPD and are likely to be worthy of further investigation.
Analysis of inflammatory cytokines in sputum might benefit from the
determination of useful clinical cut-off points. (410)
CT scanning is increasingly utilized in the diagnosis and management of COPD
in clinical practice and should perhaps become routine in the diagnostic work
up for patients with suspected COPD. CT is able to detect emphysema before an
abnormality is seen on spirometry, (211) and early diagnosis may be useful in
encouraging patients with smoking cessation. Emphysema distribution on CT
and measurement of airway dimensions may help to further characterize the
"emphysematous" and "bronchitic" phenotypes of COPD. CT data on the
distribution of emphysema and airway dimensions has been associated with
lung function parameters and with body mass index, (181,182, 203, 205, 232)
and assessment of emphysema using CT is already used in treatment decision¬
making, for example for lung volume reduction surgery. (224, 229, 230)
Our results suggest that lung volume and density measurements may be useful
in the staging of disease in COPD. Results from alpha-1 antitrypsin research
showed that CT yielded more sensitive outcome measures than physiological
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parameters or health status in these patients. (393) But the value of lung
density in ascertaining prognosis is not established. Clinical trials in alpha-1
antitrypsin deficiency have pioneered the development of protocols for CT lung
density quantification in a longitudinal setting for use in clinical trials, (193,
231) but work is still required to determine the quantity of change over time in
lung volumes and density in COPD patients with smoking related emphysema.
There are some indications that CT parameters are likely to be useful in
providing data on disease stage and prognosis in COPD. Han and co-workers
suggested that CT lung density might complement the BODE index in predicting
prognosis in COPD as they found a significant association between lung density
and each of the BODE index components. (401) The results from the NETT trial
found that CT quantity of emphysema was weakly but significantly associated
with outcome after lung volume reduction surgery. (426)
Advances in imaging methods are likely to yield useful data for characterizing
COPD and monitoring response to treatment. (172) Imaging can now provide
structural and functional data on lung ventilation and perfusion in vivo. For
example, functional imaging with 3He (hyperpolarized helium) MRI was able to
distinguish COPD patients from healthy subjects, without the use of ionizing
radiation. (427) Investigation of lung ventilation and perfusion using PET
scanning demonstrated significantly increased ventilation/perfusion
heterogeneity in COPD. (428) A study comparing 3He MRI with 3D-HRCT found
that these imaging methods provided complimentary morphological and
functional information in COPD. (429) Further research is required to
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determine which of these methods is able to determine changes in COPD over
time and in response to therapeutic interventions.
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Chapter 8: Conclusions
The aim of this thesis was to investigate the role of inflammation in the airways
and in the systemic compartment in COPD patients compared to healthy
subjects, and to investigate the relationship between inflammation and clinical
and anatomical features in COPD. The main findings were as follows:
■ Systemic and pulmonary inflammation was increased in COPD patients
compared to healthy controls.
■ Blood and sputum neutrophils were associated with the degree of
airflow limitation in COPD.
■ Systemic inflammatory markers correlated with each other but blood
markers did not correlate with sputum markers of inflammation, which
suggests that lung and systemic inflammation may be regulated
independently in COPD.
■ Increased systemic inflammation was associated with reduced quality of
life and more dyspnoea.
■ Blood neutrophils were associated with hypoxia.
■ BODE index score was associated with systemic inflammation and
sputum IL-8.
■ Quantitative CT assessment of lung density and volume were associated
with the severity of airflow limitation and BMI, but not with blood or
sputum inflammation.
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■ Expiratory CT parameters correlated better with lung function than
inspiratory parameters.
Recommendations forfuture work
Classification of COPD patients according to inflammation and quantity of
emphysema may have implications for response to treatment and prognosis.
Our results suggest that blood neutrophils, CRP, sputum IL-8 and CT
quantification of emphysema merit further investigation in longitudinal studies
to determine their association with disease progression in COPD.
Systemic and pulmonary inflammation were not related to each other in this
cohort, which suggests that systemic inflammation does not result from an
"overflow" from the pulmonary compartment. Further work is needed to
investigate the mechanisms behind systemic inflammation in COPD. Therapies
designed to target systemic inflammation may result in symptomatic
improvement.
Smoking has an important effect on inflammation and particularly affects
neutrophils in blood and sputum. Future studies should be designed with this
effect in mind.
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Appendix: CT air calibration method
A maximum intensity projection was calculated between selected slices near the
apex of the lung and the base of the lung to allow an elliptical extra-thoracic
region to be drawn avoiding clothing. The lower slice is sometimes restricted by
lack of space above the chest wall [particularly in large patients) but is usually
below the lower part of the sternum. The average value within this region
between the superior and inferior slice limits is taken. Stoel and co-workers
sample a region a constant distance from the chest wall, whereas the selected
region in the Edinburgh software does not change location relative to the couch.
(195) The average value for air calibration is used to modify the thresholds used
for pixel index 950 (pixelindex950_corrected = -950.0*aircal/-1000.0) and pixel
index 910 [pixelindex910_corrected = -910.0*aircal/-1000.0). The values used
are recorded in the spreadsheets [CORRECTED_THRESHOLDS).
The mean air offset using this method depends on the filter, but is
approximately -985 with the FC03 filter. Estimates of lung density were taken
over a long range between the apex and base of the lung, and we suggest that
the average extra-thoracic air value should be taken to at least the inferior end
of the sternum if possible. Measurements were made in the region between
clothing and the anterior limit of the image, and normally as far away as
possible. Measurements were taken over a number of slices [see Figure 1).
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The CT software was developed at Edinburgh University by Martin Connell,
medical physicist. The software produced similar results to the Leiden software
and to VIDA software when compared during site visits. The method we used to
correct for the air offset in the Toshiba scanner is described in the paper by
Berend Stoel and co-workers. (430) Toshiba stated that calibration using extra-
thoracic air using filters with beam hardening correction was their
recommended procedure around the time this document was published.
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